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Articular cartilage and fibrocartilage participate in bone-to-bone load transfer and 
provide low-friction surfaces for smooth joint motion. These tissues are susceptible to 
traumatic injury and arthritic disease, and their degeneration leads to loss of joint function 
and pain for the patient. Cells that reside in cartilage and fibrocartilage normally remodel 
the extracellular matrix in response to biochemical and mechanical signals, and 
progression of joint disease is characterized by excessive cell-mediated degradation of 
the tissues. In addition, pathologic changes in tissue composition typically result in loss 
of tissue material properties. Differences between cartilage and fibrocartilage matrix 
composition, cell metabolism, and mechanical function suggest that the mechanisms and 
functional implications of normal and pathologic remodeling may also be different. The 
goal of this work was to examine tissue-specific responses to catabolic and anabolic 
stimuli with respect to production and processing of aggrecan, a structural matrix 
molecule in cartilage and fibrocartilage. Studying matrix remodeling can contribute to 
our understanding of arthritis, and may give insight into therapeutic approaches for the 
repair or replacement of degenerative joint tissues. 
As an in vitro model of cartilage degradation, explanted cartilage and 
fibrocartilage were subjected to stimulation with a proinflammatory cytokine. Selective 
protease inhibitors were used to perturb matrix remodeling, antibodies raised to aggrecan 
neoepitopes were used to characterize protease activity, and compression and torsion tests 
were used to measure tissue material properties. Time course experiments showed that 
protease inhibitors delayed, but did not block destructive aggrecan remodeling in 
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cartilage. In contrast, fibrocartilage cultures treated with a broad-spectrum 
metalloproteinase inhibitor were protected from degradation as indicated by biochemical 
assay and mechanical testing. For the final experiments, chondrocytes and 
fibrochondrocytes were suspended in agarose and stimulated with an anabolic growth 
factor.  The cell types exhibited similar patterns of aggrecan processing, though 
proteoglycan biosynthesis and construct material properties were substantially higher in 
the chondrocyte cultures. Collectively, these results reveal intrinsic differences in tissue-
specific cellular responses to catabolic and anabolic cytokines that may underlie some 











Arthritis includes many conditions of the joints characterized by inflammation, 
pain, and loss of joint function that affect 66 million people in the U.S. alone9. During 
arthritic degeneration of articular cartilage, the resident cells, chondrocytes, exhibit 
downregulated synthesis of extracellular matrix (ECM) molecules and upregulation of 
proteolytic enzymes. Fibrochondrocytes, found in meniscal fibrocartilage, appear to 
behave in a similar way. The disrupted balance of biosynthetic and proteolytic activity in 
these tissues can be driven by proinflammatory cytokines like interleukin-1α and β (IL-
1α,β). Treatment with IL-1 initiates rapid depletion of proteoglycan, primarily aggrecan, 
from the tissue, and there is a concomitant loss of mechanical function indicating that 
aggrecan catabolism is a significant, early event in degeneration. Transforming growth 
factor-β (TGF-β) is a pleiotropic cytokine and anabolic stimulus implicated in cartilage 
development, homeostasis, and repair. Chondrocytes stimulated with TGF-β exhibit 
upregulated aggrecan expression, but also exhibit upregulation of aggrecan-degrading 
enzymes; the duality in this response suggests an important role for aggrecan catabolism 
in normal aggrecan turnover. Proteolytic systems responsible for aggrecan degradation, 
therefore, have been the focus of intense research and drug design efforts. 
Metalloproteinases, including matrix metalloproteinases (MMP) and a disintegrin 
and metollproteinase with thrombospondin motif (ADAMTS) class enzymes have 
demonstrated efficient, distinct aggrecanolysis activity in in vitro and in vivo models of 
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arthritis. ADAMTS-4 and ADAMTS-5 (aggrecanase-1 and -2, respectively) are thought 
to be primary mediators of pathologic aggrecan catabolism, while MT4-MMP (MMP-17) 
may be involved in ADAMTS activation70,78,169,197,211,223. There is growing evidence, 
however, for metalloproteinase-independent mechanisms of aggrecan catabolism199,212,219. 
The neutral cysteine proteinase m-calpain has been detected in synovial fluid and 
cartilage ECM from arthritic joints, and chondrocytes have been shown to secrete this 
typically intracellular protease66,217,218,248. Recently, in vitro m-calpain-mediated 
aggrecanolysis was shown to yield aggrecan cleavage products found in extracts of 
mature bovine articular cartilage164. It is possible that m-calpain cooperates with the 
metalloproteases to mediate aggrecanolysis in cartilage. Interestingly, the 5’-flanking 
region of the gene encoding m-calpain contains an activation protein-1 (AP-1) 
transcription factor binding site85, and many MMPs have also been shown to be regulated 
by AP-114,125,216,234. This suggests a convergence, and possible therapeutic target, in the 
upstream regulation of metalloproteinases and m-calpain expression. 
To examine the roles of aggrecanases, MMPs, and m-calpain in chondrocyte- and 
fibrochondrocyte-mediated aggrecanolysis, two investigative tools were used throughout 
the studies in this dissertation. First, low-molecular weight (300-450Da) pharmacologic 
protease inhibitors were used to selectively perturb aggrecanolysis by these enzyme 
systems. Second, antibodies raised to protease-specific “neoepitopes,” the peptide 
sequences exposed following cleavage of the aggrecan core protein, were used to detect 
aggrecan fragments in tissue extracts and conditioned media.  
Cartilage and fibrocartilage function principally as load-bearing connective 
tissues, and tissue “functionality” may be quantified by measurement of material 
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properties, such as complex moduli and tangents of the phase angle (tan δ). Moduli 
describe a material’s resistance to deformation, whereas tan δ is the ratio of viscous 
(time-dependent) to elastic (time independent) material responses. Sulfated 
glycosaminoglycans (sGAG), the negatively charged carbohydrate chains on the 
aggrecan core protein, contribute to the compression moduli and viscoelasticity of 
cartilage, and may also participate in resisting shear stresses. Dynamic mechanical tests 
for measuring compression and shear moduli were performed to evaluate the functional 
implications of aggrecan processing in cartilage and fibrocartilage. 
1.2 Research Objectives 
The overall objective of this work was to investigate metalloproteinases and m-
calpain as comediators of aggrecan turnover in articular cartilage and meniscal 
fibrocartilage. The central hypothesis of this dissertation is that aggrecanases, MMPs, and 
m-calpain differentially alter the material properties of articular cartilage and meniscal 
fibrocartilage by participating in cell-mediated aggrecan turnover.  
Specific Aims 
The first two aims address mechanisms of pathologic aggrecan processing in 
cartilage and meniscal fibrocartilage. The third aim addresses mechanisms of aggrecan 
turnover under anabolic conditions. For specific aims 1 and 2, explanted tissue was 
stimulated with exogenous IL-1α as a model of cell-mediated ECM degradation in the 
inflamed joint. Studies in aim 3 used complimentary model systems of TGF-β1-
stimulated tissue explants and cell-agarose constructs as models of cell-mediated ECM 
homeostasis and assembly, respectively, to investigate aggrecan turnover mechanisms in 
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developing cartilage and fibrocartilage. For all studies, tissue and cell sources were from 
immature bovine stifle joints. 
 
Specific Aim 1: Analyze the kinetics and functional implications of metalloproteinase-
mediated ECM degradation in IL-1-stimulated articular cartilage. 
Hypothesis 1: Aggrecanases are primary mediators of aggrecan degradation and loss of 
tissue compression and shear properties in IL-1-stimulated cartilage. 
 
In vitro stimulation of articular cartilage explants with IL-1 is a well-established model of 
cell-mediated degradation. For this aim, articular cartilage explants from immature 
bovine stifle joints were cultured with or without 20ng/mL IL-1α for up to 24 days. Some 
of the IL-1-stimulated explants were additionally treated with pharmacologic protease 
inhibitors selective for aggrecanases (including ADAMTS-4 and -5), MMPs, or both 
aggrecanases and MMPs. Inhibitor doses were determined from a preliminary dose 
response study. Explant material properties were measured through equilibrium and 
oscillatory unconfined compression tests and oscillatory torsion tests. The aggrecan and 
collagen contents of explant digests and conditioned media were quantified by 
spectrophotometric methods. To investigate aggrecanase- and MMP-mediated 
aggrecanolysis in IL-1-stimulated explants, conditioned media were probed with 
antibodies to the aggrecan G1-NITEGE and aggrecan G1-VDIPEN neoepitopes, 
respectively. Finally, aggrecan G1-NITEGE was immunolocalized in thin sections of 
explants at days 4 and 20 of the experiment.  
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Specific Aim 2: Analyze the localization, kinetics, and functional implications of 
metalloproteinase-mediated ECM degradation in IL-1-stimulated meniscal fibrocartilage. 
Hypothesis 2: Aggrecanases and MMPs are primary mediators of ECM degradation and 
loss of tissue compression and shear properties in IL-1-stimulated fibrocartilage. 
 
Initial work for this aim established regional variations in sGAG density and aggrecanase 
activity (by immunodetection of aggrecan G1-NITEGE) in freshly isolated meniscal 
fibrocartilage. In a subsequent experiment, fibrocartilage explants isolated from the 
middle region midsubstance were stimulated with or without 20ng/mL IL-1α for up to 12 
days. Some explants were additionally treated with pharmacologic protease inhibitors 
selective for aggrecanases, MMPs, or both aggrecanases and MMPs. Explant material 
properties were measured by oscillatory unconfined compression and oscillatory torsion 
tests. The aggrecan and collagen contents of explant digests and conditioned media were 
quantified by spectrophotometric methods. To investigate release of aggrecanase- and m-
calpain-generated aggrecan from IL-1-stimulated explants, conditioned media were 
probed with antibodies to the aggrecan G1-NITEGE and aggrecan-DLS neoepitopes, 
respectively. Aggrecan retained within the explants was characterized by immunoblots of 
explant extracts for the aggrecan G1 domain. The results of this aim showed that 
mechanisms of proteoglycan catabolism and release in meniscal fibrocartilage were 
distinct from those in cartilage. The work in this aim also revealed that aggrecanases 
were active in basal cultures of fibrocartilage with only moderate effects on explant 
material properties. This observation helped motivate the investigation of aggrecan 
turnover in cartilage and fibrocartilage under less catabolic conditions in aim 3. 
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Specific Aim 3: Examine the contributions and functional implications of aggrecanase-, 
MMP-, and m-calpain-mediated aggrecanolysis in TGF-β-stimulated cartilage and 
fibrocartilage. 
Hypothesis 3: Aggrecanase-, MMP-, and m-calpain-mediated aggrecanolysis are 
essential to aggrecan turnover and maintenance of tissue material properties in cartilage 
fibrocartilage. 
 
The contribution of aggrecanolysis to TGF-β-induced aggrecan turnover and ECM 
assembly in cartilage and fibrocartilage were investigated. Aggrecan turnover was 
studied first in cartilage and fibrocartilage explants, similar to those prepared in chapters 
3 and 4. Explants were cultured under serum-free conditions for up to 10 days in the 
absence or presence of 5ng/mL TGF-β1. Some of the TGF-β1-stimulated explants were 
additionally treated with 5µM of an aggrecanase-, MMP-, or calpain-selective inhibitor. 
In addition, a group of basal (unstimulated) explant cultures was treated with a 
pharmacologic inhibitor to the kinase domain of TGF-β type I receptor to investigate the 
participation of endogenous TGF-β in cartilage and fibrocartilage ECM turnover. In a 
second study investigating de novo aggrecan deposition and turnover, cells liberated from 
articular cartilage and fibrocartilage were suspended in agarose and cultured with or 
without 10ng/mL TGF-β1 for up to 16 days. Groups of TGF-β1-stimulated cell-agarose 
constructs were additionally treated with 1µM aggrecanase-, MMP-, or calpain-selective 
inhibitor. Mitochondrial activity was evaluated at the end of each study by the WST-1 
assay. The distributions of proteoglycans were quantified by measurement of sGAG in 
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tissue extracts, residual tissue digests, and conditioned media. Extracted proteoglycans 
were immunoblotted for the aggrecan G1, G2, and G3 domains and the NITEGE and 
DLS neoepitopes. Explant and construct material properties were determined by 
oscillatory unconfined compression and oscillatory torsion tests. 
1.3 Scientific Contribution 
ECM turnover describes the cell-mediated processes that underpin tissue 
development, maintenance, and numerous pathologies. Study of molecular mechanisms 
linking cytokine stimulation, aggrecan catabolism, and alterations in the material 
properties of cartilage and fibrocartilage may reveal ways of disrupting or inducing 
turnover for therapeutic benefit. This work examines tissue-specific mechanisms and 
functional implications of aggrecan processing in models of destructive and non-
destructive aggrecan turnover. 
 The work in this dissertation demonstrates marked differences in mechanisms of 
aggrecan turnover between cartilage and meniscal fibrocartilage. Stimulation with either 
IL-1 or TGF-β triggers tissue-specific patterns of proteoglycan release and retention and 
the immature meniscus exhibits regional variations in aggrecan processing. The signals 
regulating aggrecan turnover remain unclear, but tissues (or regions of tissues) that are 
abundant in high molecular weight aggrecan typically undergo compression in vivo. 
Degenerative joint disease is characterized by aberrant degradation and release of 
aggrecan from cartilage and subsequent loss of joint function. Elucidating the 
pathogenesis of cell-mediated degeneration will require understanding the quantitative 
and tissue-specific relationships between changes in aggrecan structure and loss of tissue 
function. In addition, identifying the regulatory signals that trigger tissue-specific cell 
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 2.1 Cartilage and Fibrocartilage: Pathology 
 Degenerative joint disease is increasingly responsible for compromised quality of 
life and morbidity in the aging U.S. population. Arthritis currently affects 46 million 
people and costs $86 billion annually in the U.S. alone10. The pathogenesis of 
osteoarthritis (OA), the most prevalent form, is unknown, but traumatic injury to the joint 
(i.e., injuries causing tears, lesions, sprains, or rupture of load-bearing connective tissues) 
and advanced age are prognostic for OA. OA is characterized by erosion of the cartilage 
on the articulating surfaces of bones, loss of joint range of motion, and pain. The 
mechanisms underlying cartilage degradation in OA are the subject of intense research, 
and the clinical management of injured joints and arthritis is expected to improve with the 
development of engineered tissue replacements and pharmacologic inhibitors of tissue 
destruction.  
 The knee menisci are fibrocartilage tissues located between the femoral condyles 
and the tibial plateau and are essential to maintaining healthy joint mechanics 178,237. 
Disruption of normal joint mechanics by injurious damage to the menisci leads to rapid 
onset of OA50 (Figure 2.1). Alternatively, the menisci undergo age-related degenerative 
changes in tissue composition and material properties40,67,104,161. Meniscal degeneration 
can make the joint susceptible to tears or it can persist with long-term sequellae 
characteristic of OA. Thus, identifying mechanisms of meniscal degeneration will be 
important in the pathogenesis of OA. 
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 The clinical management of joint injury begins with arthroscopic examination of 
joint surfaces and the menisci. Magnetic resonance imaging is also used to assess 
disruptions in joint spaces and some aspects of tissue structure. Focal lesions in the 
articular cartilage may be treated in a variety of ways, depending on the site and severity 
of injury. Mosaicplasty, in which fragments of cartilage are harvested from unloaded or 
peripheral joint surfaces and implanted into the injury site, and autologous chondrocyte 
implantation, in which cells isolated from periosteal tissues are expanded ex vivo and 
implanted into the injury site, are two procedures developed for repair of focal cartilage 
lesions. Menisci with tears in the “white” (inner avascular) zone may undergo partial 
resection to remove damaged tissue. Procedures ancillary to partial menisectomy, such as 
drilling and rasping, were developed to elicit intrinsic repair processes and enhance 
recruitment of progenitor cells. Surgical interventions have demonstrated substantial 
utility in the clinical management of soft tissue injury. 
 Surgical repair of injured joint tissues does not prevent the onset of degenerative 


















Subtle changes in joint mechanics 
Figure 2.1 Pathways of joint pathology stemming from damage to the meniscal 
fibrocartilage. The menisci may be injured, leading to abrupt changes in joint mechanics. 
Alternatively, meniscal fibrocartilage undergoes degenerative changes in ECM 
composition and material properties with age that predispose the menisci to tears (dotted 
arrow) or cause gradual adverse changes in joint mechanics. Both injury and 
degeneration lead to OA and loss of joint function. Image at left is from Gray, 1918, and 
is in the public domain. 
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osteoarthritis have targeted the cytokines and proteases that drive tissue degeneration. IL-
1 receptor antagonist is a competitive inhibitor of IL-1α and IL-1β that binds the IL-1 
receptor without triggering intracellular signals. Similarly, soluble tumor necrosis factor-
alpha (TNF-α) receptor or anti-TNF-α antibodies sequester TNF-α and thus reduce or 
block this cytokine’s proinflammatory effects.  Inhibition of IL-1 and TNF-α, 
individually or in combination, has demonstrated the potential to interrupt cartilage 
degeneration in a variety of arthritis models and in human 
patients15,16,54,69,103,114,167,243,254,257. Indeed, Anakinra© and Infliximab© are biologics 
based on IL-1 receptor antagonist and anti-TNF-α currently in clinical trials. Despite the 
apparent efficacy of these inhibitors of upstream signaling events, not all patients respond 
to them, suggesting that other signaling pathways can also drive degenerative joint 
disease. 
2.2 Cartilage and Fibrocartilage: Composition and Function 
Articular cartilage is a highly hydrated soft tissue that permits smooth, low 
friction transfer of compressive loads between bones. A low cell density, dense 
extracellular matrix (ECM), and minimal vascular supply contribute to the tissue’s poor 
regenerative capacity. The ECM is rich in type II collagen and the large proteoglycan, 
aggrecan117. The N-terminal globular domain (G1) of aggrecan is associated with link 
protein and a hyaluronic acid (HA) backbone (Figure 2.2). The more C-terminal regions 
of the aggrecan core protein are heavily glycosylated with chondroitin sulfate and keratan 
sulfate, forming sulfated glycosaminoglycan (sGAG) – rich regions of the proteoglycan. 
Entanglement of the HA and collagen networks allows aggrecan to be retained within the 
ECM, and interactions between the confining collagen network and the hydrated 
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proteoglycans confer biphasic compressive properties152. Compression of cartilage 
pressurizes interstitial fluid in the ECM, and this pressure is dissipated as the fluid is 
extruded from the tissue; an osmotic pressure generated by concentrated, negatively 
charged sGAG side chains on aggrecan core proteins aids rehydration and maintains 
swelling of the ECM upon unloading48. The equilibrium compressive properties of 
cartilage are dictated almost exclusively by the concentration of sGAG, as repulsive 
electrostatic interactions between negative charges of juxtaposed sGAG chains provide 
resistance to compaction of the ECM. The concentration of proteoglycan also influences 
the shear properties of the tissue106. Retention of aggrecan – especially the sGAG-rich 
portion of the molecule – is essential to the mechanical function of articular cartilage. 
Meniscal fibrocartilage shares structural and functional features with articular 
cartilage, including low cell density, a dense ECM, a complex mechanical loading 
environment, and poor regenerative capacity. There are, however, important differences 
in ECM composition and organization, cell morphology, and mechanical properties 
Figure 2.2 Aggrecan complexes with link protein (LP) and hyaluronic acid in the 
extracellular matrix (ECM). Globular domains of the aggrecan core protein are marked 
with a G. The interglobular domain (IGD), keratan sulfate domain, and 2 sulfated 
glycosaminoglycan (sGAG)-rich domains (CS-1 and CS-2) are delineated above. 










between the tissues. The menisci of the knee are semilunar-shaped structures composed 
primarily of collagen type I. Other collagens, including types II and VI, are also present 
and appear to be associated with the collagen type I fibers. The small proteoglycans, 
decorin and biglycan, which have roles in collagen fiber assembly, are found in the 
meniscus140, and the aggrecan G1 domain was recently immunolocalized along collagen 
fibers in the canine meniscus230. Collagen fibers, especially at the surface and outer 
regions of menisci, are oriented circumferentially and confer the tensile strength required 
for bearing hoop stresses generated during physiologic loading56. The inner portion of the 
meniscus bears primarily compressive loads and is richer in sGAG and intact aggrecan, 
similar to articular cartilage156. A primary function of the menisci is to minimize stress 
concentrations at the articulating surfaces of the adjacent bones. The concave triangular 
cross section and relatively high compliance of healthy menisci afford conformity and 
congruency with the pseudo-spherical femoral condyles and the planar tibial plateau. The 
menisci also reduce stress concentrations on surrounding cartilage by dissipating 
energy143,237,238. Fibrocartilage exhibits a biphasic response to loading in which energy is 
dissipated through the extrusion of water. The role of aggrecan in generating an energy 
absorbing, compliant fibrocartilage ECM is unknown, and this appears to be quite 
different from that in articular cartilage.  
2.3 Regulation of ECM Turnover in Cartilage and Fibrocartilage 
Chondrocytes and fibrochondrocytes are sensitive to physical and biochemical 
stimuli which, in concert, regulate the balance between anabolic and catabolic activity in 
ECM turnover. Oscillatory compressive loading, for example, can stimulate chondrocytes 
to secrete ECM proteins189. Chondrocyte metabolism is also regulated by insulin-like 
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growth factor (IGF) and its binding proteins (IGFBPs) and members of the transforming 
growth factor β (TGF−β) family; IGF has generally anabolic effects 142, whereas TGF-β 
can have anabolic or catabolic effects79,151. Inflammatory cytokines such as interleukin-1 
α or β (IL-1α,β) and tumor necrosis factor α (TNF-α) depress synthesis of ECM 
molecules and upregulate expression/activity of proteases responsible for ECM 
degradation190,227. Mechanisms and functional consequences of aggrecan degradation in 
articular cartilage have been studied in vitro, and IL-1 is commonly used to induce 
arthritis-like changes in tissue properties, cell signaling, and protease activity. IL-1 
stimulation of bovine cartilage explants triggers loss of sGAG and tissue biophysical 
properties22,23,170. The cytokine has been immunolocalized in osteoarthritic (OA) and 
rheumatoid arthritic (RA) tissue42,222, and serves as a potent paracrine, autocrine, and 
intracrine signal for initiation and progression of the catabolic cascade226,241. Static 
compressive loading of surface-zone cartilage has also been shown to downregulate ECM 
synthesis, and, interestingly, this response can be blocked by IL-1 receptor antagonist153.  
In explant culture, meniscal fibrochondrocytes respond to static and dynamic 
compressive stimulation by upregulation of MMPs and the small proteoglycan decorin, 
and increasing general biosynthetic activity; interaction between IL-1 signaling and 
mechanical stimulation is also reported in this model system207,228. The mechanisms of 
aggrecan turnover in meniscal fibrocartilage are largely unknown, though disrupted 
proteoglycan metabolism has been observed in long-term explant cultures232. 
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Figure 2.3 A subset of aggrecan species detected in articular cartilage and synovial fluid. 
Bolts indicate enzyme-specific sites of proteolytic attack. Neoepitope sequences are 
given with terminal residue numbers based on the sequence of bovine aggrecan. The DLS 
neoepitope can be exposed at multiple points within the CS-1 domain of aggrecan. 
Approximate molecular weights (from migration in SDS-PAGE) are shown to the right of 
each fragment. 
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2.4 Mechanisms of Aggrecan Catabolism 
Proteases responsible for ECM degradation in cartilage degeneration include 
MMP and ADAMTS class enzymes. There are 23 known MMPs, and collectively they 
are capable of hydrolyzing every type of extracellular matrix and basement membrane 
molecule. The collagenases (MMP-1, -8, -13), the gelatinases (MMP-2, -9), stromelysin-
1 (MMP-3), and membrane-type MMP-14 and -17 are expressed as zymogens by 
chondrocytes constitutively or upon stimulation with proinflammatory 
cytokines12,20,70,115,162. Regulation of MMP activity is achieved post-translationally by 
removal of pro-domains and extracellular abundance of tissue inhibitors of 
metalloproteinases (TIMPs). MMPs generally have broad substrate specificity, as MMPs-
1, -2, -3, -8, -13, and -14 are capable of degrading multiple collagens (including types I 
and II) as well as proteoglycans, including aggrecan. MMP-mediated aggrecanolysis, 
indicated by generation of the aggrecan G1-VDIPES neoepitope (Figure 2.3), does not 
contribute substantially to release of sGAG from IL-1-stimulated cartilage explants. 
ADAMTS-1, -4, -5, -8, and -15 demonstrate more specific activity, efficiently cleaving at 
multiple sites on the aggrecan core molecule39,154,182 (Figure 2.3). ADAMTS-4 
(aggrecanase-1) and ADAMTS-5 (aggrecanase-2) have been studied extensively in the 
context of cartilage degradation, and are responsible for up to 90% of the pathologic 
aggrecan catabolism observed in cartilage explants over 72 hours of IL-1 stimulation223. 
Interestingly, MMP-17 was recently shown to participate in post-translational 
modification of ADAMTS-4, indicating a possible downstream convergence point in 
regulation of MMP- and ADAMTS-mediated aggrecan catabolism70. ADAMTS-4 is 
translated as a protein that undergoes furin-mediated removal of a pro-domain within the 
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cell233 (Fig. 2.4). The resulting secreted form is capable of cleaving aggrecan only within 
the sGAG-rich region; alternatively, this form can complex with glycosylphosphatidyl-
inositol (GPI) – anchored MMP-17 at the cell surface and undergo truncation of a C-
terminal spacer domain. This mechanism generates “activated” forms of ADAMTS-4 that  
cleave within the aggrecan interglobular domain (IGD) at the classical aggrecanase site, 
thereby accelerating depletion of sGAG from the ECM70,71,111. MMPs and ADAMTSs are 
potent mediators of aggrecan catabolism in models of cartilage degeneration.  
m-Calpain is a neutral cysteine endopeptidase that is also involved in proteolysis 
of the aggrecan core protein. The enzyme is calcium dependent and generally thought be 
ubiquitous and confined to the cytosol. Several studies, however, implicate m-calpain in 
Figure 2.4 ADAMTS-class proteases undergo proteolytic processing, which modulates 
their activity. Full length ADAMTS-4 (Aggrecanase-1, 100kDa) is first activated by 
furin-mediated removal of the N-terminal pro-domain. The enzyme’s activity is enhanced 
further through C-terminal trimming by MMPs and/or autocatalysis. The 40kDa species 
is thought to be the minimal structure for retaining proteolytic activity. Adapted from 70. 






























normal and pathologic extracellular aggrecan catabolism by demonstrating extracellular 
localization and secretion by chondrocytes, potent aggrecanolytic activity, and regulation 
by proinflammatory cytokines30,66,100,213,214,217,218. Figure 2.3 depicts one product of m-
calpain-mediated aggrecanolysis, but others have been detected, including a fragment 
bearing the C-terminal neoepitope GVA719 and migrating at ~120kDa on SDS-PAGE. m-
Calpain is a likely candidate for the unidentified enzyme responsible for post-
translational cleavage of an aggrecan precursor in the endoplasmic reticulum3, and 
accumulation of m-calpain-generated aggrecan fragments in mature bovine articular 
cartilage suggests a role for this enzyme in normal ECM turnover164. m-Calpain activity 
is governed by local calcium concentration and abundance of the endogenous inhibitor 
calpastatin, and the cell can regulate these parameters by shifting localization of the 
enzyme92,93. It is unclear how, where, and whether m-calpain is activated for aggrecan 
catabolism in articular cartilage. 
2.5 Cell-agarose Constructs as Model Systems 
Three-dimensional hydrogel scaffolds, such as agarose and alginate, have 
demonstrated utility in preservation of chondrocyte phenotype and are being explored as 
therapeutic devices in cartilage repair28,34,86,157. In addition to preserving critical 
microenvironmental cues for maintaining cell-type specific behavior, cell-hydrogel 
constructs are more amenable to proteoglycan analysis than native tissues since the 
entrapping collagen network of native tissues is essentially absent. Research applications 
of these constructs have generally focused on chondrocyte biosynthetic activity and 
mechanotransduction, and less is known about specific effectors of catabolism in these 
systems. Ragan and coworkers showed that chondrocytes in alginate suspension 
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synthesize and retain predominantly intact aggrecan in the pericellular and interterritorial 
spaces, with minimal aggrecanase or MMP activity through several weeks of in vitro 
cultivation; interestingly, there is some evidence of m-calpain activity in that model 
system, including a ~120kDa G1-positive aggrecan fragment localized in the further-
removed matrix179. IL-1 stimulation of chondrocytes in alginate beads triggers release of 
proteoglycans and upregulation of pro-MMP-2 and -913,41. There is little known about the 
catabolic activity of fibrochondrocytes in the cell-hydrogel platform. Three-dimensional 
cell-scaffold constructs can recapitulate some aspects of the native tissue 




METALLOPROTEINASE-MEDIATED AGGRECAN CATABOLISM  
IN ARTICULAR CARTILAGE DEGRADATION§ 
 
3.1 Introduction 
Articular cartilage provides a low-friction surface for joint motion, and disease or 
damage to the tissue causes chronic pain and loss of joint function. The dense, highly 
hydrated extracellular matrix (ECM) of articular cartilage is composed primarily of 
water, type II collagen, and aggrecan. The aggrecan core protein bears a large number of 
sulfated glycosaminoglycans (sGAG) which are either chondroitin sulfate or keratan 
sulfate. Aggregation of aggrecan monomers on hyaluronan chains entangled in the 
collagen network results in a high matrix fixed charge density and generates an osmotic 
swelling pressure that resists compression during joint loading48. Aggrecan has also been 
shown to contribute to the shear properties of the tissue106. Progressive tissue 
degeneration in vivo is marked by release of aggrecan from the cartilage ECM and loss of 
compression and shear properties. 
Proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and 
interleukin 1 alpha and beta (IL-1α,β), stimulate chondrocytes to degrade cartilage 
aggrecan and collagen through the production of activated aggrecanases (such as 
ADAMTS-4 and -5) and collagenases (such as MMP-13), respectively. Many cartilage 
                                                 
 
 
§ From Wilson CG, Palmer AW, Zuo F, Eugui E, Wilson S, Mackenzie R, Sandy JD, Levenston ME. 
(2006) Matrix Biology, DOI:10.1016/j.matbio.2006.11.001.  
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explant studies have shown that aggrecanolysis precedes collagenolysis19,118,175,257, and it 
has been suggested175 that aggrecan protects the collagen network from proteolytic attack. 
Proinflammatory cytokines also shut down synthesis of matrix molecules, 
exacerbating their disruption of homeostatic ECM remodeling. These findings are 
physiologically important because IL-1 can be detected in degenerative cartilage226, and 
is present in synovial fluid at concentrations ranging from tens of picograms to 
nanograms per milliliter61,94. IL-1, therefore, has been implicated in the progression of 
arthritis, and in vitro stimulation of explanted cartilage with IL-1 has demonstrated utility 
as a model of the catabolic events leading to cartilage destruction. The IL-1 signaling axis 
is further regulated by the physiologic antagonist, IL-1 receptor antagonist (IL-1RA). 
Local and systemic delivery of IL-1RA alone and in combination with other 
inflammatory cytokine antogonists (e.g., soluble tumor necrosis factor receptor) can 
reduce cartilage and bone resorption in animal models of rheumatoid arthritis15,16. 
Clinical studies, however, showed that less than half of the treated patients responded to 
IL-1RA treatment68, indicating that cytokine inhibitors are not universally efficacious. 
Matrix remodeling in articular cartilage is mediated in part by the MMPs. Several 
MMPs, including the collagenases MMP-1, -8, and -13, MMP-3 (stromelysin-1), the 
gelatinases MMP-2 and -9, and membrane type MMP-14 and -17, are expressed in 
articular cartilage. Active MMPs readily degrade type II collagen and aggrecan13,115, and 
exogenous MMPs were shown to modulate the composition and material properties of 
bovine cartilage explants23. The primary substrate for MMPs on the aggrecan core protein 
is within the interglobular domain (IGD) at the VIPEN360—361FFG bond (the equivalent 
substrate in bovine aggrecan is VDIPES360—361FFG)57. Importantly, MMP-mediated 
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aggrecan catabolism appears to operate independent of aggrecanases and is thought to be 
a quantitatively minor mechanism of aggrecan degradation in injured or osteoarthritic 
cartilage62,127,195,200.  
Chondrocytes express aggrecanases of the ADAMTS family of enzymes 
(including ADAMTS-1, -4, -5, -8, -9, and -15). Proinflammatory stimuli may upregulate 
transcription of aggrecanase genes12,115, and there is mounting evidence for substantial 
post-translational processing of the enzymes that alter aggrecanase activity and 
specificity174. In human chondrosarcoma cells and bovine cartilage explants, MMP-17 
(MT4-MMP) appears to be responsible for C-terminal truncation of ADAMTS-4, a 
process which converts the enzyme from one which can cleave only the sGAG-rich 
region to one which can also cleave the interglobular domain (IGD)70,169. Aggrecanase 
activity within the IGD is marked by scission of the NITEGE392—393ARGSVI bond 197. 
ADAMTS-4 and -5 (aggrecanase-1 and -2, respectively) appear to mediate the bulk of 
destructive sGAG release from osteoarthritic human cartilage explants8, and ADAMTS-5 
is primarily responsible for destructive aggrecanolysis in vivo in the mouse211. 
MMPs, aggrecanases, and their post-translational activation mechanisms are 
obvious targets for clinical intervention in arthritis, and many natural and synthetic 
inhibitors have been investigated for potential therapeutic use32,37. Indeed, a broad 
spectrum metalloproteinase inhibitor was found to reduce aggrecan depletion and loss of 
material properties in IL-1-stimulated cartilage explants22. Inhibitors of 
glycophosphatidyl inositol-anchor formation, including mannosamine and glucosamine, 
interfere with MMP-17-mediated activation of ADAMTS-4 and reduce IL-1-induced 
sGAG release and loss of material properties in cartilage explants170. Synthetic 
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aggrecanase inhibitors delayed sGAG and collagen release from IL-1-stimulated nasal 
cartilage, and preservation of aggrecan using an aggrecanase inhibitor protected the 
collagen network from proteolytic attack175. Collectively, these studies suggest that 
inhibitors of aggrecanases specifically or metalloproteinases generally (ADAMTSs and 
MMPs) can attenuate cell-mediated aggrecan catabolism and loss of tissue function 
associated with arthritic disease. 
While several reports have shown that metalloproteinase inhibitors can abrogate 
IL-1-induced cartilage degradation, non-metalloproteinase pathways can also be 
quantitatively important. For example, Sugimoto and coworkers demonstrated that a 
broad spectrum inhibitor of MMPs and aggrecanases perturbed, but did not block, loss of 
aggrecan from IL-1-stimulated cartilage explants, and the authors concluded that IL-1 
was stimulating hyaluronidase activity212. In other work, it was shown that 
depolymerization of hyaluronic acid may contribute to extrusion of aggrecan from 
diseased or injured tissue219. The effects of aggrecan depletion by metalloproteinase-
independent pathways on changes on the material properties of cartilage, however, have 
not been characterized. Studies coupling analysis of molecular level changes in 
extracellular matrix with tissue level changes in matrix mechanical property are useful for 
evaluating the therapeutic potential of metalloproteinase inhibitors and permit 
investigation of the relationships between matrix composition, structure, and function. 
The objective of the current study was to examine the time–course of ECM catabolism 
and loss of mechanical properties in IL-1-stimulated articular cartilage explants treated 
with selective or non-selective metalloproteinase inhibitors. These studies show that 
inhibition of MMPs and/or aggrecanases does not effectively block IL-1-induced ECM 
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destruction and support the idea that other enzymes, such as hyaluronidases, participate in 
aggrecan degradation and loss of tissue function. 
3.2 Materials & Methods 
Inhibitor Selectivity Assays 
The potencies and selectivities of the inhibitors for various MMPs were 
determined (by Rebecca Mackenzie, Roche-Palo Alto) using recombinant mouse or 
human MMPs (R&D Systems, Minneapolis, MN) and the fluorogenic peptide substrate 
MCA-Pro-Leu-Gly-Leu-DAP(DNP)-Ala-Arg-NH2 (Bachem, Heidelberg, Germany). 
Recombinant enzymes were activated with 1mM aminophenylmercuric acetate (Sigma), 
and reacted with the substrate in the presence of an aggrecanase-selective inhibitor 
(RO3310769, Roche-Palo Alto, Palo Alto, CA), a MMP-selective inhibitor (RO1136222, 
Roche-Palo Alto), or a non-selective metalloproteinase inhibitor (RO4002855, Roche-
Palo Alto). The inhibitors were tested at concentrations ranging from 0-200µM. Reaction 
rates were measured by detection of the cleaved substrate’s fluorescent signal (excitation 
λ = 334nm, emission λ = 390nm) over 20min at 37°C. The results are reported as IC50, 
the inhibitor concentration causing 50% of the maximal reduction in the rate of substrate 
cleavage.  
The potencies and selectivities of the inhibitors for ADAMTS-4 were determined 
via an enzyme linked immunosorbent assay (ELISA). Recombinant human ADAMTS-4 
was produced in Sf9 cells and purified by column chromatography as previously 
described187. Aggrecan substrate was isolated from young adult bovine nasal cartilage by 
extraction in 4M guanidine hydrochloride and subsequent fractionation by CsCl density 
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gradient centrifugation. Microplates were treated with 660ng aggrecan/well overnight at 
4°C, and blocked with 1% BSA for 1h at room temperature. Recombinant ADAMTS-4 in 
reaction buffer containing 50mM Tris-HCl, 1% glycerol, 10mM CaCl2, pH 7.5 was added 
with varying concentrations of inhibitors. The digestions were carried out at room 
temperature for 2.5h. Reaction products bound to the plate were incubated with anti-
NITEGE primary antibody diluted 1:3000 over 2h at room temperature. The extent of 
digestion was then measured by reaction of an alkaline phosphatase-conjugated 
secondary antibody with the chemiluminescent substrate disodium 3-(4-
methoxyspiro(1,2-dioxetane-3,2'-(5'-chloro)tricyclo[3.3.1.13,7]decan)-4-yl)phenyl 
phosphate (CSPD, Applied Biosystems, Bedford, MA). The results are reported as IC50, 
the inhibitor concentration causing 50% of the maximal reduction in abundance of 
NITEGE-positive aggrecan fragments. 
Tissue Culture 
Articular cartilage was harvested aseptically from the femoral condyles and 
femoropatellar grooves of 1-2 week old calves (Research 87, Marlborough, MA) using a 
4mm diameter biopsy punch. Full thickness explants were then cut to 2mm thick on a 
custom sizing block. The explants were cultured in 5% CO2, 95% humidity and 37ºC for 
72 hrs in the presence of serum-free media consisting of high glucose DMEM 
(Invitrogen, Carlsbad, CA), 10mM non-essential amino acids (Invitrogen), 50ug/mL 
gentamicin (Invitrogen, Carlsbad, CA), and 50µg/mL ascorbic acid (Sigma, St. Louis, 
MO). In a dose-response study, explants were stimulated with 20ng/mL recombinant 
human IL-1α (Peprotech, Rocky Hill, NJ) and treated with 0.5, 5, or 50µM aggrecanase-, 
MMP-, or non-selective inhibitors. Stock solutions of the compounds were prepared with 
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dimethylsulfoxide (DMSO), and final concentrations of DMSO in the culture media did 
not exceed 0.2%. At doses below 1%, DMSO has been shown to have no effects on 
cartilage explant proteoglycan synthesis or viability209.  
Explants were cultured for up to 24 days with or without 20ng/mL rhIL-1α. Some 
explants were additionally treated with 20µM of the aggrecanase-selective inhibitor, 5µM 
of the MMP-selective inhibitor or 5µM of the non-selective inhibitor. The four-fold 
higher dose of aggrecanase-selective inhibitor was chosen, based on the dose-response 
study and aggrecanase inhibition assay data, to yield similar inhibition of IL-1-induced 
sGAG release as the non-selective inhibitor. Media were collected and replenished every 
two days, and conditioned media were stored at -20ºC. Inhibitors were added to the 
media with each media change. Explants harvested at days 0, 4, 8, 12, 16, 20 and 24 days 
of culture (n = 5/treatment/time point) were stored frozen until mechanical testing in 
Dulbecco’s phosphate buffered saline (DPBS) with a proteinase inhibitor cocktail 
(Calbiochem, San Diego, CA) including ethylenediaminetetraacetic acid (EDTA), 4-(2-
aminoethyl)benzenesulfonylfluoride, leupeptin, and aprotinin. In a second study, explants 
harvested at days 0, 4, 8, and 20 of culture (n = 4/treatment/time point) were immediately 
fixed in 10% neutral buffered formalin, embedded in paraffin, and sectioned to 4µm for 
immunostaining. The kinetics of sGAG release to the media were similar between these 
two studies (not shown). 
Biochemistry 
Following mechanical testing, explants were lyophilized, weighed dry, and 
digested overnight in 0.0125 mg/mg tissue proteinase K (Invitrogen) at 60°C. Explant 
digests and conditioned media were spectrophotometrically assayed for sGAG content by 
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the dimethylmethylene blue (DMMB) dye-binding method53 and for hydroxyproline 
content by the chloramine-T/para-dimethylaminobenzadehyde reaction247. Collagen 
content was calculated from the hydroxyproline content assuming a 
collagen:hydroxyproline mass ratio of 8:1180. 
Immunodetection 
Tissue sections were deparaffinized using a Leica autostainer and loaded into 
Sequenza immunostaining racks (ThermoShandon, Waltham, MA). Sections were 
deglycosylated with 0.1U/mL chondroitinase ABC (Sigma) for 1hr at 37°C and blocked 
in 2% normal goat serum, 0.1% gelatin, 1% bovine serum albumin, and 0.05% Tween-20 
for 1h at room temperature. Primary antibody or species-matched non-immune IgG 
diluted to 10µg/mL was then applied to sections for 1hr at room temperature. A goat anti-
rabbit-Alexa Fluor 488 secondary antibody (Molecular Probes) was used for detection 
and cell nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI, 
Molecular Probes). Images were captured through individual fluorescein isothiocyanate 
(FITC) and DAPI filters using a Ziess Axiovert 200 epifluorescent microscope with a 
CCD camera. All images were captured with the same exposure time, and the FITC and 
DAPI images were combined using image analysis software (Carl Zeiss MicroImaging, 
Thornwood, NY).  
To assess MMP and aggrecanase activity on endogenous substrate in the explants, 
conditioned media from the second experiment were analyzed by immunoblot with 
antibodies to the VDIPEN360 neoepitope (JSCVDI) or the NITEGE392 neoepitope 
(JSCNIT). Antibodies raised against the VDIPEN neoepitope have been previously 
shown to detect the bovine VDIPES sequence 128. Pooled media samples from days 2 and 
 28 
4, 6 and 8, or 10 and 12 of the experiment were treated with ice cold ethanol/5mM 
sodium acetate to precipitate proteoglycans, and precipitates were deglycosylated by 
sequential digestion with protease-free chondroitinase ABC (Sigma) and Keratanases I 
(Sigma) and II (Associates of Cape Cod, East Falmouth, MA) as previously described200. 
Equal quantities of sGAG (5 µg) were loaded into 4-12% gradient Tris-glycine gels 
(Invitrogen). Following electrophoresis and transfer to nitrocellulose, aggrecan fragments 
were identified with primary antibodies at 1µg/mL. Blots were developed using a 
secondary antibody conjugated with alkaline phosphatase followed by exposure to the 
fluorescent substrate ECF (Amersham, Piscataway, NJ). Bands were visualized using a 
Fuji FLA3000 Phospho-imager. 
Mechanical Testing 
Explants were thawed to room temperature in DPBS with protease inhibitors and 
weighed wet before testing in torsional shear on a CVO120 rheometer (Bohlin, East 
Brunswick, NJ) and in unconfined compression on an ELF3200 uniaxial loading frame 
(Enduratec, Minnetonka, MN). After application of a 10% compressive strain and 
relaxation for 12min, each explant was first tested in oscillatory torsion with 0.25% shear 
strain applied at 0.01-10Hz to yield a frequency-dependent dynamic shear modulus G*. 
Following a 12min reequilibration to the free-swelling state, each explant was then tested 
in compression through 4 steps of stress relaxation (5% each, 10min/step) to determine 
the equilibrium modulus E and through oscillatory compression about a 10% offset of 
±1.5% strain at 0.001-1Hz.to determine the frequency-dependent dynamic compression 
modulus E*. 
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Table 3.1 Inhibitors demonstrated differential selectivity for MMPs and aggrecanases.  
Inhibitor selectivities, indicated by concentrations of half maximal inhibition (IC50, in 
nM), were determined by recombinant enzyme-fluorescent substrate assay (MMPs) and 
ELISA (ADAMTS-4). 
Statistics  
Differences between treatment groups at a given day were evaluated by one-way 
analysis of variance and Dunnett’s post-hoc test using the IL-1 treated group as a control 
and significance at p<0.05.  
3.3 Results 
Selective and non-selective (NS) metalloproteinase inhibitors were used to 
perturb the catabolic cascade and progressive loss of tissue function in a well-established 
bovine cartilage explant model. Inhibitor selectivities, determined by recombinant 
enzyme-fluorescent substrate assays and ELISA, are summarized in Table 3.1 as 
concentrations of half-maximal inhibition (IC50). The MMP-selective inhibitor effectively 
blocked (IC50<50nM) the collagenases MMP-8 and MMP-13, the gelatinase MMP-2,  
MMP-3, and the membrane-type MMPs-14 and -17, but it had weaker activity 
(IC50>1200nM) against MMP-1, MMP-7, and ADAMTS-4. The aggrecanase-selective 
inhibitor was ineffective (IC50>5600nM) against most MMPs, partially effective 
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(IC50~710nM) against MMP-14 and highly inhibitory (IC50~8nM) against ADAMTS-4. 
The non-selective metalloproteinase inhibitor was highly inhibitory (IC50<7.5nM) to 
MMPs-2,3,8,9,13,14, and 17 and ADAMTS-4 and partially effective (IC50>260nM) 
against MMPs-1 and 7.  
As predicted from the selectivity assay IC50 data, the inhibitors exhibited different 
effects on IL-1-induced aggrecan release (as indicated by sGAG release to media) from 
explanted bovine cartilage (Figure 3.1). The aggrecanase-selective and non-selective 
compounds demonstrated dose-dependent inhibition of IL-1-induced aggrecan release in 
the 0.5-50µM range, and this was not due to cytotoxic effects as shown by Live/Dead 
staining (not shown). The MMP-selective inhibitor had no effect on sGAG release over 8 
days at 0.5-5µM and was cytotoxic at 50µM. Based on these results, subsequent 
Figure 3.1 Metalloproteinase inhibitors demonstrated dose-dependent reduction in IL-1-
stimulated sGAG release.  Articular cartilage explants were stimulated with 20ng/mL 
rhIL-1α and treated with 0.05, 5, or 50µM inhibitor for 8 days.  Cumulative sGAG 
release was measured by the DMMB-dye binding assay.  Data are mean +/- SEM, n = 5.  
Cytotoxicity was observed at 50µM for the MMP-selective inhibitor. 
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degradation-inhibitor studies were carried out with inhibitor concentrations of 5µM for 
the MMP- and non-selective inhibitors and a concentration of 20µM for the aggrecanase-
selective inhibitor. The aggrecanase inhibitor was used at a four-fold higher concentration 
than the non-selective inhibitor to account for differences in inhibitor potency against 
ADAMTS-4 (in substrate assays) and IL-1-induced sGAG release (in explant studies). 
Time courses of sGAG release to the media (per 48h in Figure 3.2A, cumulative 
in Figure 3.2B) and explant sGAG content (Figure 3.2C) were used to assess aggrecan 
degradation. As expected, IL-1α treatment caused rapid (peak rates in days 2-4) and 
extensive aggrecan release with nearly complete depletion (~93%) by day 8. The MMP-
selective inhibitor delayed the peak rate of IL-1-induced release (from days 2-4 to days 4-
6) but did not affect the extent of depletion (~93%) at day 8. The aggrecanase inhibitor  
caused longer delays (from days 2-4 to days 6-8), but it had no significant effect on the 
extent of depletion after 24 days (Figure 3.2C). The non-selective inhibitor caused a 
delay which was almost identical to the aggrecanase inhibitor, and it reduced the extent 
of depletion by about 25% relative to IL-1. 
Figure 3.2 Metalloproteinase inhibitors delayed, but did not block, IL-1-stimulated 
proteoglycan degradation. sGAG content of conditioned media (A, B) and explant digests 
(C) was measured by the DMMB dye-binding assay.  Data are mean +/- SEM, n = 5. In B 
and C, †, ‡, § = p<0.05 vs. IL-1 for AGG Inh, MMP Inh, and NS Inh, respectively. 
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To characterize IL-1-induced aggrecan degradation in the presence of selective- 
and non-selective metalloproteinase inhibitors, conditioned media were immunoblotted 
for fragments of aggrecan core protein (Figure 3.3). Conditioned media of IL-1-
stimulated tissue, but not of untreated tissue, contained aggrecan species migrating at 
50kDa and 65-70kDa corresponding to the G1-VDIPES and G1-NITEGE fragments, 
respectively. Treatment with an aggrecanase- or non-selective inhibitor abrogated release 
of the NITEGE-positive fragment through day 12, and an MMP-selective inhibitor 
delayed release of this fragment 2-4 days (Figure 3.3). In contrast, release of the G1-
VDIPES fragment was blocked by the MMP- and non-selective inhibitors. The 
aggrecanase-selective inhibitor (20µM) also reduced release of the MMP-generated 
fragment, but much less potently than the MMP- and non-selective inhibitors. 
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IL-1-induced aggrecan catabolism was further characterized by 
immunofluorescent detection of aggrecan cleavage fragments within the explants (Figure 
3.4). The NITEGE fragment was localized in IL-1-stimulated tissue at days 4 and (to a 
lesser extent) 20. Treatment with an aggrecanase- or non-selective inhibitor yielded 
weaker interterritorial staining with intense intra- or peri-cellular staining. The MMP- 
Figure 3.3 Selective and non-selective metalloproteinase inhibitors perturb release of 
aggrecan fragments from IL-1-stimulated articular cartilage.  Aggrecan cleavage in 
conditioned media was detected by immunoblot for the NITEGE (A) and VDIPES (B) 
neoepitopes.  Lanes 1, 2, and 3 contain media pooled from days 2 and 4, 6 and 8, and 10 
and 12, respectively.  Arrows indicate migration of 64kDa (A) or 50kDa (B) markers. 
Figure 3.4 Selective and non-selective metalloproteinase inhibitors perturb aggrecanase-
mediated aggrecanolysis in IL-1-stimulated articular cartilage.  Aggrecan cleavage 
fragments were localized by immunofluorescent detection of the NITEGE neoepitope.  
NITEGE-positive regions are green, and cell nuclei are blue. Non-immune IgG-treated 
negative controls showed no background staining.  Original magnification = 10x. 
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selective inhibitor did not substantially reduce or alter the spatial distribution of NITEGE 
staining, and appeared to have inhibited release of the fragment at later times. 
Hydroxyproline release to the conditioned media (Figure 3.5A&B) and explant 
hydroxyproline content (Figure 3.5C) were measured to examine collagen degradation. 
As observed in previous studies of IL-1-stimulated cartilage, IL-1-induced collagen 
release began after nearly complete depletion of aggrecan. Cell-mediated collagen 
destruction approached completion by day 24, with approximately 8% of t = 0 collagen 
content remaining. The MMP-selective and non-selective metalloproteinase inhibitors 
completely blocked collagen release from the tissue throughout the 24 days, indicating a 
central role for MMPs in degradation of the collagen network. Interestingly, the 
aggrecanase-selective inhibitor delayed and reduced hydroxyproline release to the media 
and loss from the explant by 50%. These results are consistent with a previously 
proposed model in which aggrecan protects the collagen network from proteolytic attack 
in bovine nasal cartilage175.  
Figure 3.5 MMP inhibitors block, and an aggrecanase inhibitor reduces, IL-1-induced 
collagen degradation.  Hydroxyproline content of conditioned media (A, B) and explant 
digests (C) was measured by the chloramine-T/pDAB reaction; collagen content was 
calculated assuming a collagen:hydroxyproline mass ratio of 8:1.  Data are mean +/- 
SEM, n = 5. In B and C, †, ‡, §  = p<0.05 vs. IL-1 for AGG Inh, MMP Inh, and NS Inh, 
respectively. 
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To evaluate the functional implications of perturbing metalloproteinase activity in 
IL-1-stimulated articular cartilage, explants were subjected to compression and shear 
testing. IL-1-stimulated tissue underwent substantial loss (91% and 84% reduction from t 
= 0 and untreated control explants, respectively) of the equilibrium compression modulus 
by day 8 (Figure 3.6A), with kinetics similar to proteoglycan depletion. By day 16, the 
dynamic compression (Figure 3.6B) and shear (Figure 3.7A) moduli were dramatically 
reduced (by 97% and 96%, respectively, from t = 0 explants, by 95% and 92% from day 
16 untreated controls). Treatment with the MMP-selective inhibitor did not prevent loss 
of the equilibrium modulus, but reduced loss of the dynamic compression and shear 
moduli after day 8. The aggrecanase-selective inhibitor delayed, but did not block loss of 
Figure 3.6 Selective and non-selective metalloproteinase inhibitors reduce, but do not 
block, IL-1-stimulated loss of compression properties.  Equilibrium (A) and dynamic (B) 
compression moduli were measured by stress relaxation and oscillatory loading (0.1Hz) 
tests, respectively.  Equilibrium moduli were below detection by 24 days of IL-1 
treatment.  Data are mean +/- SEM, n = 5. ‡, § = p<0.05 vs. IL-1 for MMP Inh and NS 
Inh, respectively. 
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equilibrium properties and reduced loss of the dynamic properties. The non-selective 
metalloproteinase inhibitor was able to delay and reduce, but did not block, loss of  
compression properties, and conferred the greatest protection of tissue function in IL-1-
stimulated tissue (with 47%, 59%, and 62% of same-day untreated explants’ E, E*, and 
G*, respectively). The protective effects of inhibitor treatments on dynamic shear 
modulus were comparable across all frequencies tested (Figure 3.7B). Similarly, 
protection of the dynamic compression modulus by each inhibitor was comparable for all 
frequencies tested (not shown).   
3.4 Discussion 
Selective proteinase inhibitors have demonstrated utility in the investigation of 
cartilage degeneration mechanisms and may have clinical use in the management of 
arthritis. The efficacy of these inhibitors is most often assessed by biochemical outcomes, 
Figure 3.7 Selective and non-selective metalloproteinase inhibitors reduce, but do not 
block, IL-1-stimulated loss of shear properties. Dynamic shear moduli as a function of 
culture time (A, at 0.1Hz) and frequency (B, at day 24) were measured by oscillatory 
torsion tests.  Data are mean +/- SEM, n = 5. 
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and the studies presented here extend previous work that examines the functional 
consequences of targeted perturbations in cell-mediated degradation22,23. In the present 
study, treatment of immature bovine cartilage with metalloproteinase inhibitors delayed 
or reduced IL-1-induced matrix degradation. These inhibitors were shown to potently and 
selectively target MMP or aggrecanase activity, or to broadly inhibit metalloproteinase 
activity in vitro. In control experiments (not shown), explants treated with 
metalloproteinase inhibitors (but not exposed to IL-1) had DNA, aggrecan, and collagen 
contents and basal levels of aggrecan release similar to untreated controls, indicating that 
these inhibitors do not strongly influence cell proliferation or normal matrix metabolism. 
The compounds used to study protease activity in these experiments appear to inhibit 
their targets without disrupting physiologic processes, though it is possible that they have 
non-specific effects on cell metabolism. It is also noteworthy that the doses required to 
modify aggrecanolysis in explants were 2-3 orders of magnitude higher than the IC50 
values measured in the metalloproteinase enzyme assays. This discrepancy in 
concentrations may be attributed to cellular metabolism of the compounds, transport 
limitations (e.g., partitioning) or other factors that influence inhibitor stability or delivery. 
In addition, the inhibitor selectivity assays were done with recombinant enzymes and 
artificial fluorescent substrates which may not model the natural process accurately. 
Nonetheless, the results of the explant studies support the specificity and relative activity 
of the inhibitors suggested by the selectivity assays. Complementary experiments with 
small interfering RNA, knockout animals, or dominant negative mutants perturbing 
protease activity may be required to more definitively establish the roles of individual 
enzymes.  
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Biochemical analysis of conditioned media and explant digests revealed that 
inhibition of MMPs and ADAMTSs delayed and/or reduced IL-1-induced aggrecan 
release, but did not prevent it. The aggrecanase- and non-selective inhibitors delayed IL-
1-induced release of aggrecan to conditioned media and attenuated generation of the 
NITEGE neoepitope in immunoblots of conditioned media and in the tissue as shown by 
immunohistochemistry. These data are consistent with previous reports indicating that 
aggrecanases are the primary downstream effectors of the cell-mediated catabolic 
response to IL-17,127,223. The less profound effects seen with the MMP-inhibitor may have 
been due to an inhibition of MMP-mediated activation of aggrecanases. A mechanism by 
which MMP-17 cleaves ADAMTS-4 at the cell surface appears to be active in IL-1-
stimulated bovine cartilage explants169, and inhibition of this mechanism with the MMP-
selective inhibitor may have resulted in reduced levels of fully activated enzyme60,70. The 
MMP- and non-selective inhibitors prevented IL-1-induced generation of the VDIPES 
neoepitope, indicating that MMPs also degrade aggrecan in this model.  Interestingly, 
stimulation with a lower dose (2ng/mL) of IL-1 permits a more robust reduction in 
proteoglycan release by the compounds used in this study (not shown). More potent 
inhibitors of aggrecanase activity, such as tissue inhibitors of metalloproteinases (TIMP)-
3, may also confer long-term protection of the cartilage ECM. 
The data from these studies suggest the existence of non-metalloproteinase-
mediated pathways for aggrecan release in cartilage explants treated with IL-1. 
Chondrocyte-derived hyaluronidases may be responsible, although there is conflicting 
evidence for upregulated expression and activity of hyaluronidases in response to 
inflammatory cytokines35,59. Chondrocytes also express non-metalloproteinase enzymes 
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such as cathepsin-B63 and m-calpain164 which have been shown to cleave the aggrecan 
core protein, and these enzymes may be upregulated in response to IL-1 treatment. 
The delayed aggrecan release observed in tissue treated with aggrecanase-
selective and non-selective inhibitors may be due to differential selectivity of these 
inhibitors for various aggrecanase activation states or enzymes. ADAMTS-4 undergoes 
post-translational processing to at least 4 activation states, each with distinct substrate 
specificity and matrix-binding properties that could influence inhibitor potency 71,111,225. 
As a result, the aggrecanase inhibitors used in this study may efficiently block 
aggrecanase activity in the aggrecan IGD and yet permit less destructive activity (at sites 
in the CS-2 domain) characteristic of lower activation states. In addition, the selectivity 
of these inhibitors for different aggrecanases in the ADAMTS family of enzymes has not 
been fully characterized. The ELISA used to establish inhibitor selectivity for 
aggrecanases tested the inhibitor potency against recombinant ADAMTS-4 (and with 
similar potency against ADAMTS-5, data not shown), but ADAMTS-1, -8, -9, and -15 
are also capable of generating the classical aggrecanase cleavage products. While the 
non-selective inhibitor is a more potent inhibitor of aggrecanases, a higher dose of the 
aggrecanase-selective inhibitor was used in these experiments to account for the 
difference in potency.  
Treatment with the MMP-selective inhibitor delayed IL-1-induced release of the 
G1-NITEGE neoepitope by several days and inhibited release of the fragment. The 
specific role of MMPs in release of the proteoglycan aggregate is unclear, but may be 
related to destruction of the collagen network. Blockade of collagen degradation may be 
sufficient to preserve hyaluronan entanglement and thereby inhibit its diffusion (and 
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diffusion of aggregable aggrecan fragments) from the ECM. Link protein, which 
stabilizes the interaction between aggrecan and hyaluronan, is also a substrate for MMPs 
including matrilysin and stromelysin-1 and -2158. The compounds used in this study may, 
then, interfere with MMP-mediated cleavage of link protein and release of aggrecan. 
Analysis of collagen content in explant digests and conditioned media confirmed 
the role of MMPs in collagenolysis. MMP-selective and non-selective metalloproteinase 
inhibitors completely blocked release of collagen to the media and depletion of collagen 
from the tissue. IL-1 upregulates expression of MMP-1, -3, and -13 in bovine cartilage58, 
and IL-1-induces exhaustive collagen degradation over a month or less of treatment 159. 
Significantly, the aggrecanase-selective inhibitor also conferred some protection of the 
collagen network. Using a different small-molecule aggrecanase inhibitor, Pratta and 
coworkers observed a similar result and hypothesized that aggrecan molecules can 
prevent MMPs from reaching their substrates on collagen fibers, perhaps by steric 
exclusion175. Treatment of IL-1-stimulated cartilage with the aggrecanase-selective 
inhibitor reduced cumulative collagen release by 50% through day 24 of the experiment, 
and delayed but did not prevent aggrecan release over the same period. Generation of the 
G1-NITEGE fragment, however, was reduced in this group, indicating that alternative 
paths of aggrecan processing had occurred to release the aggrecan. Several enzymes (e.g., 
m-calpain) truncate aggrecan at C-terminal sites in the sGAG-rich region and leave an 
intact IGD, yielding a “trimmed” aggrecan that could contribute to partial protection of 
the collagen network. 
Mechanical testing in compression and shear revealed that IL-1-induced 
reductions in explant material properties are attenuated by inhibition of metalloproteinase 
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activity. Compression and shear moduli are indicators of tissue mechanical function and 
depend on the abundance and integrity of ECM constituents181,205,256. Whereas IL-1-
stimulated tissue retains compression properties approximately 0-4% of the initial (t = 0) 
values by day 24, treatment with the non-selective metalloproteinase inhibitor was 
effective at preserving 15% and 42% of the initial equilibrium and dynamic compression 
moduli, respectively. These data indicate that MMPs and aggrecanases mediate part of 
the IL-1-induced loss of cartilage compression properties, and further suggest that other 
enzyme systems or mechanisms of ECM catabolism may participate. The MMP-selective 
inhibitor attenuated IL-1-induced loss of the dynamic compression modulus, but the 
aggrecanase-selective inhibitor did not confer significant protection of either compression 
property by day 24. These data are consistent with the ideas that equilibrium behavior of 
cartilage is governed by the abundance of aggrecan and the dynamic loading behavior is 
influenced by the integrity of both aggrecan aggregates and the collagen network120. In 
preventing degradation of the collagen network, the MMP-selective inhibitor partly 
preserves the tissue’s response to dynamic loading. The aggrecanase-selective inhibitor 
fails to sufficiently protect the aggrecan or collagen and does not prevent loss of 
equilibrium or dynamic properties. Indeed, destruction of the collagen network, rather 
than the aggrecan aggregate, is considered the “point of no return” in cartilage 
degeneration. Of note, the equilibrium and dynamic compression moduli of untreated 
controls fell to 31% and 54%, respectively, of initial values after 24 days of in vitro 
culture. These changes are attributed in part to collagen network damage at the cut 
surfaces sustained during explant preparation.   
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Compounds that inhibit MMP activity protected dynamic material properties of 
IL-1-stimulated tissue, whereas an aggrecanase inhibitor did not. The MMP-selective and 
non-selective metalloproteinase inhibitors reduced the loss of the dynamic compression 
modulus over 24 days of IL-1 stimulation and treatment with the non-selective inhibitor 
also reduced the loss of the dynamic shear modulus. The aggrecanase-selective inhibitor 
delayed (by ~4 days) and reduced loss of the dynamic compression modulus, but did not 
substantially alter loss of the equilibrium compression or dynamic shear moduli. These 
data are consistent with previously published findings that the dynamic material 
properties of cartilage depend upon collagen content5. Recent work in our lab, however, 
also demonstrated significant correlations between aggrecan contents and the dynamic 
shear and compression properties in IL-1-stimulated cartilage165, and the improved 
retention of explant aggrecan content by a non-selective metalloproteinase inhibitor 
observed here may contribute to protection of dynamic material properties. Trends in the 
dynamic shear properties generally followed those observed in the dynamic compression 
moduli and revealed similar sensitivities of these properties to IL-1-induced degradation.  
The results of this study indicate that selective or broad inhibition of 
metalloproteinase activity perturbs cell-mediated ECM degradation induced by IL-1-
stimulation of bovine cartilage explants. Disruption of the metalloproteinases was 
insufficient to prevent exhaustive depletion of aggrecan aggregates in this model system 
and may allow alternative pathways of aggrecan processing to proceed. In addition, these 
studies demonstrate that non-metalloproteinase mechanisms of aggrecan depletion can 
mediate IL-1-induced loss of tissue mechanical properties. Identification of these 
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pathways may reveal new therapeutic requirements for clinical management of cartilage 
degradation.   
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CHAPTER 4 
METALLOPROTEINASE-MEDIATED AGGRECAN CATABOLISM 
IN MENISCAL FIBROCARTILAGE 
 
4.1 Introduction 
 Knee menisci have essential roles in load transfer and distribution during joint 
motion, and partial or complete meniscectomy often initiates degeneration of the adjacent 
articular cartilage102,121,146,150,172,184,185,237. Studies of magnetic resonance images from 
asymptomatic knees revealed a prevalence of degenerative changes (e.g., tears) in the 
menisci, and meniscal degeneration appears to increase with age21,67,122,206. In addition, 
meniscal degeneration was strongly associated with meniscal extrusion and articular 
cartilage erosion17,40. Taken together, these findings suggest that meniscal degeneration is 
an early event in the onset of arthritis. The causes of age-related meniscal tearing and 
extrusion are not well understood, and may be related to changes in the fibrocartilage 
extracellular matrix (ECM) composition, ultrastructure, and material properties.  
The complex ECM structure and composition of the menisci allow for the 
distribution of shear, tensile, and compressive loads. The fibrocartilage ECM is rich in 
collagen types I, II, and VI, and is highly organized with circumferentially- and radially-
oriented collagen fibers110,139. The circumferentially-oriented fibers are organized into 
high tensile strength structures that bear hoop stresses during physiologic loading, and 
radially-oriented bundles and sheaths stabilize these structures55,108. Proteoglycans such 
as aggrecan, decorin, and biglycan are also found in meniscal fibrocartilage141,204,230. In 
articular cartilage, aggrecan confers compressive stiffness through an osmotic swelling 
pressure generated by its attached sulfated glycosaminoglycan (sGAG) chains188. 
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Valiyaveettil and coworkers immunolocalized aggrecan G1 (the hyaluronan-binding 
globular domain of aggrecan) along collagen fibers in the canine meniscus and proposed 
that aggrecan dissipates compressive loads in fibrocartilage230, and compressed regions of 
bovine deep flexor tendon were enriched in high molecular weight aggrecan236. The 
function of aggrecan in meniscal fibrocartilage mechanics is unclear, but aggrecan may 
contribute to the tissue’s compression and shear properties as in articular cartilage.  
A heterogeneous population of cells, known as fibrochondrocytes, resides in the 
menisci and exhibits regional differences in morphologic and metabolic 
characteristics88,210,221. Despite having similar rates of collagen synthesis, 
fibrochondrocytes from the inner region of the meniscus had higher rates of proteoglycan 
synthesis (as assessed by 35[S]O4 incorporation) than cells isolated from the outer 
region38,221. Studies of aggrecan gene expression and immunolocalization of aggrecan G1 
in the meniscus suggest that regional variations in proteoglycan content are due to 
differences in aggrecan abundance145,229,230. Conversely, matrix metalloproteinase 
(MMP)-2 and MMP-3 expression were higher in the outer region of the meniscus, 
indicating that elevated catabolic activity may also contribute to lower proteoglycan 
content in the outer region229. Sandy and coworkers observed an abundance of 62-
66kDa–sized aggrecan G1 fragments in extracts of bovine meniscal fibrocartilage and 
concluded that aggrecan cleavage within the interglobular domain (IGD) is a normal 
process in this tissue198. Furthermore, the size and C-terminal neoepitope (NITEGE) of 
those aggrecan fragments indicated that aggrecanases of the a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTS) family mediate normal 
aggrecan processing in the meniscus198. Abundance of the NITEGE neoepitope is 
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indicative of degeneration in articular cartilage, since this cleavage releases the functional 
sGAG-rich domains of the aggrecan core protein. The physiologic relevance of 
aggrecanase activity in the normal immature meniscus is unknown, and regional 
differences in aggrecanase activity of meniscal fibrocartilage have not yet been described. 
The proinflammatory cytokines interleukin-1α and β (IL-1α,β) are linked to the 
onset of arthritis183,208 and have been previously shown to initiate aggressive 
proteoglycan degradation followed by collagen network destruction in articular cartilage 
47. Aggrecan degradation is mediated almost exclusively by ADAMTS-4 and -5 
(aggrecanase-1 and -2, respectively) in IL-1-stimulated bovine articular cartilage 
explants, and the resulting sGAG depletion leads to dramatic loss of material properties, 
such as compressive stiffness22,197,223. The proteases responsible for cartilage erosion are 
obvious targets of therapeutic intervention, and pharmacologic protease inhibitors have 
demonstrated utility in perturbing pathologic cartilage catabolism in vitro 25,175,196,224. 
Aggrecanase and MMP inhibitors reduced IL-1-induced loss of cartilage material 
properties22,246, and using an aggrecanase inhibitor, Pratta and coworkers showed that 
aggrecan protected collagen from proteolytic attack175. IL-1 triggers a cell-mediated 
catabolic cascade in articular cartilage, and collagen network damage marks the 
degenerative “point of no return.” 
Fibrochondrocytes also respond to IL-1 with elevated catabolic activity, similar to 
articular chondrocytes. IL-1-stimulation of explanted lapine menisci increased nitric 
oxide and MMP production31, and cells isolated from fibrocartilage of the 
temporomandibular joint exhibited upregulated expression of MMPs in the presence of 
IL-1β46. Explants of human osteoarthritic meniscal fibrocartilage released proteoglycans 
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by an IL-1-induced cyclooxygenase-2 and prostaglandin E2 dependent mechanism84, and 
Shin and coworkers demonstrated that IL-1-stimulated fibrocartilage from porcine 
meniscus also release proteoglycans207. Neither the enzymatic mechanisms responsible 
for proteoglycan release in IL-1-stimulated fibrocartilage nor the IL-1-induced changes in 
fibrocartilage material properties have been previously reported. Identifying the 
mechanisms of aggrecan catabolism in fibrocartilage and characterizing the effects of 
aggrecan processing on the tissue’s material properties may contribute to our 
understanding of early degenerative changes in the meniscus. 
4.2 Materials & Methods 
Reagents and antibodies  
High glucose Dulbecco’s modified Eagle medium (DMEM), gentamicin, non-
essential amino acids (NEAA), N-(2-hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid 
(HEPES), trypsin-ethylenediaminetetraacetic acid, proteinase K, and phosphate buffered 
saline (PBS) were from Invitrogen (Carlsbad, CA). Antibodies to aggrecan G1 and the 
NITEGE neoepitope were prepared as previously described200. The antibody to collagen 
type I was from Abcam (Cambridge, MA). Alexafluor 488-conjugated anti-rabbit and 
Alexafluor 594-conjugated anti-mouse secondary antibodies were from Invitrogen. 
Fluorescein isothiocyanate-conjugated anti-rabbit secondary antibody was from 
Chemicon (Temecula, CA). Guanidine hydrochloride, protease-free chondroitinase ABC, 
keratanase I, chloramine-T, para-(dimethylamino)-benzaldehyde, non-immune rabbit 
IgG, alkaline phosphatase-conjugated anti-rabbit secondary antibody, 4’,6-diamidino-2-
phenylindole dihydrochloride (DAPI), and other histologic reagents were from Sigma (St. 
Louis, MO). Keratinase II was from Associates of Cape Cod (Falmouth, MA). 
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Dimethylmethylene blue (DMMB) was from Polysciences (Warrington, PA). 
Recombinant human IL-1α (rhIL-1α) was from Peprotech (Rocky Hill, NJ). Protease 
inhibitor cocktail containing ethylenediaminetetraacetic acid, 4-(2-
aminoethyl)benzenesulfonylfluoride, leupeptin, and aprotinin was from Calbiochem (San 
Diego, CA). The chemifluorescent substrate ECF was from Amersham (Piscataway, NJ). 
Small-molecule metalloproteinase inhibitors (RO3310769, aggrecanase-selective; 
RO1136222, MMP-selective; RO4002855, broad spectrum metalloproteinase) were 
provided by Roche – Palo Alto (Palo Alto, CA). Detailed selectivity profiles of these 
inhibitors have been reported previously246. Briefly, the aggrecanase-selective inhibitor 
was highly inhibitory against the aggrecanase ADAMTS-4, with a concentration of half-
maximal inhibition (IC50, lower values indicate greater inhibition) of 8nM, and IC50s > 
700nM for all MMPs tested. The MMP-selective inhibitor inhibited most MMPs tested 
with IC50s  50nM, with the exceptions of MMP-1 and -7, but did not preventADAMTS-
4 activity (IC50 = 7200nM). The broad spectrum metalloproteinase inhibitor potently 
inhibited ADAMTS-4 (IC50 = 1.5nM) and most MMPs (IC50s  7.5nM) tested, with the 
exceptions of MMP-1 and -7. Stock solutions of the compounds were prepared with 
dimethylsulfoxide (DMSO), and final concentrations of DMSO in the culture media did 
not exceed 0.2%. Previous work in our lab and others’ has shown that at concentrations 
<1%, DMSO does not substantially alter cell viability or proteoglycan metabolism in 
fibrocartilage or cartilage explants209. 
Histology and immunostaining  
Immature (1-2 weeks, Research 87, Cambridge, MA), adolescent (8 weeks, Green 
Village Packing Company, Green Village, NJ), and mature (2.5 years, Green Village 
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Packing Company) bovine menisci were harvested within 24h of slaughter. Coronal 
“slabs” from medial and lateral menisci (3-4mm thick, Figure 4.1, left) were either fixed 
in 10% neutral-buffered formalin (NBF) at 4°C for 48h and embedded in paraffin or fixed 
in 10% NBF for 4h at 4°C, incubated in 30% sucrose/PBS overnight at 4°C, embedded in 
OCT, and frozen in liquid-nitrogen cooled isopentane. Paraffin-embedded tissue was 
sectioned at 3µm and stained with safranin-O, fast green, and hemotoxylin. Frozen tissue 
was sectioned at 7µm and co-immunostained for the aggrecan NITEGE neoepitope and 
collagen type I. Sections were digested with 0.5% trypsin-EDTA in DPBS for 10min at 
37°C and blocked for 1h at room temperature with blocking buffer containing 2% goat 
serum, 0.1% gelatin, 1% BSA, 0.1% Triton, and 0.05% Tween-20 in PBS prior to 
incubation with antibodies. In our experience, chondroitinase ABC treatment is not 
required for detection of aggrecan G1230 or the NITEGE neoepitope in thin sections of 
meniscal fibrocartilage, perhaps due to the relatively low concentration of sGAG in the 
ECM. The NITEGE neoepitope and collagen type I were detected by indirect 
immunofluoresence with goat anti-rabbit Alexafluor-488 and goat anti-mouse 
Alexafluor-594 secondary antibodies, respectively. Following a tissue culture study 
Figure 4.1 Bovine menisci (immature shown) were dissected into coronal sections (A) for 
histology or cylindrical explants from the middle region (B) for tissue culture 
experiments.  
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(described below), 3-4mm thick coronal slabs of meniscal fibrocartilage were fixed in 
10% NBF for 48h at 4°C, embedded in paraffin, and sectioned at 3µm. The NITEGE 
neoepitope was detected by indirect immunofluoresence with a goat anti-rabbit FITC 
secondary antibody. All primary and secondary antibodies were used at 10µg/mL and 
antibody incubations were for 60-90min at room temperature. Cell nuclei were 
fluorescently stained with DAPI. Species-matched non-immune IgGs (10µg/mL) were 
used as negative controls. Sections were imaged on a Zeiss AxioVert 200M microscope 
using the Apotome optical sectioning module (Zeiss, Jena, Germany). 
Tissue Culture  
Menisci were harvested aseptically from immature bovine stifle joints (Research 
87, Marlborough, MA). This tissue source was selected because related tissues (e.g., 
articular cartilage and tendon) from this age and species animal are well-characterized in 
a wide body of literature covering the tissues’ mechanical properties, ECM composition, 
and response to IL-1. In an initial tissue culture study, coronal sections (Figure 4.1, left) 
were dissected from the menisci using two scalpels assembled in parallel and spaced 3-
4mm apart. The slabs were cultured flat in 6 well plates with or without 20ng/mL rhIL-
1α in serum-free media consisting of high glucose DMEM, 10mM NEAA, 50µg/mL 
gentamicin, and 50µg/mL ascorbic acid under standard conditions (5% CO2, 95% 
humidity and 37ºC). Media were prepared with fresh cytokine and exchanged after 48h. 
After four days, the tissue slabs were fixed in formalin and processed for 
immunofluorescent detection of the aggrecanase-generated NITEGE neoepitope 
(described above).  
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For inhibitor studies, full-thickness cylindrical specimens (3mm diameter) were 
harvested from the middle region of medial and lateral menisci and cut to 2mm thickness 
on a custom sizing block (Figure 4.1, right). Tissue from the surface zones (superior and 
inferior ~500µm) was excluded. Prior to cytokine and inhibitor treatments, the explants 
were cultured for 72 hrs in “basal” serum-free medium consisting of high glucose 
DMEM, 10mM NEAA, 50ug/mL gentamicin, and 50µg/mL ascorbic acid. Explants (n = 
6/group/time point) were subsequently cultured up to 12 days with or without 20ng/mL 
rhIL-1α. Some explants were additionally treated with 20µM of the aggrecanase-
selective inhibitor, 5µM of the MMP-selective inhibitor, or 5µM of the broad spectrum 
metalloproteinase inhibitor. Media were collected, prepared with fresh cytokine and 
inhibitors, and replaced every 48h. Tissue culture doses of the inhibitors were determined 
from a previously reported dose-response study (described in chapter 3) with immature 
bovine articular cartilage explants246. Over twelve days, these inhibitor doses were found 
to have no significant effect on fibrochondrocyte viability as assessed by mitochondrial 
conversion of the tetrazolium salt WST-1 (Biovision, Mountainview, CA) to formazan 
(not shown). Explants harvested at days 0, 4, and 12 days of culture were stored frozen in 
PBS with protease inhibitors. Additional explants harvested at days 0 and 8 were 
lyophilized and extracted in 10 volumes of 4M guanidine hydrochloride for 48h at 4°C. 
Biochemistry 
Following mechanical testing (described below), explants were lyophilized, 
weighed dry, and digested in 0.0125 mg/mg tissue proteinase K at 60°C. Explant digests 
and conditioned media were spectrophotometrically assayed for sGAG content by the 
DMMB dye-binding method53 and for hydroxyproline content by the chloramine-T/para-
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dimethylaminobenzadehyde reaction247. Chondroitin sulfate AC (Sigma) standards were 
used for the DMMB assays. Collagen content was calculated from the hydroxyproline 
content assuming a collagen:hydroxyproline mass ratio of 8:1180. 
Western blotting  
To assess aggrecan degradation in the inhibitor study, conditioned media and 
tissue extracts were analyzed by immunoblot with antibodies to the NITEGE and DLS 
neoepitopes and aggrecan-G1 domain, respectively. Pooled media samples from days 2 
and 4, 6 and 8, or 10 and 12 of the experiment were treated with ice cold ethanol/5mM 
sodium acetate to precipitate proteoglycans, and precipitates were deglycosylated by 
sequential digestion with protease-free chondroitinase ABC and Keratanases I and II as 
previously described200. Equal volumes of media or quantities of sGAG (5µg for explant 
extracts) were loaded into 4-12% gradient Tris-glycine gels (Invitrogen). Following 
electrophoresis and transfer to nitrocellulose, aggrecan fragments were identified with 
primary antibodies at 1µg/mL. Blots were developed using a 1:20,000 dilution of anti-
rabbit alkaline phosphatase secondary antibody followed by exposure to ECF. Bands 
were visualized using a Fuji FLA3000 (Fuji, Tokyo, Japan). 
Mechanical Testing 
Prior to testing, explants were thawed to room temperature, weighed, and the 
diameter and thickness of each explant were measured at three points using digital 
calipers. All tests were performed in the presence of PBS with protease inhibitors. 
Explants were compressed to 10% strain and allowed to relax for 12min between parallel 
plates on a CVO120 rheometer (Bohlin, East Brunskwick, NJ). Oscillatory torsion at 
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0.25% (0.03 rad) shear strain was applied at 0.001-0.1Hz to determine dynamic shear 
moduli G*. Following a 12min equilibration to the free-swelling state, the sample was 
moved to an unconfined compression chamber on an ELF3200 uniaxial loading frame 
(Enduratec, Minnetonka, MN), compressed to 10% strain at 0.1mm/s, and allowed to 
relax for 12min. Each explant was then tested in oscillatory unconfined compression at 
0.001-0.1Hz (1.5% strain amplitude) to determine the dynamic compressive moduli E*. 
Statistics  
Data were analyzed by ANOVA using a general linear model in MINITAB 
Release 14 (MINITAB, States College, PA). Pairwise comparisons between groups were 
determined by Dunnett’s test with IL-1-stimulated samples as controls and p<0.05 
significant. 
4.3 Results 
Regional variations in sGAG content and aggrecanase activity in the bovine 
meniscus 
Safranin-O staining for sulfated glycosaminoglycans in sections of bovine 
meniscus revealed regional variations in sGAG content (Figure 4.2) similar to those 
reported for immature porcine tissue155 and age variations similar to those reported for 
ovine meniscus145. In all ages, the inner region, which undergoes primarily compressive 
and shear loading in vivo, was richest in sGAG. The middle region of the meniscus, 
which additionally bears tensile loads, appeared to have much lower sGAG than the inner 
region in young tissue and progressively accumulated sGAG with age. At all ages, there 
were “pockets” of sGAG-rich ECM in the middle region colocalized with cells and  
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situated between collagen fiber bundles. The outer region of the bovine meniscus 
appeared to have low sGAG content at each of the ages examined. These data were 
consistent with previously reported regional variations in aggrecan content, aggrecan 
gene expression, and proteoglycan synthesis rates in meniscal fibrocartilage38,229,230.  
Immunostaining for the NITEGE sequence, a neoepitope exposed by 
aggrecanase-mediated cleavage of the aggrecan IGD, indicated that aggrecanase activity 
also varies across regions of the meniscus (Figure 4.3, middle panels). Whereas the inner 
region demonstrated weak staining for NITEGE, the middle and outer regions of the 
meniscus stained intensely in the intra- and peri-cellular compartments. Immunoblots of 
tissue extracts showed that regional variations in aggrecanase activity, as indicated by  
Figure 4.2 Proteoglycan distribution within the bovine meniscus depends on age. Stifle 
joint menisci of various ages were stained with safranin-O to localize sGAG (red) and 
Fast green/hemotoxylin counterstained. Original magnification = 4x (20x for insets).  
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NITEGE-bearing aggrecan, were similar in medial and lateral menisci (Figure 4.4). The 
middle and outer regions exhibited staining for NITEGE in the ECM along collagen type  
I fibers in the plane of the section and within collagen type I fibers perpendicular to the 
plane of the section (Figure 4.3, lower panels). Non-immune IgG controls showed no 
staining (not shown). The NITEGE fragment consistently appeared in regions of weak 
safranin-O staining (areas low in sGAG) suggesting aggrecanase-mediated aggrecan  
Figure 4.3 Aggrecanase activity is evident in immature bovine meniscal fibrocartilage. 
Coronal sections of immature bovine medial meniscus were stained for sulfated 
glycosaminoglycans (red) (top), or the aggrecan NITEGE neoepitope (Alexafluor-488 
secondary, green) and collagen type I (Alexafluor-594 secondary, red) (middle and 
bottom). In immunofluorescent images, the blue indicates DAPI nuclear stain. Inner, 
middle, and outer refer to the radial position in the coronal plane. Scale bars = 100µm. 
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degradation precluded accumulation of sGAG in the middle and outer regions of the 
meniscus.  
To assess IL-1-induced changes in aggrecanase activity, 3-4mm thick coronal 
“slabs” of meniscal fibrocartilage were cultured for up to 4 days in the absence or 
presence of 20ng/mL IL-1. Similar to articular cartilage, meniscal fibrocartilage 
stimulated with IL-1 rapidly released sGAG to the culture media (not shown), indicating 
that IL-1 induced cell-mediated proteoglycan degradation in this culture system. 
Immunostaining sections of cultured tissue for NITEGE again revealed regional 
variations in aggrecanase activity (Figure 4.5). In untreated controls, the surface ECM 
and pericellular compartments of the inner region showed NITEGE staining. The middle 
and outer regions showed weak staining around fiber bundles, and the pericellular 
compartments stained intensely in the outer region. After 4 days of IL-1 stimulation, the 
inner region stained intensely for NITEGE, indicative of upregulated aggrecanase activity 
(Figure 4.5, lower panels). The extensive interterritorial and pericellular staining was 
similar to that observed of age- and species-matched articular cartilage stimulated with 
IL-1246. The middle region of IL-1-stimulated tissue also demonstrated enhanced 
NITEGE staining over untreated controls, and the aggrecan fragment localized to intra-  
Figure 4.4 Aggrecanase activity in immature bovine medial and lateral menisci varies by 
region. Equal volumes of region-specific tissue extracts were separated by 
electrophoresis under reducing conditions and immunoblotted for the NITEGE 
neoepitope. Migration of globular protein standards are shown at left. 
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and peri-cellular compartments and around fiber bundles. The intensity and spatial 
localization of NITEGE in the outer region of IL-1-stimulated tissue was similar to that 
of untreated controls. These data suggest that bovine mensical fibrocartilage, like 
articular cartilage from this species, rapidly responded to IL-1 stimulation with 
aggrecanase-mediated aggrecan degradation. In addition, this response was confined to 
the inner and middle regions of the coronal slabs used in this study, perhaps due to the 
low abundance of aggrecan substrate in the outer region. 
Figure 4.5 IL-1 stimulation enhances aggrecanase activity in the immature bovine 
meniscus. Coronal slabs of meniscal fibrocartilage were cultured for 4 days in the 
absence or presence of IL-1. Formalin-fixed paraffin-embedded sections were stained 
using an antibody to the NITEGE neoepitope (FITC secondary, green) generated by 
aggrecanase-mediated cleavage of the aggrecan core protein. Cell nuclei (blue) were 
stained with DAPI. Inner, middle, and outer refer to the radial position in the coronal 
plane. Scale bar = 100µm. 
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Inhibition of IL-1-induced proteoglycan depletion by selective and non-selective 
metalloproteinase inhibitors 
To investigate mechanisms and functional consequences of IL-1-induced proteoglycan 
degradation in meniscal fibrocartilage, cylindrical tissue explants from the middle region 
of bovine menisci were cultured for up to 12 days in serum-free media. Stimulation with 
20ng/mL rhIL-1α triggered rapid release of sGAG to the media (peak rate at day 2), 
whereas untreated controls demonstrated low rates of release for the duration of the 
experiment (Figure 4.6A). Subsets of IL-1-stimulated explants were additionally treated 
with inhibitors selective for aggrecanases, MMPs, or both aggrecanases and MMPs. 
Addition of an aggrecanase inhibitor attenuated IL-1-induced sGAG release through day 
2, but led to elevated release rates after day 2 and total sGAG release over 12 days 
comparable to IL-1-only cultures. Addition of an MMP inhibitor had no effect on the 
sGAG releases through day 2, but reduced sGAG release below IL-1-only cultures at 
Figure 4.6 Inhibition of sGAG release to media (A) and loss of fibrocartilage explant 
sGAG (B) by metalloproteinase inhibitors. sGAG in conditioned media and tissue digests 
was quantified by the DMMB assay. Data are mean ± SEM, n = 6. §, †, and ‡ indicate 
p<0.05 vs. IL-1 for IL-1 + MMP Inh, IL-1 + P-M Inh, and untreated, respectively. 
A B 
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later time points. Addition of a broad spectrum metalloproteinase inhibitor capable of 
inhibiting both aggrecanase and MMP activity reduced IL-1-induced sGAG release at 
day 2, but did not substantially reduce sGAG release at later time points. These results 
indicate that aggrecanases are primary mediators of sGAG release early in the tissue’s 
response to IL-1 (through day 2), and that MMPs contribute later in the catabolic cascade. 
In addition, these data suggest that non-metalloproteinase mechanisms of sGAG release 
(e.g., hyaluronidases) are active in untreated and IL-1-stimulated fibrocartilage. 
Consistent with the sGAG release kinetics, measurements of explant sGAG 
content indicate that IL-1 stimulation triggered rapid loss of tissue sGAG (Figure 4.6B). 
Four days of IL-1 stimulation led to loss of 50% of the initial (day 0) sGAG content, and 
depletion persisted through day 12 when the sGAG contents of explants approached 40% 
of initial sGAG content. Untreated controls contained significantly more sGAG than IL-
1-stimulated explants at days 4 and 12, but by day 12 contained only 65% of the initial 
sGAG, suggesting that mechanisms of proteoglycan release are active under the basal 
culture conditions. Addition of the aggrecanase inhibitor delayed but did not reduce IL-1-
induced sGAG depletion in meniscal fibrocartilage, whereas addition of the MMP 
inhibitor significantly improved sGAG retention over IL-1-only cultures at day 12. 
Explants treated with the broad spectrum metalloproteinase inhibitor had significantly 
higher sGAG contents than IL-1-only controls at days 4 and 12. These data suggest that 
sGAG release in IL-1-stimulated fibrocartilage is initially mediated by aggrecanases and 
later by MMPs. 
To investigate the potential contributions of aggrecanases and MMPs to 
proteoglycan release from unstimulated basal explants, additional groups of explants 
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were treated with inhibitors in the absence of IL-1 stimulation. The proteoglycan release 
profile (Figure 4.7A&B) of untreated basal cultures demonstrates a peak in release at day 
2 which decays for the duration of the experiment. Addition of the aggrecanase or broad 
spectrum inhibitor significantly reduced release at through day 4, and maintained release 
rates similar to controls thereafter. The MMP inhibitor had no significant effects on 
release of proteoglycans under the serum-free conditions used in these studies. These 
results support a role for aggrecanase-mediated aggrecan IGD cleavage during “normal” 
aggrecan turnover in the immature meniscus. 
Figure 4.7 Proteoglycan release from unstimulated fibrocartilage explants was inhibited 
by aggrecanase-selective and broad spectrum inhibitors. Shown are kinetics (A) and 
cumulative proteoglycan release (B) over 12 days of serum-free culture. Conditioned 
media were assayed for sGAG by the DMMB dye-binding assay. Data are mean ± SEM, 
with n = 6. #, indicate p<0.05 for +Agg’ase Inh and +BR. Sp. Inh vs. untreated 






























































Inhibition of IL-1-induced aggrecan catabolism by metalloproteinase inhibitors 
Mechanisms of aggrecan catabolism were investigated by probing tissue extracts 
for the aggrecan G1 domain and conditioned media for the NITEGE and DLS 
neoepitopes. Anti-G1 blots of tissue extracts indicated that a doublet migrating at ~65kDa 
is the dominant aggrecan species in day 0 tissue (Figure 4.8A). In separate blots for the 
NITEGE neoepitope (not shown), the 65kDa fragment was confirmed as the aggrecanase-
generated product. In addition, there was an apparent absence of high-molecular weight 
aggrecan species in the explant extracts, consistent with the weak safranin-O staining and 
relative abundance of NITEGE observed in the middle region of freshly isolated 
immature bovine meniscus (Figure 4.2). Following 8 days of culture, there was a modest 
accumulation of this aggrecan fragment in untreated controls indicating that aggrecanase 
activity is maintained and aggrecanase-generated fragments are retained within the tissue 
under the basal culture conditions. In contrast, IL-1-stimulated tissue was exhaustively 
Figure 4.8 Immunodetection of aggrecan and decorin in explant extracts (A) and 
aggrecan neoepitopes in the media (B). In (A), equal portions of extract sGAG at day 0 or 
8 were probed with anti-G1. Below, equal volumes of day 8 explant extracts were probed 
with anti-decorin. In (B), equal volumes of media pooled from days 2 & 4, 6 & 8, or 10 
& 12 were probed for the NITEGE and DLS neoepitopes. Filled and open arrowheads 
indicate migration of the 64kDa and 250kDa molecular weight markers, respectively. 
B A 
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depleted of aggrecan G1 by day 8. Addition of the aggrecanase inhibitor had no apparent 
effect on this depletion, suggesting that release of this fragment is not mediated by 
aggrecanases. Explants treated with the MMP inhibitor showed accumulation of the G1-
NITEGE fragment, demonstrating that aggrecanases are indeed active following IL-1 
stimulation and suggesting that MMPs participate in release of this fragment. Treatment 
with the broad spectrum metalloproteinase inhibitor enhanced retention of the G1-
NITEGE fragment, similar to untreated controls. 
To evaluate the presence of other proteoglycans in fibrocartilage explants, 
extracts were also probed with anti-decorin (Figure 4.8A, lower panel). IL-1-stimulated 
tissue appeared to be substantially depleted of decorin in comparison to untreated 
controls, suggesting that some of the proteoglycans released to the conditioned media 
were small proteoglycans. Interestingly, additional treatment with any of the inhibitors 
prevented this depletion. C-terminal processing of ADAMTS-4 confers decorin-
degrading activity to the aggrecanase111, and decorin is immobilized in fibrocartilage 
through favorable interactions with the collagen network27. Thus, it is feasible that IL-1-
stimulation induced aggrecanase-mediated decorin cleavage and MMP-mediated decorin 
release. 
Neoepitope analysis of conditioned media generally reflected observations of 
tissue extracts (Figure 4.8B). Untreated tissue released G1-NITEGE and DLS-reactive 
fragments at low, steady levels through 12 days of culture. Stimulation with IL-1 led to 
dramatic release of both fragments over days 2-4, and treatment with the aggrecanase 
inhibitor attenuated and prolonged NITEGE release and reduced release of DLS for the 
duration of the experiment. Treatment with the MMP inhibitor did not substantially alter 
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NITEGE release characteristics, but reduced DLS release, and the broad spectrum 
metalloproteinase inhibitor reduced release of both fragments to untreated control rates. 
Inhibition of IL-1-induced collagen degradation by selective and non-selective 
metalloproteinase inhibitors  
Conditioned media and explant digests were assayed for hydroxyproline to 
quantify the kinetics and degree of collagen depletion. Untreated controls exhibited low 
basal rates of collagen release, and IL-1-stimulation led to elevated release rates from day 
6 through day 12 (Figure 4.9A). Addition of the aggrecanase inhibitor had no effect on 
collagen release, confirming that fibrillar collagens are not substrates for aggrecanases. 
Treatment with the MMP or broad spectrum metalloproteinase inhibitor potently 
inhibited IL-1-induced collagen depletion, indicating that MMPs are primary mediators 
of collagen network destruction in this culture system. Assays of explant proteinase K 
Figure 4.9 Inhibition of IL-1-induced collagen release to media (A) and loss from 
fibrocartilage explants (B) by metalloproteinase inhibitors. Collagen in media and explant 
digests (after 0 or 12 days) was quantified by the chloramine-T/p-
dimethylaminobenzaldehyde reaction. Data are mean ± SEM, n = 6. ‡ indicate p<0.05 vs. 
IL-1. 
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digests similarly demonstrated that IL-1 stimulation triggers collagen destruction (Figure 
4.9B). The aggrecanase inhibitor showed no protective effects, whereas treatment with 
either the MMP or broad spectrum metalloproteinase inhibitor led to significantly higher 
amounts of explant collagen than IL-1-stimulated tissue after 12 days in culture. This is 
in contrast to articular cartilage, where aggrecanase inhibition delays the onset of 
collagen destruction175,246, suggesting that aggrecan does not “protect” the collagen from 
proteolytic attack in meniscal fibrocartilage as it appears to do in articular cartilage. 
Inhibition of IL-1-induced loss of tissue mechanical properties by selective and non-
selective metalloproteinase inhibitors  
To investigate the effects of IL-1-induced matrix degradation on tissue material 
properties, explants were mechanically tested in torsion and compression. The material 
properties presented are useful for describing the functional implications of ECM 
degradation in terms of the tissue’s tendency to deform under shear and compression. In 
both testing modes, day 0 tissue exhibited trends of increasing modulus (compression, 
E*, and shear, G*) with frequency, and these trends were maintained in untreated tissue 
following 12 days of culture (Figures 4.10A&B). Unlike the shear moduli, the 
compression moduli appeared to decrease in untreated tissue after 12 days in culture. 
Stimulation with IL-1 for 12 days led to loss of 75-80% of the day 0 tissue moduli, and 
treatment with the aggrecanase inhibitor did not reduce these losses. Addition of the 
MMP inhibitor appeared to have some beneficial effects on both material properties, 
indicating that preservation of the collagen network is sufficient to partially preserve both 
the compression and shear moduli. Tissue treated with the broad spectrum 
metalloproteinase inhibitor had significantly higher compression and shear moduli than 
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IL-1-only controls, and exhibited nearly complete blockade of IL-1-induced loss of tissue 
material properties in meniscal fibrocartilage. The efficacy of the broad spectrum 
inhibitor in preventing IL-1-induced fibrocartilage destruction is in marked contrast to the 
results presented in chapter 3 from studies with articular cartilage, and this disparity may 
be attributed to differences in tissue swelling characteristics. The low abundance of 
sGAG and structural features of the fibrocartilage ECM preclude explants from swelling 
as much as articular cartilage, so fibrocartilage may be less likely to undergo culture-
induced loss of material properties. These results indicate that aggrecanases and MMPs 
are primary contributors to IL-1-induced loss of tissue material properties in meniscal 
fibrocartilage. In addition, culture-induced changes in explant material properties appear 
to be tissue-dependent. 
 
Figure 4.10 Inhibition of IL-1-induced loss of dynamic compression (A) and shear (B) 
moduli by metalloproteinase inhibitors. Explants were harvested after 0 or 12 days in 
culture and tested in oscillatory unconfined compression (1.5% amplitude) and torsion 
(0.25% amplitude) at a 10% compression offset. Data are mean + SEM, n = 6. ‡ indicate 
p<0.05 vs. IL-1 
A B 
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4. 4 Discussion 
The results of this study show that aggrecanases mediate aggrecan catabolism in 
normal fibrocartilage and both aggrecanases and MMPs mediate IL-1-induced 
proteoglycan release in meniscal fibrocartilage. In articular cartilage, aggrecanase-
mediated cleavage of the aggrecan IGD (i.e., generation of the NITEGE neoepitope) is 
indicative of destructive ECM catabolism and is essentially undetected in immature 
tissue. Yet, the G1-NITEGE fragment was readily detected in freshly isolated immature 
fibrocartilage. In addition, IL-1-stimulated fibrocartilage explants stained intensely for 
the NITEGE neoepitope in the inner and middle regions, where sGAG density was 
initially highest. This “pathologic” aggrecanase activity appears to be normal in the 
immature bovine meniscus and can be elevated in inner and middle regions with IL-1 
treatment. This idea was further supported by the suppression of proteoglyan release from 
untreated basal cultures with the aggrecanase-selective and broad spectrum inhibitors. 
Cartilage explants also release proteoglycans to the culture medium under these culture 
conditions, but do not exhibit the aggrecanase-mediated IGD cleavage detected in the 
fibrocartilage-conditioned media. These data suggest that regulation of aggrecan 
catabolism in meniscal fibrocartilage is different from that in articular cartilage.  
Spatial- and age-variations in fibrocartilage proteoglycan content appear to be 
controlled in part by regional differences in aggrecanase activity. Interestingly, safranin-
O staining is more uniformly distributed and aggrecan gene expression is higher in 
menisci from mature animals than from immature tissues138,139,155, suggesting that these 
regional variations in proteoglycan density and turnover are dependent on developmental 
stage. Age-related changes in aggrecan catabolism were previously reported for meniscal 
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fibrocartilage, as high molecular weight (~250kDa) aggrecan core protein and the G1-
NITEGE species were abundant in immature bovine fibrocartilage, and G1-VDIPES (a 
product of MMP-mediated aggrecan cleavage) and a 100-130kDa fragment were 
additionally present in menisci from mature steer198. The current study extends previous 
work by describing regional differences in aggrecanase activity in the immature meniscus 
and links these differences to the normal development and region-specific functional 
demands of fibrocartilage. The mechanisms of aggrecan turnover may be conserved 
across several tissues, since aggrecan is less expressed and more extensively processed in 
tension-bearing regions of bovine deep flexor tendon in comparison to regions of 
compressed tendon173,236. Composition-function analysis of developing meniscal 
fibrocartilage may clarify the physiologic or mechanical benefits of partial aggrecan 
processing in different regions of the tissue. It is tempting to speculate, however, that 
aggrecan species of lower molecular weights may be more readily incorporated into 
fibrocartilage-specific structures, like the large bundles of collagen fibers. In addition, 
fibrochondrocytes may use partially processed aggrecan in the assembly of a pericellular 
matrix with composition and material properties specific to fibrocartilage. Indeed, the 
apparent benefits of differential aggrecan processing may be dependent on the length and 
time scales of the structures and processes studied. 
Studies of IL-1-stimulated joint tissues have been useful in understanding the 
spatiotemporal dynamics of cell-mediated ECM degradation characteristic of arthritic 
degeneration. There is extensive evidence of IL-1-induced proteoglycan release47,227, 
aggrecanase activity7,197, and loss of material properties in articular cartilage explants 
22,123. Less is known about the catabolic response of fibrocartilage to IL-1 or its effects on 
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tissue material properties. Fibrochondrocytes, similar to articular chondrocytes, generated 
the inflammatory molecules nitric oxide and prostaglandin E2 in response to IL-131,84, 
and IL-1 abrogated the biosynthetic response of fibrochondrocytes to mechanical 
stimuli207. Surface-zone meniscal fibrocartilage explants from mature bovines were 
stimulated with IL-1 and exhibited increased MMP-3 expression, aggrecanase activity, 
and sGAG release, and lower peak compression stresses (during a ramp to 10% 
compression) than untreated control tissue119. The results of the current study are 
consistent with previous reports and support the hypothesis that IL-1 initiates a catabolic 
cascade mediated by aggrecanases and MMPs in meniscal fibrocartilage. 
The catabolic response of fibrocartilage is distinct from that of articular cartilage. 
Most strikingly, both aggrecanases and MMPs were quantitatively important in IL-1-
induced proteoglycan release. Aggrecanases were the primary mediators of aggrecan 
cleavage in fibrocartilage, evidenced by the abundance of G1-NITEGE and absence of 
MMP-generated fragments in tissue extract immunoblots. Release of sGAG, however, 
was significantly reduced by treatment with an MMP inhibitor, and not with an 
aggrecanase inhibitor. In contrast, up ~95% of the sGAG release from IL-1-stimulated 
articular cartilage is attributed to ADAMTS-4 and -5. In the absence of MMP-mediated 
aggrecan cleavage, sGAG may be released through MMP-mediated denaturation and 
degradation of the collagen network. In addition, diffusion of aggrecanases to substrates 
embedded within the fiber bundles may be limited by MMP-mediated collagen 
degradation. The organized bundles of radially- and circumferentially-oriented collagen 
fibers in meniscal fibrocartilage may demarcate a distinct metabolic pool of aggrecan for 
which release from the ECM is rate-limited by the reaction of MMPs with collagen. Akin 
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to the fascicular structures present in tendon and muscle, these structures appear to 
contain relatively thick collagen fiber bundles. Proteases may diffuse readily in directions 
parallel to the bundles, whereas diffusion into or out of these structures would be 
substantially slower. Presumably, MMP-mediated disruption of the fascicular structures 
would enhance diffusion of collagen associated aggrecan out of these structures. Thus, 
MMPs may participate directly or indirectly in the release of proteoglycans from 
fibrocartilage. 
Treatment with an aggrecanase inhibitor delayed sGAG depletion in IL-1-
stimulated fibrocartilage, but not did reduce the total depletion over 12 days. The 
selectivity of this inhibitor for aggrecanases other than ADAMTS-4 and -5 is unknown, 
so it is possible that other aggrecanases (e.g., ADAMTS-1, -8, -9, and -15) are active later 
in the cascade. Alternatively, the inhibitor might be less potent against activated forms of 
ADAMTS-471,111 generated later in the culture period. Indeed, the same inhibitor was 
shown to delay but not block aggrecanase-mediated sGAG release in articular cartilage 
explants246. Interestingly, addition of the aggrecanase or broad spectrum inhibitor to 
unstimulated cultures substantially reduced sGAG release over 12 days (data not shown), 
suggesting that aggrecanases are primary mediators of homeostatic proteoglycan turnover 
under the basal culture conditions used in this study.  
Degeneration of articular cartilage involves exhaustive, aggrecanase-mediated 
depletion of proteoglycans followed by MMP-mediated degradation of collagen type 
II116. In contrast, proteoglycan depletion in meniscal fibrocartilage was mediated by both 
aggrecanases and MMPs and persisted during degradation of the collagen network. It is 
interesting that IL-1-induced release of low molecular weight G1-NITEGE occurred in 
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the presence of the MMP inhibitor, whereas release of the high molecular weight DLS-
positive aggrecan fragment (~250kDa) was reduced by this inhibitor treatment. These 
species may reside in distinct metabolic pools of aggrecan with differing susceptibility to 
MMP-mediated release, perhaps related to differential association with the collagen 
network. Understanding the distinct features (i.e., kinetics and mechanisms) of IL-1-
induced ECM destruction in meniscal fibrocartilage may aid in the identification of 
therapeutic targets and biomarkers for the treatment and diagnosis of arthritis. 
The mechanical responses of meniscal fibrocartilage to shear and compression 
depend on the composition, integrity, and organization of its ECM4,55,255. Fibrocartilage 
explants stimulated with IL-1 for 12 days contained 44% and 67% of the day 0 tissue’s 
sGAG and collagen, respectively. Correspondingly, the depleted tissue retained only 15-
40% (depending on test frequency) of the shear stiffness and 15-22% of the compressive 
stiffness of the fresh tissue. Explants treated with the MMP inhibitor retained 100% of 
the initial collagen but only 63% of the initial sGAG. This reduction in sGAG led to a 53-
57% reduction in shear stiffness and a 53-61% reduction in compressive stiffness, 
indicating that despite comprising a quantitatively minor ECM constituent (1-3% by dry 
weight)74, proteoglycans contribute substantially to the shear and compression properties 
of meniscal fibrocartilage. The dominant aggrecan species (G1-NITEGE) detected in this 
study lacks the chondroitin sulfate binding regions of the aggrecan core molecule, so the 
IL-1-induced release of sGAG might be attributable to degradation of other 
proteoglycans. Meniscal fibrochondrocytes have been shown to express mRNA for the 
large aggregating proteoglycan versican in immature rabbit89, and aggrecanase-mediated 
versican degradation has been observed in other tissues96,193,201,242. Although decorin was 
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cleaved by activated ADAMTS-4111 and biglycan was shown to be a substrate for MMP-
13147, both proteoglycans were resistant to degradation in IL-1-stimulated bovine nasal 
cartilage220. Immunoblots of tissue extracts revealed that after 8 days of IL-1 stimulation, 
fibrocartilage explants had lost approximately 50% of the initial decorin and treatment 
with an aggrecanase, MMP, or broad spectrum metalloproteinase inhibitor prevented this 
depletion. Proteoglycan degradation clearly compromises the mechanical function of 
meniscal fibrocartilage, and it is likely that both small and large proteoglycans are 
essential for proper tissue function. 
Metalloproteinase inhibitors have demonstrated utility as investigative tools for 
physiologic and pathophysiologic ECM turnover in orthopaedic tissues, and some 
inhibitors have entered clinical trials for treatment of arthritis22,33,37,49,134,175,212,249. The 
results of this study show through the use of aggrecanase- and MMP-selective inhibitors 
that both aggrecanases and MMPs participated in release of proteoglycan from IL-1-
stimulated fibrocartilage and that aggrecanases were primary mediators of aggrecan core 
protein cleavage in this tissue. In addition, a broad spectrum metalloproteinase inhibitor 
potently inhibited IL-1-induced proteoglycan depletion and loss of the tissue’s 
compression and shear properties. The inhibitors exhibited minimal cytotoxicity as they 
had no significant effects on explant viability over 12 days in culture. These results 
underscore the importance of metalloproteinases in normal and pathophysiologic 
proteoglycan turnover in the meniscus, and suggest that delivery of non-selective 
metalloproteinase inhibitors to the degenerative joint will have therapeutic benefit for the 
preservation of fibrocartilage composition and function.  
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These studies underscore the importance of aggrecan in fibrocartilage mechanical 
function. Despite the low initial abundance of aggrecan in immature meniscal 
fibrocartilage, loss of explant compression and shear properties aligned with loss of 
sGAG from the explants. On the other hand, the collagen network also played an 
important role in load bearing. Preservation of the collagen network appeared to partially 
preserve tissue material properties, which is consistent with a model describing the 
fibrocartilage ECM as a porous fiber-reinforced composite55. Cell-mediated degradation 
of the ECM composite and concomitant reductions in fibrocartilage stiffness would 
disrupt normal joint mechanics and may be early events in meniscal degeneration. 
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CHAPTER 5 
MECHANISMS OF TGF-B-INDUCED AGGRECAN TURNOVER IN 
CARTILAGE AND FIBROCARTILAGE 
 
5.1 Introduction 
The healthy articular cartilage ECM is rich in aggrecan, a large aggregating 
proteoglycan glycosylated with up to 100 negatively charged sulfated glycosaminoglycan 
(sGAG) chains83. Aggrecan is trapped within the cartilage ECM through non-covalent 
binding to high molecular weight hyaluronic acid and entanglement with an extensive 
type II collagen network. The immobilization of charged sGAG generates an osmotic 
pressure that attracts water into the ECM and confers a biphasic, viscoelastic response to 
applied stresses that is critical to normal joint function48. The ECM of meniscal 
fibrocartilage is composed of a highly organized type I collagen network. Large collagen 
fibers are aligned circumferentially in the outer portions of the menisci to bear tensile 
hoop stresses139, and the inner region is rich in aggrecan and collagen type II110, 
consistent with its cartilage-like function of bearing primarily compressive loads. The 
aggrecan G1 (hyaluronan−binding) domain has been immunolocalized in meniscal 
fibrocartilage230 and age-related differences in safranin-O staining suggest that aggrecan 
density in the middle and outer regions of the menisci increases with age145. Data 
presented in chapter 4 shows that while aggrecan G1 is present throughout the developing 
meniscus, substantial proteolytic processing occurs in the middle and outer regions such 
that sGAG-containing portions of the core molecule are released. In contrast, aggrecan 
from age- and species- matched articular cartilage is primarily in full-length and other 
high molecular weight forms.  
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The apparently normal, though extensive, aggrecan processing in the middle and 
outer regions of developing menisci is characterized by aggrecanase-mediated cleavage 
of the aggrecan interglobular domain (IGD) and subsequent exposure of the NITEGE392 
neoepitope, which is typically associated with pathologic aggrecan catabolism in 
degenerative articular cartilage. Aggrecanolysis in articular cartilage has been studied for 
its role in progression of arthritis, and aggrecanase-, matrix metalloproteinase (MMP)-, 
and calpain-family proteases appear to be responsible for the bulk of normal and 
pathologic aggrecan processing in cartilage164,194,198. The contributions of these enzyme 
systems to fibrocartilage aggrecan turnover have not yet been described. In addition, the 
physiologic relevance or functional benefits of extensive aggrecan processing in the 
healthy, developing meniscus is unknown. 
The transforming growth factor−β (TGF-β) family of pleiotropic cytokines has 
been shown to have anabolic and anti-catabolic effects on articular cartilage 
explants133,148. TGF−β1 was detected in the synovial fluid of arthritic joints52, and 
appears to mediate the wound healing response24,76. The cartilage ECM is a reservoir of 
latent TGF−β1 that chondrocytes can engage through proteolytic processing of the latent-
TGF−β binding complex26,171. The TGF−β type I receptor (TGF−βRI) is a cell-surface 
receptor that dimerizes with TGF−β type II receptor upon binding with TGF−β and exerts 
kinase activity on intracellular signaling molecules to regulate expression of genes 
encoding downstream effectors of ECM remodeling (e.g., proteases and ECM 
molecules)79. For example, TGF−β1 has been shown to increase proteoglycan 
biosynthesis133,148 and expression of tissue inhibitor of metalloproteinases (TIMP) in 
chondrocytes240. Fibrochondrocytes in explants38,97, three-dimensional culture 
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scaffolds166,251, and monolayer221 also exhibited robust anabolic responses to TGF-β1 
stimulation. Interestingly, TGF-β stimulation elevated aggrecanase activity in cartilage 
explants151. TGF-β, along with other growth factor and cytokine signaling 
axes65,136,149,203,239, is a potent regulator of ECM remodeling in both cartilage and 
fibrocartilage. 
The aims of this study were to a) compare mechanisms of aggrecan turnover in 
articular cartilage and meniscal fibrocartilage, and b) describe the effects of TGF−β1-
induced ECM remodeling on the composition and material properties of native tissue and 
cell-agarose tissue constructs. Endogenous TGF-β signaling was characterized through 
the use of a potent and selective pharmacologic inhibitor of TGF-βRI. Pharmacologic 
protease inhibitors were used to evaluate the participation of aggrecanases, MMPs, and 
calpains in TGF−β1-stimulated ECM turnover and de novo assembly. Analysis of 
neoepitopes, the peptide sequences exposed upon cleavage of the aggrecan core protein, 
via antibodies raised to the C-terminal NITEGE392 and DLS12xx-13xx sequences afforded 
detection of aggrecanase- and calpain-specific aggrecanolysis, respectively. Immunoblots 
of SDS-PAGE-separated samples for G1-, G2-, and G3-bearing material were also used 
to identify aggrecan fragments by size. The results of this study highlight tissue- and cell-
type differences in the mechanisms and degree of aggrecanolysis between the tissues, and 
implicate all three protease systems examined in fibrochondrocyte-mediated aggrecan 
turnover. 
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5.2 Materials & Methods 
Reagents and antibodies  
High glucose Dulbecco’s modified Eagle’s medium (DMEM), 
antibiotic/antimycotic solution containing 100U/mL penicillin, 100µg/mL streptomycin, 
and 0.25µg/mL amphotericin B, 1% non-essential amino acids (NEAA), 1% N-(2-
hydroxyethyl)-piperazine-N'-2-ethanesulfonic acid (HEPES), trypsin-
ethylenediaminetetraacetic acid, proteinase K, and Dulbecco’s phosphate buffered saline 
(DPBS) were from Invitrogen (Carlsbad, CA). Antibodies to aggrecan G1, G2, G3, and 
the NITEGE and DLS neoepitopes were provided by Dr. John Sandy (Shriner’s Hospital 
for Children, Tampa, FL). The antibody LF-94 to bovine decorin was provided by Dr. 
Larry Fischer (NIDCR, Bethesda, MD). Guanidine hydrochloride, protease-free 
chondroitinase ABC, keratanase I, agarose, Hoechst 33258 dye, non-immune rabbit IgG, 
and alkaline phosphatase-conjugated anti-rabbit secondary antibody were from Sigma 
(St. Louis, MO). ITS+ Premix was from BD Biosciences (San Jose, CA). Keratinase II 
was from Associates of Cape Cod (Falmouth, MA). Dimethylmethylene blue (DMMB) 
was from Polysciences (Warrington, PA). Recombinant human TGF-β1 was from R&D 
Systems (Minneapolis, MN). Protease inhibitor cocktail containing 
ethylenediaminetetraacetic acid, 4-(2-aminoethyl)benzenesulfonylfluoride, leupeptin, E-
64, and aprotinin was from Calbiochem (San Diego, CA). The chemifluorescent substrate 
ECF was from Amersham (Piscataway, NJ). 
Small-molecule metalloproteinase inhibitors (RO3310769, aggrecanase-selective; 
RO1136222, MMP-selective) were provided by Roche – Palo Alto (Palo Alto, CA). 
Detailed selectivity profiles of these inhibitors have been reported previously246. Briefly, 
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in vitro enzyme activity assays showed that the aggrecanase-selective inhibitor was 
highly inhibitory against the aggrecanase ADAMTS-4, with a concentration of half-
maximal inhibition (IC50, lower values indicate greater inhibition) of 8nM, and IC50s > 
700nM for all MMPs tested. The MMP-selective inhibitor inhibited most MMPs tested 
with IC50s  50nM, with the exceptions of MMP-1 and -7, but did not prevent ADAMTS-
4 activity (IC50 = 7200nM). The competitive, cell-permeable calpain inhibitor 
carbobenzoxy-valyl-phenylalanial, also known as MDL-28170, was from Calbiochem. 
The manufacturer has reported an IC50 of 8nM against calpains I and II for this 
compound. Equimolar stock solutions of the protease inhibitors were prepared with 
dimethylsulfoxide (DMSO).  
A potent and selective pharmacologic inhibitor, SB431542, of TGF-β type 1 
receptor kinase was from Tocris Biosciences (Ellisville, MO). The inhibitor has been 
reported to have an IC50 of 94nM against the receptor kinase and approximately 100-fold 
selectivity over other kinases, such as p3899.  
Tissue Culture 
Articular cartilage and meniscal fibrocartilage were harvested from immature 
bovine stifle joints under aseptic conditions. Cartilage explants (n = 84) were taken from 
the patellar groove and femoral condyles using a 4mm diameter biopsy punch, and 
fibrocartilage explants (n = 84) were taken from the middle regions of medial and lateral 
menisci. Surface zone tissue was trimmed away and explants were cut to 2mm thick 
using a custom cutting block. The explants were moved to 48-well plates and cultured 
overnight in 0.5mL basal medium consisting of high glucose DMEM, ITS+, 1% NEAA, 
1% HEPES, 82µg/mL L-ascorbic acid 2-PO4, and 100U/mL penicillin, 100µg/mL 
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streptomycin, and 0.25µg/mL amphotericin B. The following day (day 0), some explants 
were removed as day 0 samples (n = 6/tissue type) and stored at -20°C in PBS with 
protease inhibitors.  
Explants were cultured for up to 10 days in basal medium with carrier (DMSO, 
0.05%), basal medium with 2µM SB431542 (TGF-β type I receptor inhibitor, TGF−βRI 
inhibitor), or with 5ng/mL TGF-β1 and carrier. Groups of TGF-β1-stimulated explants 
were additionally treated with 5µM aggrecanase-selective inhibitor, 5µM MMP-selective 
inhibitor, or 5µM calpain inhibitor III. Media were collected, replaced, and prepared with 
fresh cytokine and inhibitors every 48h; collected media were stored at -20C for 
biochemical analysis. At the end of the experiment, explant viability was evaluated by the 
WST-1 assay. The explants were rinsed in DPBS and stored at -20C in DPBS with 
protease inhibitors. 
For a second experiment using cell-agarose constructs, articular chondrocytes 
(ACs) and meniscal fibrochondrocytes (MFCs) were isolated from fresh immature bovine 
stifle joint tissues. Articular cartilage from the patellar groove and femoral condyles and 
fibrocartilage from the medial and lateral menisci were harvested aseptically. The tissues 
were minced to ~1mm3, weighed, and moved to T75 flasks. Following a 30min digestion 
at 37C with 0.025% trypsin/EDTA in Ca++/Mg++-free DPBS, the tissue was digested in 
0.4% collagenase/DMEM at 37C on a shaker plate. After 48h, the tissue digests were 
filtered through a sterile 37µm-pore size nylon mesh, and cell viability and counts were 
quantified using a Vi-Cell Analyzer. Cell-agarose constructs were prepared by mixing 
equal volumes of 45C 3% (w/v) agarose/DPBS and cells in DMEM at 20 million cells 
per milliliter. The molten cell-agarose suspensions were thoroughly mixed and cast 
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between 2 parallel glass plates approximately 2.5mm apart. The cell-agarose slab was 
polymerized for 20min at 4C, and cylindrical samples were cut from the slab using a 
6mm diameter biopsy punch (n = 48/cell type). Cell-agarose constructs were equilibrated 
overnight in basal medium containing high-glucose DMEM, ITS+, NEAA, HEPES, 
82µg/mL L-ascorbic acid-2-PO4, penicillin, streptomycin, amphotericin B. ITS+ has been 
shown to support proteoglycan synthesis and proliferation rates comparable to serum 
supplementation for chondrocytes in agarose, and thus affords use of a serum-free 
medium 113. Day 0 constructs (n = 6/cell type) were evaluated for cell viability by the 
WST-1 assay, rinsed in DPBS, moved to DPBS with protease inhibitors, and stored at 4C 
before undergoing mechanical tests within 72h. 
Constructs were cultured for up to 16 days in basal medium with carrier (DMSO, 
0.01%), or basal medium with 10ng/mL TGF-β1 with carrier. Groups of TGF-β1-
stimulated constructs were additionally treated with 1µM aggrecanase inhibitor, 1µM 
MMP inhibitor, or 1µM calpain inhibitor. Media were collected, replaced, and prepared 
with fresh cytokine and inhibitor every 48h; collected media were stored at -20C. At the 
end of the experiment, cell-agarose constructs were either fixed in 10% NBF for 4h at 4C 
and embedded in paraffin for histologic analysis (n = 2/treatment/cell type) or evaluated 
for viability by the WST-1 assay, rinsed in PBS, and stored in DPBS with protease 
inhibitors at 4C prior to mechanical testing. 
Mechanical Testing 
 Prior to mechanical testing, explants were thawed to room temperature and 
weighed, and explant thickness and diameter were measured at 3 points using digital 
calipers. All tests were performed at room temperature in DPBS and protease inhibitors. 
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Specimens were first tested in unconfined compression on an ELF3100 uniaxial testing 
frame (Enduratec, Minnetonka, MN) using a 500g button-type load cell (Sensotec, 
Columbus, OH). Each explant was positioned between parallel, impermeable platens and 
preloaded to 10-20mN to ensure contact. Following compression to 10% strain at 
0.1mm/min and relaxation for 30min, each sample underwent oscillatory compression at 
0.01, 0.1, and 1Hz and 1.5% strain amplitude. Samples were then equilibrated to the free-
swelling state in DPBS with protease inhibitors for 30min, and positioned between 
roughened, impermeable, parallel plates on a CVO120 rheometer (Bohlin, East 
Brunswick, NJ). Following compression to 10% strain and 30min relaxation, each 
explant underwent oscillatory torsion at 0.5Hz and nominal 0.25% (0.017rad) shear strain 
amplitude. After mechanical testing, explants were frozen and lyophilized prior to 
biochemical analysis (described below). 
Cell-agarose constructs were also tested in unconfined oscillatory compression. 
Prior to testing, each construct’s mass, thickness, and diameter were measured. Each 
construct was positioned between impermeable platens on an ELF3100 and brought into 
contact with the platens by application of a 10mN preload. After compression to 10% 
strain at 0.1mm/min and relaxation for 1200s, each construct was loaded in oscillatory 
compression at 0.05, 0.1, 0.5, and 1Hz and 3% strain amplitude. After testing, constructs 
were frozen and lyophilized prior to biochemical analysis. 
Total harmonic distortions were typically less than 5% for oscillatory 
compression and shear tests. Compressive and shear stress amplitudes at the fundamental 
loading frequency were determined by Fast Fourier Transform analysis of load and 
torque signals, respectively, and known sample geometries. Dynamic moduli were 
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calculated from the ratio of the measured stress amplitude to applied strain amplitude. 
The tangent of the phase angle was calculated by taking the ratio of loss to storage 
moduli. 
Biochemistry 
 Conditioned media from both experiments were assayed for released sGAG by 
the DMMB assay using chondroitin sulfate standards diluted in basal medium. Following 
mechanical testing and lyophilization, explants and constructs were weighed and 
extracted in 1mL extraction buffer containing 4M guanidine hydrochloride, 10mM MES, 
50mM sodium acetate, 5mM iodoacetic acid, and protease inhibitor cocktail, at pH 6.5. 
Extractions were performed for at least 24h at 4C on a rocker. Explant and cell-agarose 
extracts were assayed for sGAG by the DMMB assay, using chondroitin sulfate standards 
diluted in extraction buffer. The DNA content of construct extracts was also quantified by 
the Hoechst 33258 fluorometric assay with calf thymus DNA standards dissolved in 
extraction buffer 112. After extraction, explant and construct residues were frozen, 
lyophilized, weighed, and digested in 500uL 300µg/mL proteinase K/100mM ammonium 
acetate overnight at 60C. Cell-agarose residues were then melted at 100C for 10min and 
further digested with 3U (15µL) agarase overnight at 43C. Explant and construct digests 
were assayed for sGAG content.  
For both experiments, equal volumes of guanidine extracts were pooled from 
samples within a treatment group and added to 3 volumes of ice cold ethanol/5mM 
sodium acetate for overnight precipitation of sGAG at -20C. In addition, equal volumes 
of day 16 conditioned media from cell-agarose constructs were pooled from samples 
within a treatment group and ethanol precipitated. Precipitates were centrifuged at 21k x 
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g for 30min, the supernatants were removed, and the pellets were dried for 0.5-2h at room 
temperature. Pellets were resuspended in buffer containing 50mM Tris hydrochloride, 
50mM sodium acetate, 10mM EDTA, and protease inhibitors, at pH 7.5 and assayed for 
sGAG. Precipitations typically yielded 80% recovery of sGAG from guanidine extracts 
and conditioned media. Samples were deglycosylated by incubation with chondroitinase 
ABC, keratanase I, and keratanase II overnight at 37C. Samples were frozen, lyophilized, 
and resuspended in sample buffer containing 3M Urea, Tris-glycine sample buffer, and 
dithiothreitol. Extracts of articular cartilage were resuspended in a 10-fold higher volume 
of sample buffer to accommodate higher sGAG concentrations. 
Prior to electrophoretic separation, samples were melted at 110C for 5min and 
loaded into 4-12% Tris-glycine gradient gels. The samples were separated at 200V for 
45min, and transferred to nitrocellulose at 50-100V for 1-2h on ice. Membranes were 
blocked in blocking buffer for 30min at room temperature and incubated with primary 
antibodies diluted 1:1000-1:5000 for 1h at room temperature or overnight at 4C. 
Following incubation with secondary antibody (1:10,000 dilution) for 1h at room 
temperature, membranes were developed in ECF for 5min and imaged on a Fuji-
FLA3000. Membranes initially probed with anti-NITEGE antisera (1:1000 dilution) were 
subsequently stripped in 1x Re−Blot reagent (Chemicon) for 10min at room temperature 
and reprobed with anti-G1 antisera (1:5000). Membranes initially probed with anti-DLS 
antisera (1:2000) were stripped (as described above) and reprobed with anti-G2 antisera 
(1:4000). Membranes initially probed with the anti-G3 antisera were stripped and 
reprobed with the LF-94 anti-decorin antisera (1:5000).  
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Statistics 
 Data were analyzed using analysis of variance (ANOVA) and the general linear 
model in MINITAB Release 14. Pairwise comparisons between TGF-β1-stimulated 
groups were performed by Dunnett’s test with TGF−β1-only as controls. Significant 
differences were denoted by p<0.05, and trends were denoted by p<0.1. 
5.3 Results 
Explant Study 
Explant Mitochondrial Activity 
 Cell activity following 10 days of culture was assessed by the WST-1 assay. The 
tetrazolium salt WST-1 undergoes conversion to formazan by the mitochondria of live 
cells and spectrophotometric detection of the formazan product permits quantification of 
the differences in aggregate cell activity, which may be influenced by cell viability, 
metabolic activity, and cell number. Treatment with 2µM TGF-βRI inhibitor or 
stimulation with 5ng/mL TGF-β1 had no significant effect on the viability of articular 
cartilage explants (Figure 5.1). In contrast, the viability of meniscal fibrocartilage 
explants was reduced to approximately 60% of basal controls by treatment with the TGF-
βRI inhibitor and increased by approximately 30% over basal controls with TGF-β1 
stimulation. TGF- β1-stimulated articular cartilage treated with 5µM MMP-selective 
inhibitor showed significantly lower viability than TGF-β1-only controls, but was not 
lower than basal controls. 
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Tissue Swelling Characteristics 
 Explant hydration, which influences tissue sGAG concentration and material 
properties, was quantified by measuring explant wet mass (Figure 5.2A) and dry mass 
and calculating the percent water (Figure 5.2B). Articular cartilage explants cultured in 
basal medium for 10 days exhibited a 2-fold increase in wet mass and concomitant 13% 
increase in water fraction over day 0 explants. Addition of a TGF−βRI inhibitor further 
increased tissue swelling over basal controls. Cartilage explants stimulated with TGF−β1 
had significantly lower wet masses and water fractions than basal controls, indicating that 
TGF−β1-driven ECM remodeling promotes maintenance of native tissue composition. 
TGF−β1-stimulated cartilage additionally treated with an MMP-selective inhibitor 
appeared to have the lowest propensity to swell, as indicated by strong trends toward 
lower wet mass and water fraction than TGF−β1-only controls (p=0.057 and 0.063, 
respectively). Conversely, addition of a calpain-selective inhibitor to TGF−β1-stimulated  
Figure 5.1 Effects of pharmacologic inhibitors and TGF-β1 stimulation on explant 
mitochondrial activity. Mitochondrial activity was quantified by spectrophotometric 
detection of the formazan product in the supernatants of explants incubated with the 
tetrazolium salt WST-1 for 2h at 37C. Data are mean + SEM with n=6. # denotes 
significant difference (p<0.05) vs. basal.  denotes p<0.05 vs. TGF-β1-only controls. 
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Figure 5.2 TGF-β1 stimulation reduced explant swelling in articular cartilage and 
meniscal fibrocartilage as indicated by wet mass (A) and percent water (B). Data are 
mean + SEM, and n = 6. # denotes p<0.05 vs. basal.  denotes p<0.05 vs. tissue-matched 
TGF-β1-only controls. 
A B 
cartilage significantly increased swelling characteristics over TGF−β1-only controls. 
Fibrocartilage explants had lower water fractions than articular cartilage at day 0 and 
were much less likely to swell under any condition, although there was a strong trend for 
increased wet mass in TGF−β1-stimulated explants over basal controls (p=0.055). These 
results underscore important differences between cartilage and fibrocartilage swelling 
characteristics and implicate TGF−β, MMP, and calpain activity in the regulation of 
cartilage tissue hydration. In addition, explantation and serum-free culture of cartilage 
and fibrocartilage caused structural changes in the ECM that are likely to contribute to 
apparent changes in tissue composition. 
Proteoglycan Content 
 Proteoglycan turnover was evaluated by quantifying the distribution of 
proteoglycans in conditioned media, explant extracts, and residue digests (Figure 5.3).  
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For all experimental groups, articular cartilage explants had total explant (extract + 
digest) sGAG well above day 0 tissue (Figure 5.3A), indicating that chondrocyte 
proteoglycan synthesis is maintained under the basal culture conditions used in this study. 
Cartilage treated with a TGF−βRI inhibitor had significantly lower total explant content 
than basal controls, and TGF−β1-stimulated cartilage had modestly, but significantly, 
lower cumulative sGAG release than basal controls. These data suggest that endogenous 
TGF−β signaling is active in explanted cartilage, perhaps due to a greater abundance of 
TGF-β in the cartilage ECM. In sharp contrast, meniscal fibrocartilage treated with basal 
medium or basal medium supplemented with TGF−βRI inhibitor appeared to have very 
low proteoglycan synthesis (Figure 5.3B). These groups released approximately 33% of 
the day 0 tissue sGAG content to the media over 10 days in culture, and had a net loss of 
total explant sGAG. Fibrocartilage stimulated with TGF−β1, however, had significantly 




Figure 5.3 TGF-β1 stimulated sGAG accumulation in meniscal fibrocartilage. Following 
0 or 10 days in culture, immature bovine cartilage and fibrocartilage explants were 
treated with 4M guanidine to extract intact proteoglycans and residues were digested with 
proteinase K. Released sGAG was the cumulative content in conditioned media. Note the 
10-fold difference in scale between (A) and (B). Data are mean + SEM with n=6. # 
denotes significant difference (p<0.05) in total explant content (extract + digest) vs. 












































































































and retention. Based on these results, it appears that there was minimal endogenous 
TGF−β signaling in explanted fibrocartilage, and that fibrochondrocytes had a potent 
anabolic response to TGF−β1 stimulation. It is important to note that the initial sGAG 
content of fibrocartilage explants was approximately 10% of cartilage explants. 
Collectively, these data show important baseline differences in proteoglycan abundance 
and turnover between cartilage and fibrocartilage. Cartilage explants have an ECM rich 
in sGAG and relatively high proteoglycan production driven in part by endogenous TGF-
β. On the other hand, fibrocartilage explants exhibit low proteoglycan production under 
the basal serum-free conditions used in this study, and respond to TGF-β1 stimulation 
with substantially increased proteoglycan production. Fibrocartilage explants also 
consistently released a larger fraction of sGAG to the media than cartilage explants, and 
structural features of the fibrocartilage ECM (e.g., highly organized and oriented collagen 
bundles) may have facilitated diffusion of proteoglycans into the culture media. 
 To examine the roles of different enzyme systems in proteoglycan turnover in 
tissue explants, TGF−β1-stimulated tissues were additionally treated with an 
aggrecanase-, MMP-, or calpain-selective inhibitor. Consistent with a primarily anabolic 
and anti-catabolic response to TGF−β1, protease inhibitor treatments did not substantially 
alter proteoglycan distributions. TGF−β1-stimulated cartilage explants treated with the 
MMP-selective inhibitor had significantly lower total explant sGAG than TGF−β1-only 
controls, suggesting that MMPs were participating in the TGF−β-signaling axis. These 
data indicate that the aggrecanase, MMP, and calpain protease systems are not primary 
mediators of proteoglycan turnover (i.e., actively cleave proteoglycans) in TGF−β1-
stimulated cartilage and fibrocartilage. Rather, TGF-β1 may have suppressed catabolism 
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under these culture conditions. It is also possible, however, that higher doses of these 
inhibitors would have more pronounced effects on the distribution of sGAG in these 
tissues. 
 Total explant sGAG content was normalized by explant water content as a 
measure of sGAG concentration and a predictor of explant mechanical properties. 
Cartilage explants cultured for 10 days in basal medium had a lower sGAG concentration 
than day 0 tissue, and addition of the TGF−βRI inhibitor led to significantly lower sGAG 
concentration than basal controls (Figure 5.4A). Stimulation with TGF−β1 restored 
sGAG concentration of cultured cartilage to that of day 0 tissue. Similarly, fibrocartilage 
explants cultured for 10 days in basal medium had substantially lower sGAG 
concentration than day 0 tissue (Figure 5.4B), consistent with the loss of total explant 
sGAG. In contrast to cartilage, fibrocartilage treated with the TGF−βRI inhibitor did not 
Figure 5.4 TGF-β1 stimulation promoted maintenance of proteoglycan concentration in 
articular cartilage (A) and meniscal fibrocartilage (B). Proteoglycan concentration was 
calculated from total explant sGAG content (extract + digest) and the difference between 
explant wet and dry weights. Note the 7-fold difference in scales between (A) and (B). 
Data are mean + SEM, and n=6. # denotes p<0.05 vs. basal.  denotes p<0.05 vs. TGF-








show a further decrease in sGAG concentration beyond that of basal controls. As in 
cartilage, however, fibrocartilage stimulated with TGF−β1 had sGAG concentrations 
comparable to day 0 tissue.  
 Despite showing modest differences in absolute sGAG abundance, TGF−β1-
stimulated tissue additionally treated with protease inhibitors demonstrated some 
differences in explant sGAG concentration from TGF−β1-only controls. In TGF−β1-
stimulated articular cartilage, treatment with a calpain-selective inhibitor led to 
significantly lower sGAG concentration than TGF−β1-only controls. In TGF−β1-
stimulated fibrocartilage explants, none of the protease inhibitor treatments led to 















Immunodetection of Proteoglycans 
 In order to identify aggrecan species present in cultured cartilage and 
fibrocartilage tissue, explant extracts were analyzed by Western blot using antibodies to 
domains and neoepitopes of the aggrecan core protein. Blots probed with an antibody to 
the G1 (HA−binding) domain show that day 0 articular cartilage explants contain an 
abundance of aggrecan with a wide variation in degree of processing (Figure 5.5A). 
Aggrecan G1 species as small as 50kDa and as large as the full length (~350kDa) were 
present, as well as abundant ~250kDa and ~120kDa species. After 10 days of culture in 
basal medium or basal medium supplemented with TGF−βRI inhibitor, the G1 profile of 
the explants did not change substantially. Stimulation with TGF−β1 did not dramatically 
alter the size distribution of G1−bearing aggrecan species in the cartilage explants, nor 
did addition of selective protease inhibitors. In contrast, the size of G1-positive aggrecan 
species in day 0 meniscal fibrocartilage extracts was more restricted to a high molecule-
Figure 5.5 Characterization of aggrecan in fresh and cultured articular cartilage (A) and 
meniscal fibrocartilage (B). Explants were cultured in serum-free media for 0 or 10 days. 
Equal volumes of deglycosylated tissue extracts were separated by SDS-PAGE. 
Membranes were probed with anti-NITEGE, stripped, and reprobed with anti-G1. 
A B 
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weight band ~250kDa, a broad, faint 120kDa band, and a doublet at 65-70kDa. After 10 
days of culture in basal medium or basal medium supplemented with TGF−βRI inhibitor, 
fibrocartilage explants were depleted of high molecular weight aggrecan species but 
retained the low molecular weight doublet. Treatment with TGF−β1 restored the presence 
of high-molecular weight aggrecan, but did not restore the mid-molecular weight species 
detected in day 0 tissue, and addition of selective protease inhibitors did not further alter 
the size distribution of G1 species in fibrocartilage. The 65-70kDa G1 doublet in day 0 
and cultured fibrocartilage was identified as the G1-NITEGE aggrecanase-generated 
aggrecan fragments using an anti-NITEGE antibody, and these fragments were strikingly 
absent from cartilage extracts. These data highlight intrinsic differences in proteoglycan 
processing between articular cartilage and meniscal fibrocartilage and indicate, along 
with total explant sGAG data (Figure 5.2), that TGF−β1 stimulation promotes synthesis 
and retention of aggrecan in fibrocartilage explants. 
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 To further characterize the proteoglycans in fresh and cultured explants, explant 
extracts were probed for the G3 domain of aggrecan and the small proteoglycan decorin. 
G3 blots of articular cartilage explants confirmed that full length aggrecan is present in 
fresh and cultured tissue, indicated by the high molecular weight band. In addition, a 
band migrating at 120kDa was observed in all tissue extracts and indicates that a subset 
of the aggrecan population has undergone moderate C-terminal cleavage in fresh and 
cultured tissue. The size of this fragment suggests that cleavage occurred at the 
TAQE1791—1792AGEG bond, a substrate for aggrecanases200,224, but peptide sequencing 
or additional neoepitope immunoblots are required for positive identification. 
Fibrocartilage extracts exhibited a different pattern of aggrecan processing as assessed by 
G3 reactivity. As in articular cartilage, fresh fibrocartilage contained full-length aggrecan 
and a species migrating at 120kDa. After 10 days of culture in basal medium or basal 
Figure 5.6 Further Characterization of proteoglycans in fresh and cultured articular 
cartilage (A) and meniscal fibrocartilage (B). Explants were cultured in serum-free media 
for 0 or 10 days. Equal volumes of deglycosylated tissue extracts were separated by SDS-
PAGE. Membranes were probed with anti-G3, stripped, and reprobed with LF-94 anti-
decorin. The apparent shift in migration of high molecular weight bands in lanes 1-3 of 




medium with TGF−βRI inhibitor, the high molecular weight G3 species was absent and a 
fragment migrating at ~55kDa emerged. Stimulation with TGF−β1 restored the presence, 
but not the abundance, of full-length G3 positive species to the explants, and additional 
treatment with protease inhibitors did not substantially alter the restoration of full-length 
aggrecan or emergence of the low molecular weight fragment. All three protease 
inhibitors did appear to promote accumulation of full-length aggrecan, suggesting that 
aggrecanases, MMPs, and calpains are active in TGF-β1-stimulated fibrocartilage. Blots 
of cartilage and fibrocartilage extracts probed with the LF-94 antibody to bovine decorin 
indicated a single band migrating at ~55kDa. Band intensity was in similar for both 
tissues and all conditions, suggesting that differences in sGAG content (Figure 5.2) were 
not attributable to differences in decorin abundance. Collectively, these results support 
the concepts that aggrecan is a major proteoglycan in both cartilage and fibrocartilage 
and that aggrecan turnover is fundamentally different in these two tissues. 
Tissue Material Properties 
 The effects of TGF−β-driven ECM remodeling on cartilage and fibrocartilage 
material properties were investigated by oscillatory torsion and oscillatory unconfined 
compression tests. Culture of cartilage explants for 10 days in basal medium led to a 
~65% reduction in shear modulus (0.5Hz, 0.05% shear strain amplitude) from day 0 
tissue, and culture in basal medium with a TGF−βRI inhibitor led to a further, significant  
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decrease in shear modulus from basal controls. TGF−β1-stimulated cartilage explants 
exhibited similar shear properties to basal controls. Fibrocartilage explants cultured in 
basal medium underwent a 75% reduction in shear modulus (0.5Hz, 0.25% shear strain 
amplitude), but in contrast to articular cartilage, additional treatment with a TGF−βRI 
inhibitor did not induce further loss of this property. These results parallel explant sGAG 
concentration (Figure 5.4) for both tissue types, supporting the idea that explant sGAG 
concentration is a predictor of tissue material properties. It is important to note that 
TGF−β1-stimulated cartilage had sGAG concentrations similar to day 0 samples, yet 
exhibited substantially lower shear properties than the day 0 tissue, and in contrast, 
TGF−β1-stimulated fibrocartilage maintained both sGAG concentration and shear 




Figure 5.7 Retention of explant shear properties was enhanced by TGF-β1 stimulation in 
meniscal fibrocartilage (B) and by an MMP-selective inhibitor in articular cartilage (A). 
Dynamic shear moduli were determined by oscillatory torsion tests at 0.5Hz. Cartilage 
and fibrocartilage explants were tested at 0.05% and 0.25% shear amplitude, respectively. 






 The roles of aggrecanases, MMPs, and calpains on TGF−β1-mediated 
preservation of explant shear properties were investigated through the use of selective 
protease inhibitors. In both cartilage and fibrocartilage, the aggrecanase and calpain 
inhibitors had no significant effect on tissue shear modulus but treatment with an MMP-
selective inhibitor appeared to enhance retention of this property over TGF−β1-only 
controls, though this effect was not significant. Structural damage to the collagen network 
during explantation may activate latent MMPs in the ECM that denature or degrade 
collagen during culture. Alternatively, relief of pre-stresses in the collagen network 
during explantation may induce MMP secretion and activation via aberrant 
mechanotransduction signaling. In either case, blockade of enzymatic collagen 
destruction with the MMP inhibitor would feasibly have beneficial effects on 
maintenance of tissue shear properties. 
 Unconfined compression tests showed that cartilage and fibrocartilage explants 
cultured in basal medium for 10 days also underwent substantial loss of tissue 
compression properties. Cultured cartilage explants exhibited a 6-fold decrease in 
dynamic compression modulus that was consistent across the 0.01-1Hz test frequencies. 
Treatment with a TGF−βRI inhibitor led to a further and significant decrease in cartilage 
compression modulus. Cartilage stimulated with TGF−β1 had similar compression 
properties to the basal group. Fibrocartilage explants cultured in basal medium, basal 
medium with TGF−βRI inhibitor, or TGF−β1 all exhibited similar compression 
properties of approximately 33% of day 0 tissue properties. Addition of an MMP-
selective inhibitor to TGF−β1-stimulated explants appeared to increase compression 
properties over TGF−β1-only controls for both cartilage and fibrocartilage, although 
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these increases were not statistically significant. Treatment of either tissue with an 
aggrecanase- or calpain-selective inhibitor yielded no significant differences in explant 
compression properties in comparison with TGF−β1-only controls. 
Cell-Agarose Study 
Construct Mitochondrial Activity and DNA Content 
 To further investigate mechanisms of TGF−β1-induced aggrecan deposition and 
remodeling in cartilage and fibrocartilage, chondrocytes and fibrochondrocytes isolated 
from immature bovine tissues were suspended in agarose and cultured under serum free 
conditions for up to16 days. Quantitative measurements of mitochondrial activity at days 






Figure 5.8 Maintenance of explant compression properties was mediated by TGF-β in 
cartilage and by MMPs in both cartilage (A) and fibrocartilage (B). Compression moduli 
were determined by oscillatory unconfined compression (1.5% compression amplitude) 




pharmacologic inhibitors and cell proliferation over the course of the experiment (Figure 
5.9A). Culture for 16 days in basal or TGF−β1-supplemented media led to significant 
increases in both chondrocyte and fibrochondrocyte cell number over day 0 constructs. 
None of the inhibitors exhibited cytotoxic effects on either cell type. Rather, addition of a 
calpain-selective inhibitor significantly increased mitochondrial activity over TGF−β1-
only controls in both cell-types. Treatment with the MMP- or aggrecanase-selective 
inhibitors also increased the mitochondrial activity of fibrochondrocyte-agarose 
constructs over TGF−β1-only controls. To examine the possibility that the per-cell 
mitochondrial activity was in influenced by cytokine or inhibitor treatments, the DNA 
content of construct extracts (Figure 5.9B) was determined by fluorometric assay. A 
previous report indicated that guanidine could be used for efficient, near-total extraction 
of DNA from cell-agarose constructs91. TGF-β1-stimulation of both chondrocytes and 
fibrochondrocytes led to higher construct DNA contents than day 0 constructs and day 16 
Figure 5.9 Pharmacologic protease inhibitors did not exhibit cytotoxic effects in cell-
agarose constructs, as indicated by mitochondrial activity (A) and DNA content (B). Cell-
agarose constructs were cultured for 0 or 16 days in serum-free media. Data are mean + 




basal controls, indicative of TGF-β1-induced proliferation and consistent with the 
changes in mitochondrial activity. In sharp contrast to the WST-1 data, however, the 
DNA contents of calpain inhibitor-treated cell-agarose constructs were significantly 
lower than TGF-β1-only controls for both cell types. Thus, the calpain inhibitor modifies 
the responses of chondrocytes and fibrochondrocytes to TGF-β1 by inhibiting 
proliferation and increasing the per-cell mitochondrial activity. The physiologic basis for 
these perturbations is unknown, but may be related to inhibition of calpain-mediated 
activation of latent TGF-β in the pericellular matrix1. 
These results show that these pharmacologic protease inhibitors are not cytotoxic 
at the dose used (1µM) and indicate that, consistent with previous reports 38,82, 
chondrocytes and fibrochondrocytes proliferate in response to stimulation with TGF−β1. 
In addition, the calpain inhibitor consistently elevated the per-cell mitochondrial activity 
of these cells for unknown reasons. 
Construct Proteoglycan Content 
 Proteoglycan turnover in cell-agarose constructs was initially assessed by 
assaying the conditioned media for released sGAG. The cumulative sGAG released to the 
media was comparable between cell types and increased substantially with TGF−β1 
stimulation (Figure 5.10). Cumulative sGAG release from chondrocyte-agarose 
constructs was significantly reduced by treatment with an aggrecanase-, MMP-, or 
calpain-selective inhibitor to 89%, 89%, and 78% of TGF−β1-only controls, respectively. 
In contrast, the aggrecanase and MMP inhibitors had no significant effects on sGAG 
release from fibrochondrocyte-agarose constructs, and treatment with the calpain-
selective inhibitor increased sGAG release by 16%. These results indicate that  
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mechanisms of proteoglycan turnover vary by cell type. 
 Proteoglycan turnover in cell-agarose constructs was further characterized by the 
distribution of sGAG between the construct and media compartments (Figure 5.11). 
TGF−β1-stimulated constructs of both cell types exhibited significantly higher total 
construct sGAG (extract + digest) than basal controls, consistent with the expected 
anabolic responses to TGF−β. Additional treatment of chondrocytes with the calpain 
inhibitor led to significantly higher construct sGAG content than TGF−β1-only controls. 
Fibrochondrocyte constructs additionally treated with an aggrecanase-, MMP-, or 
calpain-selective inhibitor exhibited significantly higher total construct sGAG than 
TGF−β1-only controls. Perhaps the most striking feature of these data is that the 
proportion of sGAG released to the media was substantially higher for fibrochondrocyte 
(~50%) than chondrocyte constructs (~15%). These results add further evidence of 
intrinsic differences in ECM assembly and turnover between chondrocytes and meniscal  
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Figure 5.10 Cumulative sGAG release in articular chondrocyte (AC, A)- and 
fibrochondrocyte (MFC, B)-agarose constructs increased with TGF-β1 stimulation and 
was differentially modulated by selective protease inhibitors. Data are mean ± SEM with 
n=8. #,, § denote p<0.05 between TGF-β1-only and TGF + Agg’ase Inh, TGF + MMP 
Inh, and TGF + Calpain Inh groups, respectively. 
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fibrochondrocytes, and indicate that structural differences between cartilage and 
fibrocartilage are not enough to explain the tissue-specific proteoglycan distributions 
observed in explants.  
Immunodetection of Aggrecan 
 Aggrecan processing in cell-agarose constructs was examined by Western blot of 
construct extracts. G3 (Fig 5.12, upper left panel), G2 (middle left), and G1 blots (data 
not shown) indicated the presence of full length aggrecan in chondrocyte-agarose 
constructs cultured for 16 days in basal serum-free medium. In addition, the presence of a 
G3-positive band migrating at 120kDa indicates that aggrecan underwent some 
aggrecanase-mediated C-terminal trimming in these constructs. Stimulation of 
chondrocytes with TGF−β1 increased the intensity of the 120kDa G3 band, and  
A B 
Figure 5.11 sGAG accumulation in cell-agarose constructs was dependent on cell type 
and can be modulated by treatment with pharmacologic protease inhibitors. Following 0 
or 16 days in culture, articular chondrocyte (AC, A)- and fibrochondrocyte (MFC, B)- 
agarose constructs underwent extraction of intact proteoglycans in 4M guanidine and 
residues were digested in proteinase K and agarase. Note the 4-fold difference in scale 
between A and B. Data are mean + SEM, with n=6. # denotes significant difference 











































































































Figure 5.12 Characterization of aggrecan extracted from chondrocyte-agarose (left) and 
fibrochondrocyte-agarose (right) constructs. Equal volumes of extracts from day 0 or day 
16 constructs were deglycosylated and separated by SDS-PAGE on 4-12% gradient gels. 
Anti-G2 blots are reblots of membranes initially probed with anti-DLS. 
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substantially reduced intensity of the high molecular weight band observed in basal 
constructs, suggesting that TGF−β1 stimulation promoted aggrecan processing. Aggrecan 
G2 blots confirmed this finding, showing a broad, faint band migrating at 250kDa, an 
intense band at ~140kDa, and a doublet at 50-55kDa in TGF−β1-stimulated samples. The 
~140kDa band was later identified as an m-calpain-generated aggrecan fragment bearing 
the GVA791 C-terminal neoepitope (not shown). Fibrochondrocyte-agarose constructs 
demonstrated different patterns of G3- and G2-positive aggrecan species. In contrast to 
the chondrocyte-agarose constructs, fibrochondrocyte-agarose constructs cultured in 
basal serum-free medium contained very little full length aggrecan as indicated by weak 
staining in the high molecular weight regions of G3 (Figure 5.12 upper right), G2 (Figure 
5.12 middle right), and G1 (data not shown) blots. Consistent with enhanced C-terminal 
trimming in fibrochondrocyte constructs, G3 blots also revealed the presence of several 
aggrecan fragments, including a 120kDa band similar to that observed in chondrocyte 
constructs and bands at 140kDa, 65kDa, and 40kDa. The 140kDa fragment may also be 
aggrecanase-generated 224. Fibrochondrocytes stimulated with TGF−β1 accumulated high 
molecular weight aggrecan species positive for the G1, G2, and G3 domains, but G3 blots 
showed that variable C-terminal trimming persisted in TGF−β1-stimulated constructs. 
More specifically, G3-reactive bands migrating at ~40kDa, 70kDa, and 120kDa were 
present in fibrochondrocyte constructs and absent in chondrocyte constructs. 
Surprisingly, the aggrecan G1-NITEGE product was not detected in extracts of 
fibrochondrocyte cultures (Figure 5.12, bottom panels) as it was in tissue extracts. This 
suggests that agarose culture inhibits or prevents the aggrecanase-mediated IGD cleavage 
characteristic of fibrochondrocytes in their native ECM. These results show that aggrecan 
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is processed in different ways by chondrocytes and fibrochondrocytes under the basal 
conditions used in this study, and demonstrate that TGF−β1-induced changes in aggrecan 
processing are cell-type specific. In addition, agarose culture does not appear to support 
some mechanisms of fibrochondrocyte-mediated aggrecan turnover detected in native 
tissue. 
 Western blots of constructs extracts for the DLS neoepitope also revealed 
differences in aggrecan processing between cell type and with culture condition (Figure 
5.12 lower panels). Day 0 chondrocyte-agarose constructs contained DLS-reactive 
material migrating at ~250kDa, suggesting that this product is intracellular or tightly 
bound in the pericellular compartment. Culture in basal medium for 16 days appeared to 
reduce the abundance of this fragment, and TGF−β1 stimulation yielded a similar result 
to basal constructs. In contrast, meniscal fibrochondrocyte constructs exhibited no DLS 
reactivity at day 0 but accumulated this product upon culture for 16 days in basal medium 
or with TGF−β1-stimulation (Figure 5.12, lower right). These results indicate that the 
abundance and accumulation of calpain-generated aggrecan fragments in cell-agarose 
constructs was cell-type dependent. 
 Treatment with selective pharmacologic protease inhibitors perturbed TGF−β1-
driven aggrecan processing in both chondrocyte- and fibrochondrocyte-agarose 
constructs. In chondrocyte-agarose constructs, treatment with any of the protease 
inhibitors enhanced retention of high-molecular weight G1 (data not shown), G2, and G3 
reactive material (Figure 5.12, upper and middle left, lanes 4-6), and these effects were 
similar in fibrochondrocyte-agarose constructs (Figure 5.12, upper and middle right, 
lanes 4-6). In addition, accumulation of DLS-reactive aggrecan species was also 
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increased with inhibitor treatments for both cell types. Consistent with the sGAG 
accumulation data in Figure 5.11, these results show that inhibition of aggrecanases, 
MMPs, or the calpains enhanced retention of full length and other high molecular weight 
aggrecan species. Most strikingly, these inhibitor treatments appeared to reduce TGF−β1-
induced aggrecan processing in articular chondrocyte-agarose constructs. 
 Aggrecan species released from cell-agarose constructs were characterized by G1 
and G3 immunoblots of conditioned media from the final 48h of the experiment. 
TGF−β1-stimulated chondrocyte and fibrochondrocyte constructs released high 
molecular weight G1 and G3 reactive species, whereas media from basal cultures showed 
Figure 5.13 Characterization of aggrecan released to media from cell-agarose constructs. 
Equal volumes of conditioned media from day 16 of the experiment were probed with 
antibodies to the G1 (left) and G3 (right) domains of the aggrecan core molecule. 
Chondrocyte- and fibrochondrocyte-agarose samples were loaded in lanes 1-5 and 6-10, 
respectively. 
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no reactive material (Figure 5.13). G3 blots from media conditioned by either cell type 
exhibited a weak band at 120kDa, indicating that these fragments of C-terminally 
trimmed aggrecan freely diffuse to the media compartment. Interestingly, other mid- and 
low-molecular weight G3-reactive species identified in construct extracts (Figure 5.12 
upper panels) were not detected in day 16 media. The aggrecan G3 domain contains 
lectin domains known to associate with tenascin-C, a glycoprotein found in developing 
cartilage. Perhaps de novo ECM assembly by chondrocytes and fibrochondrocytes 
involves some aspects of development, including tenascin-C deposition, and subsequent 
retention of G3 fragments. Treatment with pharmacologic protease inhibitors had no 
dramatic effects on the size of aggrecan species released to media from constructs of 
either cell type. 
Construct Material Properties 
 The functional implications of proteoglycan accumulation and aggrecan 
processing in cell-agarose constructs were examined by testing the constructs in 
oscillatory unconfined compression. Constructs cultured in basal medium for 16 days 
exhibited higher dynamic compression moduli and a lower tangent of the phase angle 
[tan δ, defined as the ratio of viscous (loss) modulus to elastic (storage) modulus] than 
day 0 constructs (Figure 5.14), indicating that the encapsulated cells assembled a 
load−bearing extracellular matrix. TGF−β1-stimulation significantly increased the 
dynamic compression moduli of chondrocyte and fibrochondrocyte constructs above 
basal controls by 89% and 7%, respectively, and also decreased tan δ below basal 
controls for both cell types. Consistent with the increase in construct sGAG content 
(Figure 5.11), treatment with a calpain-selective inhibitor significantly increased the 
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dynamic compression modulus of TGF−β1-stimulated chondrocyte constructs above 
TGF−β1-only controls (Figure 5.14A). Inhibitor-treated fibrochondrocyte constructs had 
compression moduli similar to TGF−β1-only controls, and the aggrecanase- and MMP-
selective inhibitors had no effects on TGF−β1-stimulated chondrocyte constructs. Taken 
together, these results indicate that TGF−β1 stimulates chondrocytes and 
fibrochondrocytes to assemble a loading-bearing extracellular matrix and suggest that 
Figure 5.14 TGF-β1-stimulation increases material properties of cell-agarose constructs. 
The dynamic compression moduli (0.5Hz, A,B) and tangents of the phase angles, (0.05-
1Hz, tan δ) (C,D) of chondrocyte-(A,C) and fibrochondrocyte-seeded constructs (B,D) 
were measured after 0 or 16 days of culture. Note the 2-fold difference in scale between 
(A) and (B). Data are mean ± SEM, with n=6. # denotes significant difference p<0.05 
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calpains participate in this response in chondrocytes.  
5.4 Discussion 
 The current study was designed to identify mechanisms of aggrecan turnover in 
articular cartilage and meniscal fibrocartilage and to characterize tissue-level changes in 
ECM function (i.e., material properties) under anabolic conditions. In vitro culture of 
tissue explants and cell-agarose constructs were used to evaluate TGF-β-induced 
aggrecan turnover and de novo ECM assembly, respectively, and pharmacologic protease 
inhibitors were used to identify active proteases. Describing the tissue-dependent 
differences in aggrecan processing between meniscal fibrocartilage and articular cartilage 
may be useful in identifying tissue-specific therapeutic targets for the treatment of 
arthritis and engineering grafts with tissue-specific aggrecan compositions for joint 
repair.  
TGF−β signaling promotes aggrecan turnover in both cartilage and fibrocartilage 
explants in tissue-specific ways. Cartilage treated with a TGF−βRI inhibitor (in basal 
medium, without exogenous TGF-β) had lower proteoglycan content and material 
properties than basal controls, suggesting that endogenous anabolic TGF−β signaling was 
active in this tissue. Fibrocartilage exhibited apparently low endogenous TGF-β signaling 
activity, as explants treated with the TGF−βRI inhibitor had similar proteoglycan content 
and material properties to untreated basal controls. There may be more TGF-β available 
for endogenous TGF-β-signaling in the cartilage ECM than in fibrocartilage. Inhibitor 
treatment significantly reduced the mitochondrial activity of fibrocartilage explants 
below basal controls, however, suggesting that some endogenous TGF−β signaling 
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provided a survival or proliferative signal for fibrochondrocytes. Although the inhibitor 
may be specifically cytotoxic to fibrochondrocytes at this dose, several cell types have 
tolerated this inhibitor at doses up to 30µM90,99. Cartilage explants stimulated with 
exogenous TGF−β1 swelled significantly less than basal controls and exhibited 
proteoglycan synthesis similar to basal. Indeed, TGF−β1-stimulated maintenance of 
proteoglycan concentration was due primarily to maintenance of tissue water content. 
Cartilage swelling is highly dependent on the collagen network, and TGF−β1-stimulation 
may have induced anti-catabolic activity (e.g., downregulated MMP expression or 
upregulated TIMP expression) that reduced denaturation or degradation of the collagen. 
In contrast to cartilage and consistent with previous reports38, fibrocartilage explants 
responded to exogenous TGF−β1 with significantly higher proteoglycan synthesis than 
basal controls, and cytokine treatment had no effect on tissue swelling. It is interesting to 
note that both tissues responded to exogenous TGF−β1 by maintaining proteoglycan 
concentrations, rather than absolute abundance, comparable to day 0 tissues. This 
suggests a point of convergence in two otherwise disparate mechanisms of TGF−β1-
induced aggrecan turnover. Alternatively, this may have simply been an artifact of the 
tissue explant culture system and changes in swelling related to the collagen network. 
TGF−β1 stimulation promotes maintenance of fibrocartilage shear properties, but 
is not sufficient to prevent loss of cartilage or fibrocartilage compression properties. 
Fibrocartilage cultured for 10 days in the presence of TGF−β1 had shear moduli 
comparable to day 0, whereas identically treated cartilage explants retained <50% of the 
day 0 moduli. Both tissues underwent substantial loss (~67%) of compression moduli 
after 10 days in culture, suggesting that the abundance and/or integrity of non-
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proteoglycan ECM constituents were altered during the experiment. Changes in the 
collagen network were not characterized in this study, but likely contributed substantially 
to the culture-induced loss of compression and shear properties. Indeed, TGF−β1-
stimulated explants (of both tissue types) treated with an MMP-selective inhibitor 
exhibited the greatest retention of compression and shear moduli. Thus, MMP-mediated 
collagen degradation may have precluded complete preservation of tissue function. 
Preparation of the explants involved separation from surrounding structures that would 
support the maintenance and development of tissue material properties. Thus, the 
contributions of non-proteoglycan constituents and the tissue culture model to changes in 
tissue material properties cannot be completely decoupled from the effects of aggrecan 
turnover in this study.  
MMPs regulate TGF−β1-stimulated ECM remodeling in both cartilage and 
fibrocartilage. Treatment of TGF−β1-stimulated cartilage with a potent MMP-selective 
inhibitor led to significantly lower mitochondrial activity than TGF−β1-only controls (but 
not lower than basal cultures), suggesting that MMPs regulate survival or proliferation 
signals in cartilage. MMP-3 can activate latent TGF−β1 in the cartilage ECM131,132, and 
treatment with an MMP inhibitor would thus be expected to interfere with the activity of 
endogenous TGF−β1 and progression of autocrine TGF−β signaling72,186. The 
significantly lower sGAG content of MMP-inhibitor-treated tissue may be the indirect 
result of reducing TGF−β-stimulated cell survival or proliferation. MMPs also regulated 
tissue swelling in cartilage explants, as MMP-inhibitor treated cartilage had the lowest 
wet weight and water fraction of all culture conditions. In contrast to cartilage, the MMP 
inhibitor had no effect on fibrocartilage viability. TGF−β1-stimulated fibrocartilage 
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treated with the MMP-inhibitor had higher sGAG content and concentration and a lower 
fraction of sGAG released to the media than TGF−β1-only controls, which suggests that 
MMP activity potentiated the TGF−β1-induced increase in proteoglycan synthesis and 
contributed to loss of sGAG from the fibrocartilage ECM. It is unclear how MMPs might 
potentiate the TGF−β1 stimulus, but MMPs may mediate sGAG release by cleaving link 
protein and interfering with proteoglycan aggregation. Despite the disparate tissue-
dependent effects of MMP inhibition on explant viability and proteoglycan synthesis, the 
MMP inhibitor treatments revealed another point of convergence in ECM remodeling: 
MMP inhibition with TGF−β1-stimulation conferred the greatest preservation of explant 
material properties. Thus, MMPs are likely participants not only in proteolytic disruption 
of each tissue’s collagen network, but also as regulators of the TGF−β signaling axis and 
retention of sGAG in articular cartilage and meniscal fibrocartilage.  
 The balance of proteoglycan synthesis and processing in meniscal 
fibrochondrocytes is different from that of articular chondrocytes. TGF−β1-stimulated 
explants and constructs derived from both tissues had increased proteoglycan 
biosynthetic activity than basal controls. However, the rate of proteoglycan synthesis in 
fibrochondrocytes (as indicated by accumulation of sGAG in the cultures) was 
approximately 10% of that in articular chondrocytes. This result is consistent with 
previous reports and work in our lab using 35SO4 incorporation as an index of 
proteoglycan synthesis 38,97,101,231. Interestingly, proteoglycans synthesized by 
fibrochondrocytes were less likely to be retained within the explant or construct than 
were proteoglycans synthesized by chondrocytes. Over 10 days, approximately 14-34% 
(depending on culture condition) of the total sGAG in fibrocartilage cultures was found 
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in the media, whereas analogous cartilage cultures released 7-11%. Differences between 
the collagen networks of these tissues might explain differences in sGAG retention, as 
proteoglycans may diffuse more readily along the more oriented collagen fibrils in 
fibrocartilage. However, cell-agarose constructs with immature collagen networks 
exhibited similar differences in sGAG retention: fibrochondrocyte constructs released 48-
58% of the total sGAG when chondrocyte constructs only released 11-17%. Differences 
in the abundance, molecular weight, and/or localization of hyaluronan in 
fibrochondrocyte cultures may preclude retention of newly synthesized proteoglycan. 
Indeed, fibrocartilage is known to have a restricted localization of hyaluronan, often 
appearing exclusively between collagen fibrils and lamellar structures98,235. For the same 
anabolic stimulus, fibrochondrocytes have lower proteoglycan synthesis and retain a 
lower fraction of newly synthesized proteoglycans than articular chondrocytes. 
 Fibrochondrocytes process aggrecan more extensively than chondrocytes. Despite 
the anabolic culture conditions used in this study, fibrocartilage explants exhibited 
proteolysis of the aggrecan IGD, indicated by the presence of G1-NITEGE, and G3 blots 
of explant and construct extracts showed additional sites of C-terminal aggrecan 
trimming by fibrochondrocytes that were not detected in chondrocytes cultures. Cell-type 
differences in aggrecan catabolism appear to be intrinsic, since they were observed in day 
0 tissues, basal cultures, and TGF−β1-stimulated cultures. Fibrochondrocyte cultured in 
agarose did not exhibit aggrecanase-mediated IGD cleavage, as indicated by the lack of 
aggrecan G1-NITEGE in the extracts (Figure 5.12, bottom right panel) and BC-3-reactive 
material in the conditioned media (not shown). These results suggest that suspending 
these cells in agarose reduces their catabolic activity. Proteoglycans from the inner region 
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of immature menisci contain substantially less aggrecan G1-NITEGE than material 
extracted from the outer region, and cells from the inner meniscus are more 
phenotypically similar to articular chondrocytes (e.g., exhibit rounded morphology and 
express more aggrecan and collagen type II)88,156,204,221. Thus, agarose suspension may 
induce fibrochondrocytes to exhibit a less aggrecan-destructive phenotype characteristic 
of cells isolated from the inner meniscus, and there is no doubt that native ECM is a 
potent regulator of cell metabolism as well. Regardless of culture system, however, 
fibrochondrocytes consistently demonstrated more extensive aggrecan catabolism 
(evidenced by IGD cleavage and/or more extensive C-terminal trimming) than articular 
chondrocytes and these differences in aggrecan processing may explain the propensity for 
fibrochondrocytes to release a larger fraction of sGAG to the media. 
  The calpain protease system regulates the response of fibrochondrocytes and 
chondrocytes to TGF−β1. Calpain is a primarily cytosolic protease that regulates a 
variety of intracellular signaling events 144,202. In addition, m-calpain (calpain-2, active in 
the presence of mM-range Ca++ concentrations) is secreted to the extracellular space in 
osteoarthritic tissues66,213,217,218,248 and efficiently cleaves aggrecan164,214. Antibodies to 
the calpain-generated neoepitopes (bearing the C-terminal sequence DLS12xx-13xx) were 
used to identify calpain-modified aggrecan in these studies. Abundant DLS reactive 
material was detected in cartilage and fibrocartilage explants (data not shown), as well as 
in chondrocyte and fibrochondrocyte-agarose construct extracts. In the explant study, 
calpain-inhibitor-treated tissue was generally similar to TGF−β1-only controls, although 
cartilage explants treated with the calpain inhibitor had higher wet weights (p<0.05) and 
water fractions (p<0.1) than TGF−β1-only controls. Thus, calpain regulated cartilage 
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swelling, but the mechanism is unclear and does not appear to be due to differences in the 
population of aggrecan species. In cell-agarose constructs, calpain inhibitor treatment led 
to significantly higher mitochondrial activity and sGAG content than TGF−β1-only 
controls for both fibrochondrocytes and chondrocytes. Calpain activity also had different 
effects on proteoglycan release and construct material properties in fibrochondrocyte and 
chondrocyte cultures. Whereas calpain inhibitor-treated chondrocyte constructs had 
significantly less sGAG release and higher compression moduli than TGF−β1-only 
controls, calpain inhibitor-treated fibrochondrocyte constructs exhibited significantly 
higher sGAG release than controls and no differences in construct material properties. 
These differences were not readily explained by differences in aggrecan processing; even 
the generation of DLS-reactive material in conditioned media (data not shown) and 
construct extracts was unchanged with calpain inhibitor-treatment. Rather, calpain 
appears to regulate proteoglycan turnover by an upstream mechanism, perhaps related to 
cell metabolism and proliferation, as evidenced by increased mitochondrial activity and 
decreased DNA content in constructs treated with the calpain inhibitor. Calpain can 
regulate cell proliferation6, and the cell adhesion molecules focal adhesion kinase and 
talin are substrates for calpain18,64. It is feasible that the calpain inhibitor perturbed basic 
cell functions such as division, migration, or adhesion, and these perturbations led to 
differences in cell metabolism. Further work, perhaps with inhibitors that can selectively 
target calpain’s aggrecanolytic activity, will be necessary to elucidate the functional 
implications of calpain-mediated aggrecan processing in cartilage and fibrocartilage. 
 Collectively, the results of these experiments indicate that fibrochondrocytes 
exhibit a pattern of anabolic aggrecan turnover that is distinguished from chondrocytes by 
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lower overall synthesis rates and more extensive processing. The material properties of 
TGF−β1-stimulation generally promoted maintenance of tissue-specific aggrecan 
populations for up to 10 days in tissue explants and 16 days in cell-agarose constructs, 
and perturbation of TGF−β1-driven remodeling with selective protease inhibitors resulted 
in differences in tissue-level material properties for both tissue types. Injury- or age-
related divergence from tissue-specific ECM remodeling pathways may be an early event 





 Arthritis refers to several conditions causing joint pain and degeneration and is the 
nation’s leading cause of disability. As the population ages, the number of arthritis 
diagnoses is expected to increase to nearly 65 million patients by the year 2030. The 
pathogenesis of arthritis is largely unknown, but advanced age and joint injury are highly 
prognostic for the onset of osteoarthritis. Traumatic injury triggers an aggressive 
inflammatory response and disrupts normal joint biomechanics, and these factors 
potentiate each other as joint degeneration progresses. Increasing evidence suggests that 
arthritis with advanced age, in contrast, is due to more subtle processes in which joint 
tissues undergo degenerative shifts in material properties. The cell-mediated mechanisms 
of ECM remodeling underlying injury- and age-related degeneration are not well 
understood, but aggrecan, a large aggregating proteoglycan abundant in knee joint 
tissues, may be one of the earliest targets of cell-mediated ECM degradation in the 
degenerative joint. The work in this dissertation investigated mechanisms by which cells 
of articular cartilage and meniscal fibrocartilage process aggrecan and the effects of 
aberrant aggrecan turnover on tissue material properties. 
 The studies presented in Chapter 3 describe the kinetics, mechanisms, and 
functional implications of IL-1-stimulated articular cartilage destruction. In this model of 
aggressive degradation, cartilage explants are completely resorbed over a period of 
weeks, whereas in vivo this process takes years to decades. Aggrecanase-selective, MMP-
selective, and broad spectrum metalloproteinase inhibitors demonstrated differential 
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perturbation of IL-1-induced ECM destruction. Consistent with previous reports73,134,175, 
proteoglycans were released first from the tissue by aggrecanases and subsequent 
degradation of the collagen network was MMP-mediated. The aggrecanase inhibitor 
treatment also inhibited collagen degradation, and this finding supports the hypothesis 
that aggrecan protects collagen from proteolytic attack in articular cartilage175. Hence, the 
function of aggrecan in cartilage is more than just mechanical, and clinical interventions 
that maintain intact aggrecan within articular cartilage may have the additional benefit of 
preventing collagen degradation. Indeed, the pharmacologic inhibitors used in this work 
were designed for therapeutic use with that rationale. Metalloproteinase inhibitors, 
however, ultimately failed to prevent proteoglycan depletion and loss of tissue function. 
Conditioned media from aggrecanase inhibitor-treated cultures contained aggrecanase-
generated aggrecan at later time points (not shown) and immunostaining showed that 
intra- or pericellular aggrecanase activity persisted with aggrecanase inhibitor treatment. 
Thus, aggrecanases were present in stoichiometric excess of the inhibitor, other 
aggrecanases not inhibited by the inhibitors were active, or aggrecanases were somehow 
sequestered from exposure to the inhibitors. ADAMTS-9 is a candidate molecule that 
may be protected from exposure to the inhibitors, since it does not readily diffuse through 
the ECM. This aggrecanase is localized to the cell-surface and upregulated at the mRNA 
and protein levels by IL-1 in chondrocytes45,95 These studies demonstrated that articular 
cartilage responds to IL-1 with high levels of aggrecanase activity which ultimately led to 
exhaustive proteoglycan depletion and loss of tissue compression and shear properties.  
 Chapter 4 summarizes studies of aggrecan catabolism and IL-1-induced ECM 
degradation in meniscal fibrocartilage. Aggrecanase-mediated cleavage of the aggrecan 
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IGD activity, typical of IL-1-stimulated articular cartilage, was detected in freshly 
isolated tissue from the middle and outer regions of the menisci. IL-1 stimulation 
triggered formation of the NITEGE neoepitope in the inner and middle regions. NITEGE 
positive material was consistently localized along radial fibers and along and within 
circumferential collagen fibers in the meniscus, indicating that aggrecan is present and 
processed in these compartments of the fibrocartilage ECM. IL-1-stimulated 
fibrocartilage exhibited aggrecanase-mediated sGAG release and, in contrast to articular 
cartilage, MMP-mediated sGAG release. Aggrecanases triggered the initial “burst” of 
sGAG release, whereas MMP activity later in the experiment maintained a lower, 
persistent rate of sGAG release. Whereas the bulk of IL-1-induced aggrecan catabolism 
occurs within the first 2-4 days, treatment with an aggrecanase-selective inhibitor 
prolonged release of NITEGE-positive fragments through days 6 or 8 of the experiment, 
when collagen degradation began. Treatment with the MMP-inhibitor promoted 
accumulation of NITEGE-positive aggrecan in the tissue and reduced release of DLS-
positive aggrecan, perhaps by completely blocking collagen degradation. In addition, 
collagen degradation in IL-1-stimulated fibrocartilage began prior to exhaustive 
proteoglycan depletion. These results indicated that disruption of the collagen network is 
required for release of a substantial fraction of the tissue sGAG. In this way, notably 
opposite from articular cartilage, the collagen network protected the aggrecan in 
fibrocartilage (from release, but not necessarily from proteolytic attack). Treatment with 
the aggrecanase inhibitor did not influence the extent or kinetics of collagen degradation 
as it did in IL-1-stimulated articular cartilage, which suggests that the abundance and/or 
molecular species of aggrecan in the fibrocartilage matrix are insufficient to protect 
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collagen from proteolytic attack. Although aggrecanase-selective and MMP-selective 
inhibitor treatments did not significantly reduce IL-1-induced loss of material properties, 
treatment with a broad spectrum inhibitor of both aggrecanases and MMPs completely 
blocked degradation. Broad spectrum inhibitor-treated samples had compression and 
shear properties similar to day 0 tissue after 12 days of stimulation with IL-1. It is clear 
from these results that proteoglycan, putatively aggrecan, in vulnerable and collagen-
protected compartments contributes to the mechanical competence of meniscal 
fibrocartilage. In addition, these studies revealed mechanisms of normal and pathologic 
ECM remodeling that distinguish fibrocartilage from articular cartilage. 
 The complementary set of experiments in Chapter 5 explored the role of aggrecan 
turnover under anabolic conditions. Based on the literature198 and results of earlier 
experiments, the aggrecan population in native meniscal fibrocartilage appeared to be 
more extensively processed than that of articular cartilage and these experiments aimed to 
resolve the functional consequences, and potential benefits, of such processing. 
Oscillatory mechanical testing of fresh tissue explants showed that cartilage had 
substantially higher shear (~50x) and compression (~25x) moduli than fibrocartilage, and 
biochemical analysis of these tissues showed that cartilage has a 10-fold higher 
concentration of sGAG than fibrocartilage. Western analysis of tissue extracts revealed 
similarities and differences between the native aggrecan populations of cartilage and 
fibrocartilage. High molecular weight G3-bearing aggrecan (presumably full length) and 
250kDa DLS-bearing aggrecan were present in both tissues. As described in Chapter 4, 
however, G1-NITEGE fragments were localized exclusively in fibrocartilage. Explants 
and cell-agarose constructs served as models of aggrecan turnover and de novo matrix 
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assembly, respectively. In the presence of TGF-β1, cartilage and suspended chondrocytes 
maintained and assembled a matrix rich in full length aggrecan. TGF-β1-stimulation 
promoted retention of initial value material properties and swelling characteristics in 
cartilage explants over 10 days in culture, with minimal release of sGAG to the medium. 
TGF-β1 stimulation also promoted maintenance of tissue material properties, sGAG 
content, and fibrocartilage-specific aggrecan species (e.g., G1-NITEGE) in fibrocartilage. 
TGF-β1-stimulated fibrochondrocytes in both explants and agarose gel cultures retained a 
lower fraction of sGAG in the ECM than chondrocytes, suggesting that there are 
fundamental differences in the ways these cells assemble and deposit proteoglycans. 
Perturbation of TGF-β1-driven ECM turnover with pharmacologic protease inhibitors 
had no dramatic effects on aggrecan processing. Rather, these inhibitors appeared to have 
more pronounced effects on other aspects of cell metabolism and ECM remodeling. 
Treatment with the calpain inhibitor consistently enhanced mitochondrial activity and 
MMP inhibitor-treated cartilage demonstrated less tissue swelling and proteoglycan 
production than TGF-β1-only controls. Although TGF-β1 has been shown to upregulate 
ADAMTS-4 expression at the mRNA and protein levels in chondrocytes95,151, 
supplementation of TGF-β1-stimulated cultures (of both tissue and cell types) with a 
potent and selective aggrecanase inhibitor had only subtle effects on aggrecan processing 
and construct material properties. Chondrocyte-agarose constructs cultured for 16 days 
had substantially higher moduli and a lower tendency to dissipate stress (evidenced by 
lower tan δ) than day 0 cell-agarose constructs, whereas fibrochondrocyte constructs 
assembled a matrix with only a minimal increase in construct stiffness. Thus, these two 
cell types exhibit distinct biosynthetic and catabolic activities with respect to the 
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aggrecan component of their ECMs, and the material properties of tissue explants and 
cell-agarose constructs are related to the tissue-specific ECM remodeling activities. 
6.2 Conclusions 
The work in this dissertation shows that chondrocytes and fibrochondrocytes 
exhibit distinct kinetics and mechanisms of aggrecan turnover in response to catabolic 
and anabolic stimuli. Correlation studies181,244 and microstructural models29,48 have 
previously indicated that soft tissue compression properties increase with aggrecan 
concentration, and mechanistic descriptions of this relationship cite the electrochemical 
properties of the sGAG chains attached to aggrecan80. Cartilage is loaded primarily in 
compression and the abundance of aggrecan is substantially higher in cartilage than 
fibrocartilage, and regions of the menisci that undergo primarily compressive loading 
(e.g., the inner region) were richer in sGAG and exhibited higher rates of proteoglycan 
production38,101,221. The middle and outer regions of the menisci, which bear higher 
tensile loads, contain extensively processed aggrecan, low sGAG contents, and low rates 
of aggrecan expression and production38,229,230. Similar relationships between sGAG 
abundance and loading environment have been observed in tendon and even the 
developing heart valve75,236,252. Thus, production and accumulation of sGAG-bearing 
aggrecan appears to be a conserved mechanism in soft tissues exposed to compressive 
loads.  
Aggrecanase-mediated cleavage of the aggrecan IGD is normal in developing 
meniscal fibrocartilage. Lower quantities of sGAG in the middle and outer regions of calf 
fibrocartilage coincide with increased abundance of aggrecan G1-NITEGE, and such 
extensive aggrecan catabolism may be necessary for the proper assembly and 
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organization of large collagen fibers in these regions. It remains unclear what signal(s) 
regulate this spatial variation in aggrecan processing, although region-specific 
mechanical signals may be predominant regulators of aggrecan anabolism and 
catabolism. In this scenario, sGAG is localized to regions of compressive loading through 
elevated proteoglycan synthesis rates and suppressed protease expression. In regions 
where the ECM undergoes less compression and more tensile loading, sGAG 
accumulation is reduced by lower rates of aggrecan production and increased aggrecan 
degradation. There is precedent for such a mechanism in tendon51,75. Age-related 
increases in compressive loading and sGAG content of the middle and outer regions 
might be due to increases in animal weight and/or activity. The proximity of 
fibrochondrocytes to a vascular supply may also regulate aggrecan turnover, as the 
peripheral one third of the menisci is vascularized, whereas the inner one third is 
avascular and sustained by the synovial fluid. Thus, regional variations in access to 
soluble factors such as cytokines, growth factors, and oxygen in the blood may be an 
important regulator of aggrecan turnover in the meniscus.  
IL-1 stimulation induces cell-mediated ECM degradation in cartilage and 
fibrocartilage explants. IL-1-stimulated chondrocytes and fibrochondrocytes use similar 
downstream signaling effectors, including nitric oxide and prostaglandin E2, in the 
downregulation of proteoglycan production and upregulation of protease 
expression87,124,160,207. In addition, IL-1 triggers aggrecanase and MMP activity in both 
cartilage and fibrocartilage. IL-1 disrupts ECM homeostasis in arthritic joints and elicits 
potent autocrine signaling in chondrocytes and fibrochondrocytes from the intervetebral 
disc 105,163,226. IL-1-induced disruption of ECM turnover is also modulated by mechanical 
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stimulation in both tissue types36,97,192,207,228 . Thus, the physical proximity, shared 
exposure to cytokines in synovial fluid, and similar responses to IL-1 underscore the 
potential convergence in the upstream regulation of proteoglycan turnover in cartilage 
and fibrocartilage.  
The IL-1-induced catabolic cascade is different for cartilage and fibrocartilage. 
Most strikingly, the concomitant proteoglycan release and collagen degradation in 
fibrocartilage is markedly different from the apparent requirement in articular cartilage 
for exhaustive proteoglycan depletion prior to collagen degradation. The lower 
abundance of proteoglycans or different interactions between proteoglycans and collagen 
in fibrocartilage may favor diffusion of collagen-degrading proteases for reaction with 
their substrates. In addition, since the collagen network is degraded relatively early in the 
fibrocartilage catabolic cascade, the menisci may be more susceptible to degenerative 
tears than articular cartilage during the progression of joint disease. On the other hand, 
metalloproteinase inhibitors are more effective at preventing IL-1-induced degradation in 
fibrocartilage than cartilage. Pharmacologic inhibition of aggrecanases and MMPs 
abolishes IL-1-induced loss of fibrocartilage composition and material properties over 12 
days, but is substantially less effective at preserving the composition and properties of IL-
1-stimulated cartilage over the same time period. These results suggest that the ECM of 
immature meniscal fibrocartilage is more vulnerable to cell-mediated destruction, but that 
fibrochondrocytes exhibit a less robust catabolic response to IL-1 than articular 
chondrocytes. Future studies will need to examine the relevance of these findings to 
mature human tissues and the progression of joint degeneration. 
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Inhibiting ADAMTS and MMP family proteases may not be sufficient for the 
clinical management of degenerative or damaged cartilages. Potent ADAMTS and MMP 
inhibitors delayed, but did not block, the destruction of IL-1-stimulated articular 
cartilage, suggesting that redundant or compensatory degradation mechanisms were 
active in this model. More upstream targets in the catabolic cascade, such as the 
cytokines and/or receptors that enhance protease production and activation, may have 
more therapeutic potential. IL-1-receptor antagonist (Anakinra©) and anti-TNF-α 
(Infliximab©) are biologics that were recently approved for clinical use. They appear to 
prevent the proinflammatory cytokines IL-1 and TNF-α, respectively, from binding cell-
surface receptors and can reduce degenerative joint damage in some rheumatoid and 
osteoarthritis patients15,69,103,114,243,257. Indeed, the compounds used to block ADAMTS 
and MMP activity in this dissertation research were initially developed for therapeutic 
use, but were ultimately abandoned for compounds targeting more upstream cell 
signaling events.  
In contrast to articular cartilage, meniscal fibrocartilage explants are depleted of 
proteoglycans and lose tissue material properties in serum-free culture conditions. The 
basal (unstimulated) culture conditions used in these studies do not support maintenance 
of fibrochondrocyte ECM biosynthesis, and explanted fibrocartilage from the 
midsubstance of bovine menisci undergoes cell-mediated and cell-independent loss of 
sGAG. This loss occured in the absence or presence of ITS+ supplementation, and 
addition of an aggrecanase-selective inhibitor significantly reduces this loss, indicating 
that aggrecanases are primary mediators of aggrecan catabolism in basal fibrocartilage 
cultures. Cell-independent proteoglycan loss, amounting to approximately 15% of the 
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initial sGAG content over 12 days, is presumably due to diffusion of proteoglycans out of 
the tissue. The explants’ cut surfaces and highly oriented collagen fibers in fibrocartilage 
would facilitate this process. Also in contrast to articular cartilage, meniscal 
fibrocartilage treated with a TGF-β type I receptor inhibitor has proteoglycan synthesis 
and rates of release similar to untreated controls, so endogenous TGF-β-driven ECM 
synthesis in fibrocartilage appears to be much lower than in articular cartilage; this could 
be due to a low abundance of latent TGF-β in the fibrocartilage in the ECM. Stimulation 
with exogenous TGF-β1, however, induces sufficient proteoglycan production to 
maintain fibrocartilage sGAG concentrations similar to day 0 tissue. Serum-
supplemented media has also been shown to support proteoglycan synthesis and retention 
in intact menisci through two weeks of culture232, and other anabolic stimuli, such as 
insulin-life growth factor and platelet-derived growth factor, may also promote matrix 
homeostasis in fibrocartilage97,126,166.  
Chondrocytes and fibrochondrocytes assemble functionally distinct ECMs. Native 
fibrocartilage has lower compression and shear moduli and lower hydraulic permeability 
than articular cartilage56,176. Mechanical testing data from the studies in this thesis are 
generally consistent with previously published reports. Fibrocartilage explants exhibit 
much lower moduli and higher tangents of the phase angle (tendency to dissipate vs. store 
energy) than articular cartilage. Accordingly, fibrochondrocytes in agarose gels 
synthesize a de novo ECM with substantially lower compressive stiffness than 
chondrocytes in agarose. These cells inherently produce different ECMs, and the agarose 
gel culture system appears to preserve some aspects of tissue-specific behavior. 
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The role of aggrecan in meniscal fibrocartilage mechanics appears to be different 
from that in articular cartilage. The apparent sGAG density in fibrocartilage is quite low, 
on the order of 6-10mg/mL. In contrast, the sGAG density of age-matched articular 
cartilage is 60-80mg/mL. Microstructural models of proteoglycan solutions indicate that 
electrostatic effects contribute to tissue stiffness at sGAG densities of 40mg/mL29,44. 
The studies in this dissertation demonstrate that aggrecan confers compressive stiffness to 
meniscal fibrocartilage, despite the tissue’s low bulk sGAG density. This may be 
reconciled by the possibility that localized regions of the ECM in the pericellular space, 
at the junctions of collagen fibers, or surrounding collagen fibers contain high 
concentrations of aggrecan. Consistent with this idea, safranin-O staining show pockets 
of sGAG-rich ECM in the middle region of the meniscus. Aggrecan also contributes to 
fibrocartilage shear properties, although its function in bearing shear loads is 
considerably less clear. In contrast to compression, shear deformations do not introduce 
volumetric deformations, and time-dependent effects observed in the shear stress-strain 
response are attributed to inherent viscoelasticity of the ECM solid fraction (i.e., 
independent of water extrusion). It is possible that aggrecan localized to the surfaces of 
collagen fibers in some way alters the viscoelasticity of the collagen network, perhaps by 
altering the frictional coefficient between adjacent fibers. Indeed, aggrecan has been 
localized in the plane of the circumferentially-oriented collagen fibers found in the outer 
region of the menisci. The sGAG in fibrocartilage is less readily extracted than aggrecan 
in articular cartilage, which suggests that aggrecan in fibrocartilage is more tightly 
associated with the collagen network.  
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The physiologic benefits of differential aggrecan processing in cartilage and 
fibrocartilage remain unclear. Aggrecan contributes to the compression and shear 
properties of both tissues, yet there are marked differences in the abundance and degree 
of proteolytic processing between the two tissues. Aggrecan has been shown to inhibit 
nerve outgrowth in part due to the presence of sGAG, and perineuronal nets are 
composed of aggrecan107,137. It is possible that fibrochondrocytes, particularly in the 
middle and outer regions of the meniscus, would not attach to the ECM or retain a stellate 
morphology in the presence of abundant full-length aggrecan. Indeed, there is a direct 
relationship between rounded cell morphology and sGAG abundance in articular cartilage 
and the developing meniscus. Maintenance of the stellate morphology may be essential 
for fibrocartilage—specific mechanotransduction pathways, which in turn regulate 
fibrochondrocyte-specific ECM remodeling responses. Aggrecan may also exhibit 
differential associations with other ECM molecules in cartilage and fibrocartilage. The 
relative abundance of G3-bearing aggrecan fragments in fibrocartilage extracts suggests 
that these molecules are functional. The G3 domain of aggrecan contains repeated lectin 
domains that can bind the glycoproteins tenascin C and fibulin11,43,130, which have been 
immunolocalized in developing meniscal fibrocartilage and cartilage, respectively191,253. 
In addition, the sizes of aggrecan G3 fragments detected in tissue extracts indicate that 
they contain sGAG chains from the chondroitin sulfate-rich 2 domain. Thus, aggrecan 
fragments resulting from extensive proteolytic processing may still be functional in 
fibrocartilage. 
Tissue-specific patterns of aggrecan turnover appear to be the result of intrinsic 
differences in cell activity. Clarifying the function of different aggrecan processing 
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events and aggrecan species in the development of a mechanically competent tissue will 
be useful in the design and evaluation of engineered tissue grafts. In addition, 
identification of aggrecan cleavage products indicative of pathologic fibrochondrocyte 
ECM remodeling may be useful in the early detection of arthritis. On this point, however, 
it is important to note that while aggrecan G1-NITEGE is indicative of pathologic 
remodeling in articular cartilage, it is indicative of normal developmental remodeling in 
meniscal fibrocartilage. Identification of alternative biomarkers, such as the recently-
characterized fibronectin neoepitope in arthritic cartilage250, may be necessary to 
distinguish tissue development from tissue degeneration within the joint.  
6.3 Future Directions 
 The work in this thesis raises many more questions than it answers. The tissue 
source used in most of the studies presented here was the immature bovine stifle joint. 
This tissue source was abundant, received disease- and injury-free, and well- 
characterized by decades of research on the material properties, chondrocyte metabolism, 
and aggrecan turnover of the cartilage and fibrocartilage. An important extension of this 
work, however, will be investigation of chondrocyte- and fibrochondrocyte-mediated 
ECM remodeling in human tissues of varying ages. Species-dependent variations in 
meniscus composition and material properties have been reported2,109,215, and 
chondrocytes exhibit diminished sensitivity to growth factor stimulation with age81,135. 
Thus, elucidation of human-specific ECM remodeling in pathologic, developmental, and 
homeostatic states will be important. 
 Differences in injury-induced mechanisms of proteoglycan remodeling in 
cartilage and fibrocartilage will also be worth investigating. IL-1 stimulation of explanted 
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tissue loosely approximates a traumatic tissue tear and ensuing inflammatory cascade. 
However, in the absence of mechanical overload, this model fails to capture the roles of 
collagen network fissures and apoptosis in injury-induced ECM catabolism. Bovine and 
human articular cartilage release proteoglycans following compressive overload, and 
addition of IL-1 to injured cultures synergizes with the injury to enhance proteoglycan 
release168,177. Examination of loading mode will also be relevant for study of injury-
induced cell-mediated ECM remodeling in meniscal fibrocartilage.  
 The loading environment is known to have profound effects on chondrocyte and 
fibrochondrocyte metabolism, and future studies would benefit from the superposition of 
physiologic loading on cytokine-stimulated explants. The cytokine treatments used in this 
dissertation provided aggressive stimuli for perturbing cell metabolism. Nevertheless, the 
effects of the cytokine treatments cannot be fully decoupled from the effects of being 
removed from an actively loaded environment. Dynamic compression enhanced IL-1-
induced proteoglycan release from fibrocartilage explants207, and static compression 
suppressed proteoglycan synthesis in fibrocartilage explants97. Adaptation of the current 
studies to in vivo models of fibrocartilage development and degeneration would be 
helpful in maintaining physiologic mechanical signals. 
 The role of inter-tissue paracrine signaling in regulating ECM turnover during 
development and degeneration would be another interesting extension of this work. 
Chondrocytes exhibit autocrine IL-1 and TGF-β signaling163,240, and release of these and 
other signaling molecules to the synovial fluid may play a significant role in the 
pathogenesis of arthritis. The co-culture of explanted tissues or isolated cells under 
catabolic and anabolic conditions may reveal important kinetic and mechanistic features 
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of arthritic changes in one tissue compartment resulting from injury or inflammatory 
insult to the other.  
 The use of pharmacologic inhibitors is ultimately limited by the specificity of the 
inhibitors for their target. Non-specific effects of inhibitor treatments can be manifested 
in obvious cell death and aberrant behavior, or in more subtle shifts in cell metabolism 
that are difficult or impossible to detect. The inhibitors and range of doses used in this 
dissertation work demonstrated low or no adverse effects on the mitochondrial activity of 
tissue explants and cell-agarose constructs. Evidence of specific enzyme activity in 
aggrecan processing events, however, should be substantiated by alternative methods of 
protease blockade. Aggrecanase-1 or -2 knockout animals77,78,211 would be helpful in 
characterizing the functional implications of aggrecanase-mediated aggrecan cleavage in 
the developing meniscus. Specific inhibition of MMP- and calpain- mediated 
aggrecanolysis is problematic because they are so multifunctional, but cleavage site-
directed mutagenesis of the aggrecan core protein is a promising approach129.  
 Further investigation of the signals regulating ECM molecule abundance, 
structure, and localization in cell-scaffold constructs may aid in the development of 
engineered tissue replacements and model tissues. TGF-β1-stimulated explant cultures 
maintained sGAG concentration, rather than absolute sGAG quantity, suggesting that 
homeostatic proteoglycan turnover is regulated by sGAG concentration. A model 
describing the kinetics of chondrocyte-mediated de novo tissue formation postulates that 
the rate of ECM molecule deposition is related to a “target” abundance of that ECM 
component245. Chondrocytes and fibrochondrocytes may exhibit cell type-specific target 
ECM compositions that depend on the culture conditions, and these responses may be 
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governed by a common mechanism. In addition, the chondrogenic or fibrochondogenic 
potential of viable tissue engineering cell sources, such as bone-marrow-derived stromal 
cells (BMSCs), may be characterized by the kinetics and mechanisms of aggrecan 
processing. Pilot experiments with BMSCs cultured in agarose and chondrogenic media 
demonstrated increases in construct material properties in the presence of an 
aggrecanase-selective inhibitor, suggesting that BMSCs expressed aggrecanases and 
exhibited some aspects of fibrochondrocytic ECM turnover. Engineered tissue constructs 
can thus serve as useful model systems for examining ECM remodeling, tissue 
development, and ECM composition-function relationships. 
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APPENDIX A 
MATERIALS & SUPPLIES 
Product    Vendor   Location 
Anti-collagen I antibody Abcam Cambridge, MA 
 
ECF substrate Amersham Piscataway, NJ 
 
Keratanase II Associates of Cape Cod E. Falmouth, MA 
 
ITS+ media supplement Becton Dickinson San Jose, CA 
 
Gel/Mount Biomeda Foster City, CA 
 
WST-1 reagent BioVision Mountain View, CA 
 
Calpain inhibitor III (MDL 28170) Calbiochem La Jolla, CA 
Protease inhibitor cocktail set I Calbiochem La Jolla, CA 
 
Re-blot plus stripping buffer Chemicon Temecula, CA 
 
0.11µm Polyethersulfone filter Corning Corning, NY 
 
ELF3200 Enduratec Minnetonka, MN 
ELF3100 Enduratec Minnetonka, MN 
 
Proteinase K EMD Chemicals Gibbstown, NJ 
 
24-Well tissue culture plates Falcon Franklin Lakes, CA 
48-Well tissue culture plates Falcon Franklin Lakes, CA 
 
Dimethyl sulfoxide Fisher Scientific Pittsburg, PA 
Sodium dodecyl sulfate Fisher Scientific Pittsburg, PA 
Triton X-100 Fisher Scientific Pittsburg, PA 
 
FLA-3000 phosphorimager FujiFilm Lifescience Stamford, CT 
 
SMT1 5.6lbf load cell Interface Scottsdale, Arizona 
SMT1 1.1lbf load cell Interface Scottsdale, Arizona 
 
2x Sample loading buffer Invitrogen Carlsbad, CA 
4’,6-Diamidino-2-phenylindole Invitrogen Carlsbad, CA 
4-12% Tris glycine PAGE gels Invitrogen Carlsbad, CA 
AlexaFluor 488 goat anti-rabbit Invitrogen Carlsbad, CA 
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AlexaFluor 594 goat anti-mouse Invitrogen Carlsbad, CA 
Antibiotic/antimycotic Invitrogen Carlsbad, CA 
Collagenase Type II Invitrogen Carlsbad, CA 
Fungizone (Amphotericin B) Invitrogen Carlsbad, CA 
Gentamicin Invitrogen Carlsbad, CA 
HEPES buffer Invitrogen Carlsbad, CA 
High glucose Dulbecco’s Modified  Invitrogen Carlsbad, CA 
Eagle’s Medium 
Non-essential amino acids Invitrogen Carlsbad, CA 
Phosphate buffered saline Invitrogen Carlsbad, CA 
SeeBlue Plus MW markers Invitrogen Carlsbad, CA 
Trypsin-EDTA Invitrogen Carlsbad, CA 
 
p-dimethylaminobenzaldehyde JT Baker Phillipsburg, NJ 
Urea JT Baker Phillipsburg, NJ 
 
anti-aggrecan G1 antibody John Sandy, PhD Tampa, FL 
anti-aggrecan G2 antibody John Sandy, PhD Tampa, FL 
anti-aggrecan G3 antibody John Sandy, PhD Tampa, FL 
anti-DLS antibody John Sandy, PhD Tampa, FL 
anti-NITEGE antibody John Sandy, PhD Tampa, FL 
anti-VDIPEN antibody John Sandy, PhD Tampa, FL 
 
anti-decorin antibody (LF-94) Larry Fisher, PhD Bethesda, MD 
 
Chloramine-T Mallinckrodt Paris, KY 
 
Bohlin CVO 120 rheometer Malvern Worcestershire, UK 
 
4mm Biopsy punch Miltex York, PA 
6mm Biopsy punch Miltex York, PA 
 
rhIL-1α R & D Systems Minneapolis, MN 
rhTGF-β1 R & D Systems Minneapolis, MN 
 
Bovine calf stifle joints Research 87 Marlborough, MA 
 
Broad Spectrum inhibitor Roche-Palo Alto Palo Alto, CA 
Aggrecanase inhibitor Roche-Palo Alto Palo Alto, CA 
MMP inhibitor Roche-Palo Alto Palo Alto, CA 
 
Model 31 250g load cell Sensotec Columbus, OH 
 
Guanidine-HCl Shelton Scientific Shelton, CT 
 
Agarase Sigma St. Louis, MO 
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Alkaline Phos. anti-rabbit antibody Sigma St. Louis, MO 
Ammonium acetate Sigma St. Louis, MO 
1,9-Dimethylmethylene Blue Sigma St. Louis, MO 
Bovine serum albumin Sigma St. Louis, MO 
Calf thymus DNA Sigma St. Louis, MO 
Chondroitin sulfate Sigma St. Louis, MO 
Chondroitinase ABC Sigma St. Louis, MO 
Dithiothreitol Sigma St. Louis, MO 
Goat serum Sigma St. Louis, MO 
Hoechst 33258 Sigma St. Louis, MO 
Hydroxyproline Sigma St. Louis, MO 
Hydrochloric acid Sigma St. Louis, MO 
Iodoacetic acid Sigma St. Louis, MO 
Keratanase I Sigma St. Louis, MO 
L-ascorbic acid Sigma St. Louis, MO 
L-ascorbic acid 2-PO4 Sigma St. Louis, MO 
MES Sigma St. Louis, MO 
Non-immune rabbit IgG Sigma St. Louis, MO 
Rabbit serum Sigma St. Louis, MO 
Safranin O  Sigma St. Louis, MO 
Sodium acetate Sigma St. Louis, MO 
Sodium chloride Sigma St. Louis, MO 
Tris base  Sigma St. Louis, MO 
TWEEN-20 Sigma St. Louis, MO 
 
Sequenza staining racks/chambers Thermo Electron Waltham, MA 
 
SB431542 Tocris Ellisville, MO 
 
#12 Razor blades VWR Scientific West Chester, PA 
#22 Scalpel blades VWR Scientific West Chester, PA 
Filter paper VWR Scientific West Chester, PA 
Nitrocellulose VWR Scientific West Chester, PA 
 




B.1 Western Blotting 
B.1.1 Sample Preparation 
1. Proteins were precipitated from conditioned media or tissue/construct extracts in 3 
volumes of ice cold ethanol/5mM sodium acetate overnight at -20C. Lyophilized 
and minced explants or constructs were first extracted in 1mL 4M 
GuanidineHCl/10mM MES/50mM sodium acetate/5mM EDTA/pH 6.5 with 
supplemented with protease inhibitor cocktail I (Calbiochem). Extractions were 
typically performed 24-48h with gentle agitation at 4C. Volumes of media or 
extract for precipitation should contain no more than ~100µg sGAG, as 
determined by DMMB dye-binding assay. 
2. Precipitates were spun at max speed at 4C for 30 minutes, and the supernatant 
removed. Pellets were allowed to dry 15-30min on the bench (with tube tops 
open). 
3. Pellets were resuspended in 100-200µL chondroitinase buffer (50mM 
TrisHCl/50mM sodium acetate/10mM EDTA supplemented with protease 
inhibitor cocktail I) and assayed for sGAG to check recovery. Stubborn pellets 
were warmed to 37C for 15-30min and triturated with a micropipet. Recovery 
should be approximately 80% of the sGAG in the initial volume of media or 
extract. 
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4. Samples were deglycosylated with protease-free chondroitinase ABC (5µL of 
stock at 4U/mL), Keratanase I (1µL of stock at 60U/mL), and Keratanase II (3µL 
of stock at 0.1U/mL) overnight at 37C. It was helpful to periodically examine the 
deglycosylation efficiency by assay the digest for sGAG. Effective 
deglycosylation yields at least an 80% reduction in measureable sGAG. 
5. Samples were frozen and lyophilized, then resuspended in sample loading buffer 
consisting of 2X Tris-glycine sample buffer, 6M urea, and DTT (stock composed 
of 200µL sample buffer, 200µL 6M urea, and 12mg DTT). Samples were diluted 
in sample loading buffer to approximately 1mg sGAG/mL. 
B.1.2 Immunoblotting 
1. Samples in sample loading buffer were boiled at 100C for 5 min. Screw-top or 
lockable lids worked best. 
2. 10-15µL of molecular weight standards or experimental samples were loaded into 
12- or 15-lane 4-12% Tris-glycine gradient gels. 
3. Proteins were separated at 200V for 45-50min at room temperature. Running 
(“electrode”) buffer was prepared from the following recipe: [6g Tris base 
(50mM) + 28.8g Glycine (384mM) + 2g SDS + 1L deionized water]. 
4. Gels were moved to immunoblot transfer modules with nitrocellulose membranes. 
Transfer buffer was prepared from the following recipe: [3.03g Tris base (25mM) 
+ 14.4g Glycine (192mM) + 800mL deionized water + 200mL molecular biology 
grade methanol]. The best transfers were achieved at 70V for 2-3h, with the 
transfer boxes packed with ice. Transfer also appeared complete following 30V 
overnight at 4C. 
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5. Following transfer, membranes were rinsed in Tris buffered saline with TWEEN 
(TBS-T) in an empty micropipet tip box. A 10X stock of TBS was prepared form 
the following recipe: [24.2g Tris base (200mM) + 80g sodium chloride (1.37M) + 
1L deionized water & pH’d to 7.6]. TBS-T was prepared by adding 1mL 
TWEEN-20 to 1L 1X TBS. 
6. Membranes were blocked 30-60min with gentle agitation at room temperature in 
blocking buffer. Blocking buffer was prepared by adding 800mg non-fat dry milk 
to 80mL TBS-T. Occasionally, membranes were blocked overnight at 4C. 
7. Membranes were incubated with primary antibody diluted (typically 
1:1000~1:5000) in Blotto with TWEEN. Blotto with TWEEN was prepared by 
adding 4g non-fat dry milk to 80mL TBS-T. Incubations with primary antibody 
were either 1h at room temperature or overnight at 4C, with gentle agitation. 
8. Membranes were then washed with TBS-T 3 x 5min. 
9. Membranes were then incubated with secondary antibody diluted (typically 
1:10,000~1:30,000) in Blotto with TWEEN. Incubations with secondary antibody 
were either 1h at room temp or overnight at 4C with gentle agitation. 
10. Membranes were washed with TBS-T 3 x 10min. 
11. Membranes were developed by exposure to 1mL of Amersham’s ECF substrate 
for 5min at room temperature, on a transparency (protein-side of membrane faced 
“down” into pool of ECF). 
12. Developed membranes were imaged on an FLA-3000 FujiFilm phosphorimager. 
13. Membranes that underwent re-blotting were immediately stripped in Re-Blot Plus 
solution (Chemicon) for 10min at room temperature with gentle agitation. 
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14. Stripped membranes were rinsed 3 x 5min in TBS-T and subject to primary, 
secondary, and development steps as described in steps 7-12. 
B.2 Immunostaining 
1. Paraffin-embedded sections of tissue explants or gel constructs cut at 4-7µm and 
placed on Superfrost+ slides were first deparaffinized in a Leica autostainer. 
2. Slides were then loaded into Sequenza staining cassettes and racks with ~300µL 
PBS.   
3. The sections typically underwent enzymatic antigen retrieval. With sections of 
cartilage, in particular, detection of many epitopes required deglycosylation. 
Sections were typically incubated with 150µL 0.1U/mL Ch’ase ABC at 37C for 
30-60min. Detection of collagen (types I and II, in particular) could be enhanced 
by brief incubation with trypsin (0.5x, 37C, 10-30min) or pepsin. 
4. Following antigen retrieval, sections were rinsed with PBS 3 x 500µL. 
5. Sections were blocked for 1h at RT with a blocking buffer prepared from the 
following recipe: [3.4mL PBS + 1mL 5% BSA (dissolved in PBS, supplemented 
with 0.1% azide to prevent mold growth) + 25µL 10% TWEEN-20 (in PBS) + 
100µL normal goat serum + 500µL 1% gelatin (in PBS)]. 
6. Sections were incubated with primary antibody diluted (typically 1:100~1:200) in 
primary antibody buffer consisting of: [3.5mL PBS + 1mL 5% BSA (as above) + 
500µL 1% gelatin (as above)]. Incubations were either for 1h at room temperature 
or overnight at 4C. For some experiments, a second primary antibody, raised in a 
different species (mouse vs. rabbit), was also added during this step. 
7. Sections were rinsed 3 x 500µL PBS. 
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8. Sections were incubated with secondary antibody diluted (typically 1:200~1:500) 
in PBS for 1h at room temperature. The fluorescent nuclear stains Hoetsch 33258 
or DAPI were added at this step as well. Again, dual stained sections were 
additionally treated with a secondary to the second primary (anti-mouse vs. anti-
rabbit). 
9. Sections were rinsed 3 x 500µL PBS, removed from the racks, mounted in 
Gelmount, coverslipped, and allowed to set overnight at 4C. 
10. Following mounting, coverslips were fixed to the slides with a bead of clear nail 
polish. 
 
• In some follow-up experiments not included in the dissertation, an alternative 
approach to dual labeling was developed. The approach was designed to 
accommodate use of two primary antibodies raised in the same species. It 
required the use of a biotinylated primary antibody, an avidin- or streptavidin-
fluorophore, and sequential use of the antibodies. Following blocking, the 
sections were incubated only with the non-biotinylated primary and then with the 
corresponding secondary antibody. After this step, the sections were blocked for 
endogenous biotin with a commercially available kit (Vector Labs), and 
subsequently incubated with the biotinylated primary antibody. After rinsing, the 
sections were then incubated with avidin-AlexaFluor 594 and DAPI for 1h at 




B.3 Mechanical Testing 
• Samples were stored in an isotonic solution (e.g., PBS) supplemented with 
protease inhibitor cocktail I to ensure that sample material properties were not 
substantially influenced by the activity of endogenous proteases. Tissue explants 
were stored for long periods (weeks to months) at -20C prior to testing, whereas 
the much softer gel constructs were stored at 4C for less than 1wk prior to testing. 
• Samples were typically tested in torsional shear prior to testing in compression. 
• A typical testing protocol is outline below. 
1.  Sample was thawed or warmed at room temperature for 30min. 
2. Sample was patted dry on a laboratory napkin, and the wet mass was measured on 
a fine balance. 
3. Sample diameter and thickness was measured in 3 separate sample locations (for 
each dimension) using digital calipers. 
4. Sample was placed between two parallel, impermeable plates (6mm Ø, with 600 
grit water proof sandpaper glued to the surfaces). The “gap” was defined in the 
Bohlin software to be 90% of the sample thickness (in µm), and the upper plate 
was then moved to the gap setting to compress the sample to 10% strain. The 
sample was enveloped with a bead of room temperature PBS with protease 
inhibitors, and the humidity chamber put in place to prevent dehydration. 
5. Sample was allowed to equilibrate to the new stress state for 15-30min 
(depending on sample type). 
6. Sample was loaded in oscillatory torsion over a) a range of frequencies or b) a 
range of peak strains.  Frequency sweeps were performed at ±0.25% strain from 
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0.001-1Hz. Amplitude sweeps were performed at 0.1Hz from ±0.1-2.5% strain. 
Samples were cycled for 30s prior to measurements of stress and strain. 
7. Bohlin software automatically calculated complex, storage, and loss moduli, and 
phase angles, from these tests. All data was either manually transcribed or copied 
from the Bohlin software window into a Microsoft Excel© spreadsheet for further 
analysis. 
8. Following shear testing, the sample was returned to free swelling conditions in 
PBS with protease inhibitors for 30min at room temperature. Compression test 
parameters were defined in the Enduratec Wintest software. The “Block” 
waveform was used to define and collect data from stress relaxation steps. 
Oscillatory compression tests were programmed using either the Block waveform 
(as in chapter 4) or the Dynamic Mechanical Analysis package (as in chapters 5 & 
6). 
9. Sample was placed into an unconfined compression chamber in either the 
ELF3100 or ELF3200 uniaxial loading frame. Sample was immersed in 3-5mL 
PBS with protease inhibitors. The main actuator with attached 12mm Ø indenter 
was moved to the zero displacement position and the load channel was tared. The 
compression chamber was then moved into close proximity of the indenter using 
the motorized stroke extender (on the ELF3200) or manually adjustable lower 
platen (on the ELF3100). 
10. The sample was then manually preloaded to 10-20mN with the stroke extender 
(ELF3200) or the main actuator (ELF3100). 
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11. All compression tests involved ramping to 10% compressive strain (at a rate of 
100µm/min), a period of stress relaxation (20-30min, depending on sample type), 
and oscillatory loading over a range of frequencies at ±1.5% strain. Oscillatory 
loading tests were performed at frequencies ranging from 0.001Hz-5Hz. Some 
experiments (presented in chapter 4) included 4 steps of stress relaxation (5% 
each up to 20% strain) for measurement of an equilibrium modulus.  
12. The Dynamic Mechanical Analysis package was used to collect data from the 
oscillatory loading tests performed in chapters 5 and 6. For the experiments 
described in chapter 4, a custom MATLAB code was written to extract material 
properties from the oscillatory loading test data. More specifically, the code 
imported raw time-displacement and time-load waves, applied a fast fourier 
transform to these waves to determine the magnitude of the fundamental 
sinusoidal components of the waves, and outputted a complex modulus and phase 
angle for each frequency tested. 
13.  Following testing, the sample was moved to an empty screw-top 2mL tube, 
frozen, and lyophilized for biochemical analysis. 
 
The code for the MATLAB routine is given below: 
infile = char(textdata(1,1)); 
[p, name] = fileparts(infile); 
outfile = [name ' fft.txt']; 
 
prompt = {'Enter Sample Radius (mm):', 'Enter Sample Thickness (mm)'}; 
dlg_title = 'Your input is Requested!'; 
num_lines= 1; 
def2 = {'2.0', '2.0'}; 
dim = inputdlg(prompt,dlg_title,num_lines,def2); 
radius = str2num(char(dim(1,1))); 
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thickness = str2num(char(dim(2,1))); 
 
LoadWave1 = data(2403:2602, 5); 
LW1Freq = 0.001; 
LoadWave2 = data(2604:3003, 5); 
LW2Freq = 0.01; 
LoadWave3 = data(3005:4004, 5); 
LW3Freq = 0.1; 
LoadWave4 = data(4006:5005, 5); 
LW4Freq = 1; 
LWFFT1 = fft(LoadWave1); 
LWFFT2 = fft(LoadWave2); 
LWFFT3 = fft(LoadWave3); 
LWFFT4 = fft(LoadWave4); 
lm1 = abs(LWFFT1); 
lm2 = abs(LWFFT2); 
lm3 = abs(LWFFT3); 
lm4 = abs(LWFFT4); 
lm1(1,1) = 0; 
lm2(1,1) = 0; 
lm3(1,1) = 0; 
lm4(1,1) = 0; 
lm1(102:200) = []; 
lm2(202:400) = []; 
lm3(503:1000) = []; 
lm4(504:1000) = []; 
 
DispWave1 = data(2403:2602, 4); 
DW1Freq = 0.001; 
DispWave2 = data(2604:3003, 4); 
DW2Freq = 0.01; 
DispWave3 = data(3005:4004, 4); 
DW3Freq = 0.1; 
DispWave4 = data(4006:5005, 4); 
DW4Freq = 1; 
DWFFT1 = fft(DispWave1); 
DWFFT2 = fft(DispWave2); 
DWFFT3 = fft(DispWave3); 
DWFFT4 = fft(DispWave4);  
dm1 = abs(DWFFT1); 
dm2 = abs(DWFFT2); 
dm3 = abs(DWFFT3); 
dm4 = abs(DWFFT4); 
dm1(1,1) = 0; 
dm2(1,1) = 0; 
dm3(1,1) = 0; 
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dm4(1,1) = 0; 
dm1(102:200) = []; 
dm2(202:400) = []; 
dm3(503:1000) = []; 
dm4(504:1000) = []; 
 
f1 = 0.2*(1:100)/200; 
f2 = 2*(1:200)/400; 
f3 = 20*(1:500)/1000; 
f4 = 200*(1:500)/1000; 
 
[a,flpos1] = max(lm1); 
[a,flpos2] = max(lm2); 
[a,flpos3] = max(lm3); 
[a,flpos4] = max(lm4); 
 
[a,fdpos1] = max(dm1); 
[a,fdpos2] = max(dm2); 
[a,fdpos3] = max(dm3); 
[a,fdpos4] = max(dm4); 
 
langle1 = (angle(LWFFT1)); 
langle2 = (angle(LWFFT2)); 
langle3 = (angle(LWFFT3)); 
langle4 = (angle(LWFFT4)); 
 
dangle1 = (angle(DWFFT1)); 
dangle2 = (angle(DWFFT2)); 
dangle3 = (angle(DWFFT3)); 
dangle4 = (angle(DWFFT4)); 
 
phanglediff1 = (180/(pi))*(dangle1(fdpos1)-langle1(flpos1)); 
phanglediff2 = (180/(pi))*(dangle2(fdpos2)-langle2(flpos2)); 
phanglediff3 = (180/(pi))*(dangle3(fdpos3)-langle3(flpos3)); 
phanglediff4 = (180/(pi))*(dangle4(fdpos4)-langle4(flpos4)); 
 
freq1_dyn_mod = (max(lm1)/((pi)*(radius)))/(max(dm1)/(thickness)); 
freq2_dyn_mod = (max(lm2)/((pi)*(radius)))/(max(dm2)/(thickness)); 
freq3_dyn_mod = (max(lm3)/((pi)*(radius)))/(max(dm3)/(thickness)); 
freq4_dyn_mod = (max(lm4)/((pi)*(radius)))/(max(dm4)/(thickness)); 
 
freq = [0.001, 0.01, 0.1, 1]; 
dyn_mod = [freq1_dyn_mod, freq2_dyn_mod, freq3_dyn_mod, freq4_dyn_mod]; 
phase_angle = [phanglediff1, phanglediff2, phanglediff3, phanglediff4]; 
 
sumd = zeros(1,4); 
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THDd = zeros(1,4); 
suml = zeros(1,4); 
THDl = zeros(1,4); 
    for i = 2:1:25; 
        sumd(1) = ((dm1(i*fdpos1))^2) + sumd(1); 
        sumd(2) = ((dm2(i*fdpos2))^2) + sumd(2); 
        sumd(3) = ((dm3(i*fdpos3))^2) + sumd(3); 
        sumd(4) = ((dm4(i*fdpos4))^2) + sumd(4); 
         
        THDd(1) = 100*((sumd(1))^.5)/max(dm1); 
        THDd(2) = 100*((sumd(2))^.5)/max(dm2); 
        THDd(3) = 100*((sumd(3))^.5)/max(dm3); 
        THDd(4) = 100*((sumd(4))^.5)/max(dm4); 
         
        suml(1) = ((lm1(i*flpos1))^2) + suml(1); 
        suml(2) = ((lm2(i*flpos2))^2) + suml(2); 
        suml(3) = ((lm3(i*flpos3))^2) + suml(3); 
        suml(4) = ((lm4(i*flpos4))^2) + suml(4); 
         
        THDl(1) = 100*((suml(1))^.5)/max(lm1); 
        THDl(2) = 100*((suml(2))^.5)/max(lm2); 
        THDl(3) = 100*((suml(3))^.5)/max(lm3); 
        THDl(4) = 100*((suml(4))^.5)/max(lm4); 
    end; 
     
         









output = [freq; dyn_mod; phase_angle; THDd; THDl]; 
 
fid = fopen(outfile,'w'); 
fprintf(fid,'Frequency(Hz), Dynamic Modulus(MPa), Phase(degrees), dispTHD(%%), 
loadTHD(%%) \r'); 
fprintf(fid,'radius = %1.3f\r', radius); 
fprintf(fid,'thickness = %1.3f\r', thickness); 




RETINOIC ACID STIMULATES AGGRECAN PRODUCTION AND 
PROCESSING IN MENISCAL FIBROCARTILAGE 
 
 
C.1 Introduction   
The vitamin A derivative all-trans retinoic acid (RA) is a pleiotrophic cytokine 
with demonstrated roles in skeletal patterning and chondrocyte differentiation.  In 
explanted articular cartilage, RA induces aggrecanase-mediated release of sulfated 
glycosaminoglycans (sGAG) leading to loss of material properties, and RA upregulates 
MMP-2 in growth plate chondrocytes.  Interestingly, RA dramatically upregulates 
expression of the small proteoglycan decorin in isolated articular chondrocytes, and RA 
has anti-inflammatory effects in a collagen-induced model of arthritis.  It is unknown, 
however, what roles RA may play in fibrocartilage development.  The objective of this 
study was to examine the effects of RA on proteoglycan turnover and material properties 
of explanted meniscal fibrocartilage. 
C.2 Methods  
Fibrocartilage explants (n=24, 4mm dia, 2mm thick) were harvested aseptically 
from the middle zone midsubstance of menisci from a 1-2 week old calf.  Explants were 
cultured in serum free high-glucose DMEM in the absence or presence of 1 or 10M 
RA.  Media were changed every 2 days.  Explants were removed after 10 days and stored 
at –20C with protease inhibitors for subsequent analysis. Explants were tested at room 
temperature in torsional shear and in unconfined compression.  Complex shear moduli 
G* were determined via oscillatory shear testing with 0.1 - 5% shear strain at 0.1Hz and a 
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10% compressive offset.  Dynamic compression moduli E* were determined via 
sinusoidal compression with a 1.5% strain amplitude at 0.01 – 3.16 Hz and a 10% 
compressive offset.  Following mechanical testing, explants were lyophilized and 
extracted in 4M Gn•HCl with protease inhibitors.  Residual explant tissue was digested in 
proteinase K.  Extracts, digests, and conditioned media were then assayed for sGAG 
content via the DMMB assay.  Extracts and media samples were ethanol precipitated, 
deglycosylated, separated by SDS-PAGE and immunoblotted for aggrecan G1 and 
decorin. 
C.3 Results & Discussion 
Untreated fibrocartilage demonstrated a low basal release of sGAG (Fig. C1A) 
which led to a significant decrease in explant sGAG (extract+digest) (Fig. C1B).  
Treatment with RA induced a dose-dependent increase in sGAG release that peaked at 
day 4.  Total sGAG (extract+digest+media) in RA-treated tissue was higher than in 
untreated controls, suggesting that sGAG release is due to both anabolic and catabolic 
activity.  Western blots of conditioned media indicate that basal aggrecanolysis occurs 
via the aggrecanases, denoted by a 65-70kDa species corresponding to the G1-NITEGE 
fragment; this aggrecanase activity was not attenuated by RA treatment (Fig.C2A).  
Interestingly, RA treatment induced release of full-length aggrecan in a dose-dependent 
manner, and G1-blots of tissue extracts show that RA-treatment led to accumulation of 
high molecular weight aggrecan species essentially absent in untreated tissue (Fig. C2B).  
Untreated tissue released decorin to the media, and RA treatment appeared to reduce 
release (Fig. C2C).  Decorin was detected in tissue extracts from all groups.  Oscillatory 
compression and shear tests indicate that RA treatment produced dose-dependent 
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increases in tissue material properties over untreated controls (Fig. C3A&B).  The 
unconfined compression modulus exhibited characteristic increases with frequency, 
whereas the shear modulus showed characteristic strain softening for all groups. RA 
stimulation was shown to maintain proteoglycan turnover and enhance material 
properties in explanted immature bovine meniscus.  RA treatment sustained aggrecanase 
activity of untreated controls, and in contrast to its effects on articular cartilage from 
immature bovines, RA appears to stimulate proteoglycan synthesis as evidenced by 
accumulation of full length aggrecan in the tissue.  RA-treated tissue contains an 
aggrecan population similar to that of day 0 tissue, including full-length and near full 
length species, suggesting that RA is driving homeostasis in this model.  Interestingly, the 
increases in compressive and shear properties were not associated with elevated sGAG 
content in tissue.  RA-induced increases in the mechanical properties may, then, be due to 





Figure C.1 sGAG release to media (A) and sGAG content (B) of 




















































Figure C.2 Aggrecan G1 (A&B) and decorin (C) blots of media (A,C) and  tissue 
extracts after 10 days. (B,C).  Equal volumes of media or quantities of sGAG (extracts) 
were loaded per lane. D0 = Day 0, U = Untreated. In A & B, < denotes migration of 
full-length aggrecan. 
 
Figure C.3 Dynamic compression (A) and shear (at 0.1Hz) (B) properties of 
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